exv10w8



 





Exhibit 10.8




COLLABORATIVE RESEARCH AND LICENSE AGREEMENT




between




ARCHEMIX CORP.




and




MERCK, KGaA




January 17, 2007




Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.















 








TABLE OF CONTENTS




	 	 	 	 	 
	 	 	Page	 
	1. DEFINITIONS
	 	 	1	 
	 
	 	 	 	 
	2. ADMINISTRATION OF THE COLLABORATION
	 	 	19	 
	 
	 	 	 	 
	2.1 Joint Steering Committee
	 	 	19	 
	2.2 Joint Project Team
	 	 	21	 
	 
	 	 	 	 
	3. RESEARCH PROGRAM
	 	 	24	 
	 
	 	 	 	 
	3.1 Implementation of the Research Program
	 	 	24	 
	3.2 Annual Research Plans
	 	 	25	 
	3.3 Conduct of Research Program
	 	 	25	 
	3.4 Records
	 	 	26	 
	3.5 Selection of Program Targets
	 	 	27	 
	3.6 Identification of Lead Compounds and Optimized Lead Compounds
	 	 	29	 
	3.7 Development Candidates
	 	 	29	 
	3.8 MERCK Decision Not to Go Forward
	 	 	29	 
	3.9 Supply of Proprietary Materials
	 	 	30	 
	3.10 Research Program Term
	 	 	30	 
	 
	 	 	 	 
	4. DEVELOPMENT PROGRAM; COMMERCIALIZATION OF PRODUCTS
	 	 	30	 
	 
	 	 	 	 
	4.1 Objectives of the Development Program
	 	 	30	 
	4.2 Responsibility for Development of Development Candidates and Commercialization
of Products
	 	 	30	 
	4.3 Annual Development Plans
	 	 	31	 
	4.4 Product Commercialization Plans
	 	 	31	 
	4.5 Development and Commercialization Diligence
	 	 	31	 
	4.6 Compliance
	 	 	32	 
	4.7 Cooperation
	 	 	32	 
	4.8 Exchange of Reports; Information; Updates
	 	 	32	 
	4.9 Development and Commercialization Rights and Restrictions
	 	 	34	 
	4.10 Product Recalls
	 	 	35	 
	 
	 	 	 	 
	5. PAYMENTS
	 	 	35	 
	 
	 	 	 	 
	5.1 Technology Access and License Fee
	 	 	35	 
	5.2 License Maintenance Fee
	 	 	35	 
	5.3 R&D Funding
	 	 	35	 
	5.4 Milestone Payments
	 	 	36	 
	5.5 Payment of Royalties; Royalty Rates; Accounting and Records
	 	 	38	 





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.





i









 






	 	 	 	 	 
	 	 	Page	 
	6. TREATMENT OF CONFIDENTIAL INFORMATION; PUBLICITY; NON-SOLICITATION
	 	 	42	 
	 
	 	 	 	 
	6.1 Confidentiality
	 	 	42	 
	6.2 Publicity
	 	 	44	 
	6.3 Publications and Presentations
	 	 	44	 
	6.4 Prohibition on Solicitation
	 	 	45	 
	 
	 	 	 	 
	7. LICENSE GRANTS; EXCLUSIVITY
	 	 	45	 
	 
	 	 	 	 
	7.1 Research and Development Licenses
	 	 	45	 
	7.2 Commercialization License
	 	 	50	 
	7.3 Right to Sublicense
	 	 	50	 
	7.4 Right to Subcontract
	 	 	50	 
	7.5 No Other Rights
	 	 	50	 
	7.6 Exclusivity
	 	 	51	 
	 
	 	 	 	 
	8. INTELLECTUAL PROPERTY RIGHTS
	 	 	51	 
	 
	 	 	 	 
	8.1 ARCHEMIX Intellectual Property Rights
	 	 	51	 
	8.2 MERCK Intellectual Property Rights
	 	 	51	 
	8.3 Joint Technology Rights
	 	 	51	 
	8.4 Patent Coordinators
	 	 	51	 
	8.5 Inventorship
	 	 	52	 
	8.6 Cooperation
	 	 	52	 
	 
	 	 	 	 
	9. FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS
	 	 	52	 
	 
	 	 	 	 
	9.1 Patent Filing, Prosecution and Maintenance
	 	 	52	 
	9.2 Legal Actions
	 	 	55	 
	9.3 Trademark and Copyright Ownership Prosecution, Defense and Enforcement
	 	 	58	 
	 
	 	 	 	 
	10. TERM AND TERMINATION
	 	 	58	 
	 
	 	 	 	 
	10.1 Term
	 	 	58	 
	10.2 Termination
	 	 	59	 
	10.3 Consequences of Termination of Agreement
	 	 	59	 
	10.4 Rights and Duties of the Parties following Breach by MERCK of Diligence
Obligations
	 	 	62	 
	10.5 Surviving Provisions
	 	 	62	 
	 
	 	 	 	 
	11. REPRESENTATIONS AND WARRANTIES
	 	 	63	 
	 
	 	 	 	 
	11.1 Mutual Representations and Warranties
	 	 	63	 
	11.2 ARCHEMIX’ Representations and Warranties
	 	 	63	 
	11.3 Acknowledgment of MERCK
	 	 	64	 





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.





ii









 






	 	 	 	 	 
	 	 	Page	 
	12. INDEMNIFICATION
	 	 	64	 
	 
	 	 	 	 
	12.1 Indemnification of MERCK by ARCHEMIX
	 	 	64	 
	12.2 Indemnification of ARCHEMIX by MERCK
	 	 	65	 
	12.3 Indemnification of Gilead and UTC by MERCK
	 	 	65	 
	12.4 Conditions to Indemnification
	 	 	65	 
	12.5 Warranty Disclaimer
	 	 	66	 
	12.6 No Warranty of Success
	 	 	66	 
	12.7 Limited Liability
	 	 	66	 
	 
	 	 	 	 
	13. MISCELLANEOUS
	 	 	66	 
	 
	 	 	 	 
	13.1 Arbitration
	 	 	66	 
	13.2 Change of Control
	 	 	68	 
	13.3 Notices
	 	 	69	 
	13.4 Governing Law
	 	 	70	 
	13.5 Binding Effect
	 	 	70	 
	13.6 Headings
	 	 	70	 
	13.7 Counterparts
	 	 	70	 
	13.8 Amendment; Waiver
	 	 	70	 
	13.9 No Third Party Beneficiaries
	 	 	71	 
	13.10 Purposes and Scope
	 	 	71	 
	13.11 Assignment and Successors
	 	 	71	 
	13.12 Force Majeure
	 	 	71	 
	13.13 Interpretation
	 	 	71	 
	13.14 Integration; Severability
	 	 	71	 
	13.15 Further Assurances
	 	 	72	 






Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




iii









 






	 	 	 
	List of Schedules	 	 
	 
	Schedule 1

	 	Optimized Lead Compound Selection Criteria
	Schedule 2A

	 	Program Targets
	Schedule 2B

	 	Target Replacement List
	Schedule 3

	 	Licensed Patent Rights
	Schedule 4

	 	Excluded Aptamers
	Schedule 5

	 	Excluded Targets
	Schedule 6

	 	Development Candidate Selection Criteria
	Schedule 7

	 	Form of Press Release
	Schedule 8

	 	Regional Offices or Countries in which Patent Applications are to be Nationalized or
Otherwise Prosecuted, Filed and Maintained
	Schedule 9

	 	Material Terms to be Included in Form of Co-Promotion Agreement
	Schedule 10

	 	Merck’s Standard Exchange Rate Methodology Applied In Its External Reporting
	Schedule 11

	 	Program Chemistries







Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




iv









 








COLLABORATIVE RESEARCH AND LICENSE AGREEMENT




     This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of
January 17, 2007, by and between Archemix Corp., a Delaware corporation with offices at 300 Third
Street, Cambridge, MA 02142 (“ARCHEMIX”), and Merck KGaA, a company organized under the laws of
Germany with offices at Frankfurter Str. 250, 64293 Darmstadt, Germany (“MERCK”). Each of MERCK
and ARCHEMIX is sometimes referred to individually herein as a “Party” and collectively as the
“Parties.”



     WHEREAS, ARCHEMIX has developed and controls certain technology, patent rights and proprietary
materials related to (a) the identification and optimization of aptamers using its proprietary
SELEXTM process and SELEXTM technology, and (b) the use of such aptamers for treating, preventing or
delaying onset or progression of human diseases or conditions; and



     WHEREAS, MERCK is engaged in the research, development and commercialization of human
therapeutics; and



     WHEREAS, the Parties desire to enter into a collaboration for the purposes of identifying
aptamers against certain identified targets, and developing and commercializing products derived
from such aptamers for the prevention, treatment and delay of onset or progression of cancer.



     NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good
and valuable consideration, the Parties hereto, intending to be legally bound, hereby agree as
follows:



1. DEFINITIONS




     Whenever used in this Agreement with an initial capital letter, the terms defined in this
Section 1 and in Schedule 9 attached hereto shall have the meanings specified.



     1.1 “Adverse Event” means any untoward, undesired or unplanned medical occurrence in a
human clinical trial subject or a patient, which occurrence has a temporal relationship to
administration of a Development Candidate or Product, whether or not considered related to the
Development Candidate or Product, including, without limitation, any undesirable sign (including
abnormal laboratory findings of clinical concern), symptom or disease associated with the use of
such Development Candidate or Product.



     1.2 “Affiliate” means, with respect to any Person, any other Person that, directly or
indirectly through one or more affiliates, controls, or is controlled by, or is under common
control with, such Person. For purposes of this definition, “control” means (a) ownership of fifty
percent (50%) or more of the shares of stock entitled to vote for the election of directors in the
case of a corporation, or fifty percent (50%) or more of the equity interests in the case of any
other type of legal entity, (b) status as a general partner in any partnership, or (c) any other
arrangement whereby a Person controls or has the right to control the board of directors of a
corporation or equivalent governing body of an entity other than a corporation.



     1.3 “Annual Development Plan” means, with respect to each Optimized Lead Compound and
Development Candidate and Contract Year, the written plan for the Development



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.














 




Program for such Optimized Lead Compound and Development Candidate for such Contract Year, as
such written plan may be amended, modified or updated, as further described in Section 4.3.




     1.4 “Annual Net Sales” means, with respect to any Calendar Year, the aggregate amount
of the Net Sales for such Calendar Year.



     1.5 “Annual Research Plan” means the written plan describing the research activities
to be carried out by each Party during each Contract Year of the Research Program Term in
conducting the Research Program pursuant to this Agreement as well as a budget therefore, as such
written plan may be amended, modified or updated, as further described in Section 3.2.



     1.6 “Applicable Laws” means Federal, state, local, national and supra-national laws,
statutes, rules and regulations, including any rules, regulations, guidance, guidelines or
requirements of Regulatory Authorities, national securities exchanges or securities listing
organizations, that are in effect from time to time during the Term and apply to a particular
activity hereunder.



     1.7 “Aptamer” means (a) any naturally or non-naturally occurring oligonucleotide
identified by ARCHEMIX through the SELEX® Process that binds with high specificity and
affinity to a Target; and (b) any oligonucleotide Derived from the oligonucleotide of (a) that has
such high specifity and affinity.



     1.8 “ARCHEMIX Background Technology” means any Technology that is used by ARCHEMIX, or
provided by ARCHEMIX for use, in the Research Program and/or the Development Program that is (a)
Controlled by ARCHEMIX as of the Effective Date or (b) conceived or first reduced to practice by
employees of, or consultants to, ARCHEMIX after the Effective Date other than in the conduct of
ARCHEMIX Research Activities or ARCHEMIX Development Activities and without the use in any material
respect of any MERCK Technology (other than Collaboration Aptamers), MERCK Patent Rights or MERCK
Materials. For purposes of clarity, ARCHEMIX Background Technology (a) shall include the
SELEX® Process and SELEX® Technology and (b) shall not include Collaboration
Aptamers, ARCHEMIX Program Technology or ARCHEMIX’s interest in Joint Technology.



     1.9 “ARCHEMIX Decision” means a decision with respect to the following issues: (a)
the conduct of the [***] against [***]; (b) whether ARCHEMIX is to incur any [***]; (c) whether
ARCHEMIX is to be obligated to perform any [***]; (d) whether ARCHEMIX is to incur any [***] in the
performance of [***] or [***]; (e) the expansion, at MERCK’s request, of the number of FTEs to be
provided by ARCHEMIX under the Research Program beyond [***] in any [***]; and (f) the inclusion of
any [***] MERCK as [***] Program Target.



     1.10 “ARCHEMIX Development Activities” means all Development activities specified to
be conducted by ARCHEMIX in any Annual Development Plan (or amendment thereto) and approved by
ARCHEMIX’s representatives on the JPT and JSC (without resort to the dispute resolution procedures
set forth in Section 2.1.6).



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




2









 





     1.11 “ARCHEMIX-Gilead License Agreement” means the License Agreement between Gilead
Sciences, Inc. and ARCHEMIX dated October 21, 2001, as amended.



     1.12 “ARCHEMIX Materials” means any Proprietary Materials that are Controlled by
ARCHEMIX and used by ARCHEMIX, or provided by ARCHEMIX for use, in the Research Program and/or the
Development Program. For purposes of clarity, ARCHEMIX Materials shall include all Aptamers
provided by ARCHEMIX for use in the Research Program.



     1.13 “ARCHEMIX Patent Rights” means any Patent Rights Controlled by ARCHEMIX that
contain one or more claims that cover ARCHEMIX Technology.



     1.14 “ARCHEMIX Program Technology” means (a) any oligonucleotide of an Enriched Pool
that is not a Program Oligonucleotide; (b) any Program Technology that is conceived or first
reduced to practice by employees of, or consultants to, ARCHEMIX, alone or jointly with any Third
Party, without the use in any material respect of any MERCK Technology (other than Collaboration
Aptamers), MERCK Patent Rights, MERCK Materials or Joint Technology; and (c) any Program
Technology, regardless of whether conceived or first reduced to practice by employees of, or
consultants to, ARCHEMIX, MERCK, or both Parties, alone or jointly with any Third Party, that
relates to, or constitutes, the SELEX® Process or SELEX® Technology. For
purposes of clarity, ARCHEMIX Program Technology does not include Program Generic Technology,
Program Aptamer-Specific Technology and/or Development Program Technology.



     1.15 “ARCHEMIX Research Activities” means all activities specified to be conducted by
ARCHEMIX in any Annual Research Plan (or amendment thereto) that are (a) approved by the JPT and
the JSC and (b) to the extent involving matters that are ARCHEMIX Decisions, approved by ARCHEMIX
in accordance with Section 2.1.6.



     1.16 “ARCHEMIX Technology” means, collectively, ARCHEMIX Background Technology and
ARCHEMIX Program Technology.



     1.17 “Calendar Quarter” means each successive period of three (3) consecutive calendar
months commencing on January 1, April 1, July 1 or October 1, as the case may be, and ending on
March 31, June 30, September 30 or December 31, respectively; provided, that, the initial Calendar
Quarter shall commence on the Effective Date and end on March 31, 2007.



     1.18 “Calendar Year” means each successive period of twelve (12) months commencing on
January 1 and ending on December 31.



     1.19 “Change of Control” means, with respect to a Party, (a) a merger, consolidation,
share exchange or other similar transaction involving such Party and any Third Party which results
in the holders of the outstanding voting securities of such Party immediately prior to such merger,
consolidation, share exchange or other similar transaction ceasing to hold more than fifty percent
(50%) of the combined voting power of the surviving, purchasing or continuing entity immediately
after such merger, consolidation, share exchange or other similar transaction, (b) any transaction
or series of related transactions (other than an investment transaction by an entity



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




3









 







not engaged in the pharmaceutical or biotechnology business, the purpose of which is to raise
capital for a Party) in which a Third Party, together with its Affiliates, becomes the beneficial
owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of
such Party, or (c) the sale or other transfer to a Third Party of all or substantially all of such
Party’s assets which relate to this Agreement.



     1.20 “Collaboration” means the alliance of ARCHEMIX and MERCK established pursuant to
this Agreement for the purposes of identifying, researching and Developing Development Candidates
and Commercializing Products in the Field in the Territory.



     1.21 “Collaboration Aptamer” means, collectively, Program Oligonucleotides, Program
Aptamers, Lead Compounds, Optimized Lead Compounds, Development Candidates and/or Products.



     1.22 “Combination Product” means a combination or bundled product that is sold
together in a single package or as a unit at a single price by a Party, its Affiliates or
sublicensees (or Sublicensees, as the case may be) and that includes: (a) a Product; and (b) a
Supplemental Product that is not within the Licensed Patent Rights, where both the Product and the
Supplemental Product are required to treat the intended Indication and/or to achieve the intended
use or effect.



     1.23 “Commercialization” or “Commercialize” means any and all activities
directed to the commercialization of a Product after Commercialization Regulatory Approval has been
obtained, including marketing, manufacturing for commercial sale, promoting, detailing,
distributing, offering to sell and selling a Product, importing a Product for sale, conducting
post-marketing human clinical studies and interacting with Regulatory Authorities regarding the
foregoing. When used as a verb, “to Commercialize” and “Commercializing” means to engage in
Commercialization and “Commercialized” has a corresponding meaning.



     1.24 “Commercially Reasonable Efforts” means (a) with respect to activities of
ARCHEMIX in the Research Program, or, with respect to the conduct of ARCHEMIX Development
Activities, if any, or, with respect to activities of ARCHEMIX in the Commercialization of a Waived
Compound which is the subject of a transition plan pursuant to Section 7.1.2(c), the efforts and
resources comparable to those undertaken by ARCHEMIX in pursuing the research, discovery,
development, commercialization and intellectual property protection of proprietary materials and
the development of product candidates, as applicable, that are not subject to the Collaboration and
that are at an equivalent stage of development or commercialization and have similar market
potential and are at a similar stage in their lifecycle, and (b) with respect to activities of
MERCK in the Research Program, the Development of a particular Development Candidate or the
Commercialization of a particular Product, the efforts and resources comparable to those undertaken
by MERCK in pursuing intellectual property protection and development of product candidates and
commercialization of products, as applicable, that are not subject to the Collaboration and that
are at an equivalent stage of development or commercialization and have similar market potential
and are at a similar stage in their lifecycle. For purposes of both (a) and (b) above, all
relevant factors as measured by the facts and circumstances at the time such efforts are due shall
be taken into account, including, as



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




4









 







applicable and without limitation, mechanism of action; efficacy and safety; product profile;
actual or anticipated Regulatory Authority approved labeling; and the nature and extent of market
exclusivity (including patent coverage, proprietary position and regulatory exclusivity; cost, time
required for and likelihood of obtaining Commercialization Regulatory Approval; competitiveness of
alternative products and market conditions; actual or projected profitability and availability of
capacity to manufacture and supply for commercial sale).



     1.25 “Commercialization Regulatory Approval” means, with respect to any Product, the
Regulatory Approval required by Applicable Laws to sell such Product for use in the Field in a
country or region in the Territory. “Commercialization Regulatory Approval” shall include, without
limitation, the approval of any Drug Approval Application. For purposes of clarity,
“Commercialization Regulatory Approval” in the United States shall mean final approval of an NDA
for the first Indication or sNDA for an additional Indication permitting marketing of the
applicable Product in interstate commerce in the United States, “Commercialization Regulatory
Approval” in the European Union shall mean marketing authorization for the applicable Product
pursuant to Council Directive 2001/83/EC, as amended, or Council Regulation 2309/93/EEC, as amended
and “Commercialization Regulatory Approval” in Japan shall mean final approval of an application
submitted to the Ministry of Health, Labor and Welfare and the publication of a New Drug Approval
Information Package permitting marketing of the applicable Product in Japan, as any of the
foregoing may be amended from time to time.



     1.26 “Competitive Entity” means any Third Party in the top [***] companies ranked by
[***] in the most recently completed Calendar Year for which such ranking is readily available from
an unaffiliated Third Party.



     1.27 “Competitive Program” means any research, development or commercialization
activity that involves an Aptamer that targets a Program Target for use in the Field.



     1.28 “Confidential Information” means (a) with respect to ARCHEMIX, all tangible
embodiments of ARCHEMIX Technology, (b) with respect to MERCK, all tangible embodiments of MERCK
Technology and (c) with respect to each Party, (i) all tangible embodiments of Joint Technology and
(ii) all information, Technology and Proprietary Materials disclosed or provided by or on behalf of
such Party (the “disclosing Party”) to the other Party (the “receiving Party”) or to any of the
receiving Party’s employees, consultants, Affiliates or sublicensees (or Sublicensees, as the case
may be); provided, that, none of the foregoing shall be Confidential Information if: (A) as of the
date of disclosure, it is known to the receiving Party or its Affiliates as demonstrated by
contemporaneous credible written documentation, other than by virtue of a prior confidential
disclosure to such receiving Party; (B) as of the date of disclosure it is in the public domain, or
it subsequently enters the public domain through no fault of the receiving Party; (C) it is
obtained by the receiving Party from a Third Party having a lawful right to make such disclosure
free from any obligation of confidentiality to the disclosing Party; or (D) it is independently
developed by or for the receiving Party without reference to or use of any Confidential Information
of the disclosing Party as demonstrated by contemporaneous credible written documentation. For
purposes of clarity, unless excluded from Confidential Information pursuant to the proviso at the
end of the preceding sentence, any scientific, technical or financial information of a Party that
is disclosed at any meeting of the JSC, JPT or JMC or disclosed



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




5









 







through an audit report shall constitute Confidential Information of the disclosing Party.
Notwithstanding anything herein to the contrary, the terms of this Agreement shall constitute
Confidential Information of each Party.



     1.29 “Contract Year” means (a) the period beginning on the Effective Date and ending
on the first anniversary of the last day of the calendar month in which the Effective Date falls
and (b) each succeeding twelve (12) month period thereafter.



     1.30 “Control” or “Controlled” means (a) with respect to Technology or Patent
Rights, the possession by a Party of the right to grant a license or sublicense to such Technology
or Patent Rights as provided herein without the payment of additional consideration to, and without
violating the terms of any agreement or arrangement with, any Third Party and without violating any
Applicable Laws and (b) with respect to Proprietary Materials, the possession by a Party of the
right to supply such Proprietary Materials to the other Party as provided herein without the
payment of additional consideration to, and without violating the terms of, any agreement or
arrangement with any Third Party, and without violating any Applicable Laws.



     1.31 “CTN” means the notification submitted to the Japanese Ministry of Health, Labor
and Welfare prior to the Initiation of a clinical trial in Japan.



     1.32 “Derived” means identified, obtained, developed, created, synthesized, generated,
designed or resulting from, based upon, containing or incorporating; conjugated to or complexed
with (whether directly or indirectly, or in whole or in part).



     1.33 “Detail” means, with respect to a Co-Promoted Product, an interactive, live,
face-to-face contact of a Representative within the Co-Promotion Territory with a medical
professional with prescribing authority or other individuals or entities that have a significant
impact or influence on prescribing decisions, in an effort to increase physician prescribing
preferences of such Co-Promoted Product for its approved uses within the Co-Promotion Territory.
When used as a verb, “Detailing” means performing Details. When used as an adjective, “Detailing”
means of or related to performing Details.



     1.34 “Development” or “Develop” means, with respect to each Optimized Lead
Compound and Development Candidate, all non-clinical and clinical activities performed in order to
obtain Regulatory Approval of a Product Derived from such Optimized Lead Compound or Development
Candidate in accordance with this Agreement up to and including the obtaining of Commercialization
Regulatory Approval of such Product. For purposes of clarity, these activities include, without
limitation, in vivo animal efficacy testing, preclinical safety testing, test method development
and stability testing, regulatory toxicology studies, formulation, process development,
manufacturing, manufacturing scale-up, development-stage manufacturing, quality assurance/quality
control development, statistical analysis and report writing, clinical trial design and operations,
preparing and filing Drug Approval Applications, and all regulatory affairs related to the
foregoing. When used as a verb, “Developing” means to engage in Development and “Developed” has a
corresponding meaning.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




6









 





     1.35 “Development Candidate” means any Optimized Lead Compound that the JPT nominates
and the JSC accepts as a Development Candidate as set forth in Section 3.7 and for which MERCK has
paid the Development Candidate Milestone Payment in the time allotted for such payment in Section
5.4.1; provided, that, no Collaboration Aptamer shall, after [***], be nominated or accepted as a
Development Candidate.



     1.36 “Development Candidate Milestone Payment” means the payment to be made to
ARCHEMIX upon occurrence of Milestone 2 pursuant to Section 5.4.1.



     1.37 “Development Candidate Selection Criteria” or “DCSC” means the guideline
criteria for selecting Optimized Lead Compounds that are sufficiently promising to warrant further
Development as Development Candidates as set forth in Schedule 6 attached hereto, as such
Schedule 6 shall be amended from time to time by the JSC, which amendment shall occur
before any activities with respect to such Development Candidate are initiated, in any material
respect, in the Development Program.



     1.38 “Development Program” means the Development activities to be conducted during the
Term with respect to each Optimized Lead Compound and Development Candidate pursuant to the Annual
Development Plan, with the objective of developing such Optimized Lead Compound or Development
Candidate into a Product.



     1.39 “Development Program Technology” means any Technology that is first conceived or
reduced to practice within the Development Program including but not limited to a process for
modifying, optimizing, using, formulating, delivering and/or stabilizing a Collaboration Aptamer.



     1.40 “Diagnosis” means (a) the determination or monitoring of (i) the presence or
absence of a disease, (ii) the stage, progression or severity of a disease or (iii) the effect on a
disease of a particular treatment; and/or (b) the selection of patients for a particular treatment
with respect to a disease.



     1.41 “Diagnostic Product” means In Vitro Diagnostics, In Vivo Diagnostic Agents and
any product used for Diagnosis. For purposes of clarity, the term Diagnostic Product shall not
include a product used for the delay of the onset or progression of, or the treatment or prevention
of, an Indication.



     1.42 “Drug Approval Application” means, with respect to a Product in a particular
country or region, an application for Commercialization Regulatory Approval for such Product in
such country or region, including without limitation: (a) an NDA or sNDA; (b) a counterpart of an
NDA or sNDA in any country or region in the Territory (including, without limitation, a CTN); and
(c) all supplements and amendments to any of the foregoing.



     1.43 “Enriched Pool” means a pool of oligonucleotides used to perform the
SELEX® Process against a Program Target in the performance of the Research Program that
(a) has undergone [***] or more [***] of [***] and (b) wherein, using an [***] with
[***] of [***] (i.e., [***]) and [***] of the applicable Program Target, at least [***]% of the
input pool of [***] is



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




7









 




[***] in the assay by the Program Target and the [***] fraction of the [***] pool is at least
[***] relative to the [***] fraction for [***] (i.e., [***]) pool of [***].




     1.44 “Effective Date” means the date first set forth above.



     1.45 “Excepted Decision” means any of the following decisions requiring the unanimous
approval of all members of the JSC: (a) any decision as to whether a milestone has been achieved
under this Agreement for which a milestone payment is payable; and (b) any decision as to whether a
proposed Target is a [***].



     1.46 “Excluded Aptamer” means any Aptamer listed on Schedule 4 attached
hereto.



     1.47 “Excluded Target” means any Target listed on Schedule 5 attached hereto.



     1.48 “Failed Compound” means any Collaboration Aptamer directed against a Failed
Target.



     1.49 “Failed Target” means (a) any Program Target as to which the JPT concludes and
the JSC agrees, that ARCHEMIX is unable or unlikely to identify [***] Program Target, (b) any
Program Target for which ARCHEMIX fails to identify [***]; (c) any Program Target for which MERCK
discontinues Development of [***], provided, that, at such time no other [***] for such Program
Target are in Development, and (d) any Program Target for which [***] meeting the applicable [***]
exists and for which MERCK has not [***] the [***] in the time allotted for such [***] in Section
5.4.1. For purposes of clarity, a Failed Target shall not be considered a Program Target.



     1.50 “FDA” means the United States Food and Drug Administration or any successor
agency or authority thereto.



     1.51 “FDCA” means the United States Federal Food, Drug, and Cosmetic Act, as amended.



     1.52 “Field” means [***]. For purposes of clarity, the Field shall not include the
research, development, manufacture, use or sale of Diagnostic Products or Radio Therapeutics.



     1.53 “First Commercial Sale” means, with respect to a Product in a country in the
Territory, the first sale, transfer or disposition for value or for an end user of such Product in
such country.



     1.54 “Force Majeure” means any occurrence beyond the reasonable control of a Party
that (a) prevents or substantially interferes with the performance by such Party of any of its
obligations hereunder and (b) occurs by reason of any act of God, flood, fire, explosion,
earthquake, strike, lockout, labor dispute, casualty or accident, or war, revolution, civil
commotion, act of terrorism, blockage or embargo, or any injunction, law, order, proclamation,
regulation, ordinance, demand or requirement of any government or of any subdivision, authority or
representative of any such government.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




8









 





     1.55 “FTE” shall mean [***] hours of work devoted to or in support of the ARCHEMIX
Research Activities or the ARCHEMIX Development Activities that is carried out by one or more
appropriately trained employees of ARCHEMIX, measured in accordance with ARCHEMIX’s time allocation
practices from time to time.



     1.56 “FTE Cost” means, for any period, the applicable FTE Rate multiplied by the
applicable number of FTEs in such period.



     1.57 “FTE Rate” means (a) for the [***] Contract Year, [***] Dollars (US $[***]); (b)
for the [***] Contract Year, [***] Dollars (US $[***]); (c) for the [***] Contract Year, [***]
Dollars (US $[***]); (d) for each FTE or portion thereof greater than [***] in [***] Contract Year
during the Research Program Term, [***] Dollars (US $[***]); and (e) for [***] Contract Year on and
after the expiration of the Research Program Term, an amount per Contract Year to be determined by
multiplying [***] Dollars (US $[***]) by the [***] in the Consumer Price Index since the Effective
Date ([***] for all items; [***]; available at [***] and adding or subtracting the product of such
multiplication to or from [***] Dollars (US $[***]). The FTE rate includes all salary, employee
benefits, materials and all other expenses including support staff and overhead for or associated
with ARCHEMIX scientists performing activities but does not include Third Party Costs as set forth
in Section 5.3.3.



     1.58 “GAAP” means United States generally accepted accounting principles, consistently
applied.



     1.59 “Hatch-Waxman Act” means the Drug Price Competition and Patent Term Restoration
Act of 1984, as amended.



     1.60 “ICC” means the International Chamber of Commerce in Paris, France.



     1.61 “IND” means: (a) an Investigational New Drug Application as defined in the FDCA
and regulations promulgated thereunder or any successor application or procedure required to
initiate clinical testing of a Development Candidate in humans in the United States; (b) a
counterpart of an Investigational New Drug Application that is required in any other country or
region in the Territory before beginning clinical testing of a Development Candidate in humans in
such country or region; and (c) all supplements and amendments to any of the foregoing.



     1.62 “Indication” means any human indication, disease or condition in the Field, which
can be treated, prevented, cured or the progression of which can be delayed. For purposes of
clarity, distinctions between human indications, diseases or conditions with respect to a Product
shall be made by reference to the World Health Organization International Classification of
Diseases, version 10 (as revised and updated, “ICD10”).



     1.63 “Initiation” means, with respect to a human clinical trial, the first date that a
subject or patient is dosed in such clinical trial.



     1.64 “In Vitro Diagnostics” means the use of the SELEX® Process or Aptamers
or PhotoAptamers identified through the use of the SELEX® Process in the assay, testing
or



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




9









 







determination, outside of a living organism, of a substance in a test material. In Vitro
Diagnostics shall include, among other things, the use of the SELEX® Process or Aptamers
or PhotoAptamers identified through the use of the SELEX® Process in the assay, testing
or determination: (a) outside of a living organism, (i) of a human substance in a test material,
often to identify or follow the progression of a disease or disorder, or to select a patient for
treatment; (ii) of a plant substance, animal substance or other substance in a test material, often
to identify or follow the progression of a disease, process, or disorder in a human or non-human
organism; and (iii) of environmental substances (as in water quality testing); and (b) of a
substance on a test material such as cells (as in FACS analysis or other measurements of pathogens
within biological samples).



     1.65 “In Vivo Diagnostic Agent” means any product containing one or more Aptamers that
is used for any human in vivo diagnostic purpose related to (inter alia) the identification,
quantification or monitoring of the propensity toward, or actual existence of, any disease state.



     1.66 “Joint Patent Rights” means Patent Rights that contain one or more claims that
cover Joint Technology.



     1.67 “Joint Project Team” or “JPT” means the committee composed of ARCHEMIX
and MERCK representatives established pursuant to Section 2.2.



     1.68 “Joint Steering Committee” or “JSC” means the committee composed of
ARCHEMIX and MERCK representatives established pursuant to Section 2.1.



     1.69 “Joint Technology” means (a) all Program Generic Technology and (b) any Program
Technology other than Program Aptamer-Specific Technology, that is (i) jointly conceived or reduced
to practice by employees of or consultants to MERCK and employees of or consultants to ARCHEMIX or
(ii) conceived or reduced to practice solely by employees of or consultants to a Party with the use
in any material respect of any Technology, Patent Rights or Proprietary Materials of the other
Party. For the avoidance of doubt, any Program Technology that relates to the SELEX®
Process or to the SELEX® Technology shall not be considered Joint Technology
irrespective of which Party conceived or reduced to practice such improvement.



     1.70 “Knowledge” means, with respect to a Party, the actual knowledge of any employee
of such Party.



     1.71 “Lead Compound” means any Program Aptamer that [***] Program Target that is first
identified in the conduct of the Research Program or Development Program, or any Aptamer [***]
first identified in the conduct of the Research Program or Development Program that [***] Program
Target; provided, that, no Collaboration Aptamer shall, after [***], be nominated or designated as
a Lead Compound.



     1.72 “Licensed Patent Rights” means any ARCHEMIX Patent Rights and ARCHEMIX’s interest
in Joint Patent Rights that (a) contain one or more claims that cover any Collaboration Aptamer,
including its manufacture or its formulation or a method of its delivery



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




10









 







or of its use, or (b) are necessary for MERCK to exercise the licenses granted to it pursuant
to Sections 7.1 and 7.2. For purposes of clarity, Licensed Patent Rights existing as of the
Effective Date include those listed on Schedule 3 attached hereto.



     1.73 “Licensed Technology” means any ARCHEMIX Technology and ARCHEMIX’s interest in
Joint Technology that (a) relates to any Collaboration Aptamer, including its manufacture or its
formulation or a method of its delivery or of its use, and (b) is necessary for MERCK to exercise
the licenses granted to it pursuant to Sections 7.1 and 7.2.



     1.74 “Major Market Country” means each of the [***] and [***].



     1.75 “MERCK Background Technology” means any Technology that is used by MERCK, or
provided by MERCK for use, in the Research Program and/or Development Program that is (a)
Controlled by MERCK as of the Effective Date or (b) conceived or first reduced to practice by
employees of, or consultants to, MERCK after the Effective Date other than in the conduct of MERCK
Research Activities or MERCK Development Activities and without the use in any material respect of
any Collaboration Aptamers, ARCHEMIX Technology, ARCHEMIX Patent Rights, or ARCHEMIX Materials.
For purposes of clarity, MERCK Background Technology shall not include MERCK Program Technology or
MERCK’s interest in Joint Technology.



     1.76 “MERCK Development Activities” means all Development activities specified to be
conducted by MERCK in any Annual Development Plan (or amendment thereto).



     1.77 “MERCK Materials” means any Proprietary Materials that are Controlled by MERCK
and used by MERCK, or provided by MERCK for use, in the Research Program and/or the Development
Program.



     1.78 “MERCK Patent Rights” means any Patent Rights Controlled by MERCK that contain
one or more claims that cover MERCK Technology.



     1.79 “MERCK Program Technology” means (a) any Program Technology that (i) is not
ARCHEMIX Program Technology or Joint Technology and (ii) is conceived or first reduced to practice
by employees of, or consultants to, MERCK, alone or jointly with any Third Party, without the use
in any material respect of any ARCHEMIX Technology, ARCHEMIX Patent Rights, ARCHEMIX Materials or
Joint Technology; (b) any Program Aptamer-Specific Technology; and (c) any Development Program
Technology.



     1.80 “MERCK Research Activities” means all activities specified to be conducted by
MERCK in any Annual Research Plan (or amendment thereto) that are approved by the JPT and JSC.



     1.81 “MERCK Technology” means, collectively, MERCK Background Technology and MERCK
Program Technology.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




11









 





     1.82 “Minimum FTE Funding Commitment” means the funding of at least [***] ARCHEMIX
FTEs at the applicable FTE Rate for each Contract Year during the Research Program Term.



     1.83 “NDA” means a New Drug Application, as defined in the FDCA and regulations
promulgated thereunder or any successor application or procedure required to sell a Product in the
United States.



     1.84 “Net Sales” means the gross amount billed or invoiced by MERCK or any of its
Affiliates or Sublicensees to Third Parties throughout the Territory for sales or other
dispositions or transfers for value of Products less (a) allowances for normal and customary trade,
quantity and cash discounts actually allowed and taken, (b) transportation, insurance and postage
charges, if prepaid by MERCK or any Affiliate or Sublicensee of MERCK and included on any such
party’s bill or invoice as a separate item, (c) credits, rebates, returns pursuant to agreements
(including, without limitation, managed care agreements) or government regulations, to the extent
actually allowed, and (d) sales, use and other consumption taxes similarly incurred to the extent
included on the bill or invoice as a separate item. In addition, Net Sales are subject to the
following:


If MERCK or any of its Affiliates or Sublicensees effects a sale, disposition or transfer of a
Product to a customer in a particular country other than on customary commercial terms or as part
of a package of products and services, the Net Sales of such Product to such customer shall be
deemed to be “the fair market value” of such Product. For purposes of this subsection, “fair
market value” shall mean the value that would have been derived had such Product been sold as a
separate product to another customer in the country concerned on customary commercial terms.



In the case of pharmacy incentive programs, hospital performance incentive program chargebacks,
disease management programs, similar programs or discounts on “bundles” of products, all discounts
and the like shall be allocated among products on the basis on which such discounts and the like
were actually granted or, if such basis cannot be determined, in proportion to the respective list
prices of such products or such other reasonable allocation method as the Parties shall agree.



For purposes of clarity, use of any Product in clinical trials, pre-clinical studies or other
research or development activities, or disposal or transfer of Products for a bona fide charitable
purpose or a commercially reasonable sampling program, shall not give rise to any Net Sales.




     1.85 “Optimized Lead Compound” means any [***] Compound that the JPT nominates and the
JSC accepts as meeting the OLSC for such Program Target; provided, that, no [***] shall, after
becoming a [***], be nominated or designated as an Optimized Lead Compound.



     1.86 “Optimized Lead Compound Selection Criteria” or “OLSC” means the
guideline criteria for selecting Lead Compounds that are sufficiently promising to warrant further
research as an Optimized Lead Compound as set forth in Schedule 1 attached hereto, as such
Schedule 1 may be amended from time to time by the JSC, which amendment shall occur before



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




12









 







any research activities are initiated with respect to such Optimized Lead Compound against the
applicable Program Target. Notwithstanding anything to the contrary set forth in Schedule
1, for purposes of determining whether a Lead Compound has been designated as an Optimized Lead
Compound for Milestone 1 in Section 5.4.1, [***] shall be required to be performed with respect to
such Lead Compound, whether or not included as part of the OLSC.



     1.87 “Patent Rights” means the rights and interests in and to issued patents and
pending patent applications (which, for purposes of this Agreement, include certificates of
invention, applications for certificates of invention and priority rights) in any country or
region, including all provisional applications, substitutions, continuations,
continuations-in-part, divisions, renewals, all letters patent granted thereon, and all reissues,
re-examinations and extensions thereof, and all foreign counterparts of any of the foregoing.



     1.88 “Permitted Screening Activities” means, [***] to any [***], any [***] ARCHEMIX
[***] to such [***] for [***] and/or for [***] for the [***] of [***] Aptamers [***] bind to a
[***] a [***].



     1.89 “Person” means an individual, sole proprietorship, partnership, limited
partnership, limited liability partnership, corporation, limited liability company, business trust,
joint stock company, trust, incorporated association, joint venture or similar entity or
organization, including a government or political subdivision, department or agency of a
government.



     1.90 “Phase I Clinical Trial” means a clinical trial conducted in healthy humans or
patients, which clinical trial is designed to establish the safety, drug-drug interactions and/or
pharmacokinetics of an investigational drug given its intended use, and to support continued
testing of such drug in Phase II Clinical Trials.



     1.91 “Phase II Clinical Trial” means a clinical trial conducted in patients with a
particular disease or condition, which clinical trial is designed to establish the safety,
appropriate dosage and pharmacological activity of an investigational drug given its intended use,
and to initially explore its efficacy for such disease or condition.



     1.92 “Phase III Clinical Trial” means a pivotal clinical trial conducted in patients
with a particular disease or condition, which clinical trial is designed to ascertain efficacy and
safety of an investigational drug for its intended use and to define warnings, precautions and
Adverse Events that are associated with the Development Candidate in the dosage range intended to
be prescribed, with the purpose of preparing and submitting applications for Regulatory Approval or
label expansion to the pertinent Regulatory Authority in any country.



     1.93 “Product” means any pharmaceutical or medicinal item, substance or formulation
that contains, incorporates or comprises a Collaboration Aptamer or any Aptamer Derived therefrom
that binds a Program Target. Notwithstanding the above, if a first pharmaceutical or medicinal
item, substance or formulation is deemed to be a Product for purposes of this Agreement, any
subsequent pharmaceutical or medicinal item, substance or formulation will be considered to be an
additional Product for purposes of this Agreement only



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




13









 







to the extent that it is a new chemical entity (as defined by the FDCA) with respect to the
existing Product(s).



     1.94 “Product Commercialization Plan” means, with respect to each Product, the written
plan for the Commercialization of such Product in the Territory (including, without limitation,
expected manufacturing scale-up, manufacture, formulation and filling requirements for such Product
and a detailed strategy, budget and proposed timelines), as such plan may be amended or updated.



     1.95 “Product Trademark” means any trademark or trade name, whether or not registered,
or any trademark application or renewal, extension or modification thereof, in the Territory, or
any trade dress and packaging, in each case (a) that are applied to or used with any Product by
MERCK and (b) together with all goodwill associated therewith and promotional materials relating
thereto.



     1.96 “Program Aptamer” means any [***] that is an [***] that [***] and that is first
identified in the performance of the Research Program or during Development and/or any [***] that
[***] that is [***] from such [***] and that is first identified in the performance of the Research
Program or during Development.



     1.97 “Program Aptamer-Specific Patent Rights” means all Patent Rights that cover only
Program Aptamer-Specific Technology.



     1.98 “Program Aptamer-Specific Technology” means any Program Technology that relates
specifically to (a) any Collaboration Aptamer or (b) the manufacture, formulation, delivery,
production or use of a Collaboration Aptamer.



     1.99 “Program Generic Patent Rights” means Patent Rights that cover only Program
Generic Technology.



     1.100 “Program Generic Technology” means any Program Technology that relates generally
to the manufacture, formulation, delivery, production or use of Aptamers.



     1.101 “Program Oligonucleotide” means the [***] and [***] obtained from an [***] and
[***] and [***] in the performance of the [***] against a [***] that is not a [***].



     1.102 “Program Target” means the Targets listed on Schedule 2A attached
hereto, as amended from time to time in accordance with Section 3.5.



     1.103 “Program Technology” means any Technology (including, without limitation, any
new and useful process, method of manufacture or composition of matter) or Proprietary Materials
that are conceived or first reduced to practice (actively or constructively) by either Party in the
conduct of the Research Program.



     1.104 “Proprietary Materials” means tangible chemical, biological or physical
materials (a) that are furnished by or on behalf of one Party to the other Party in connection with
this Agreement, whether or not specifically designated as proprietary by the Transferring Party



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




14









 







or (b) that are otherwise conceived or reduced to practice in the conduct of the Research
Program or the Development Program.



     1.105 “Quarterly FTE Payment” means the minimum amount payable by MERCK to ARCHEMIX
for FTEs during each Calendar Quarter of the Research Program Term pursuant to Section 5.3, which
shall equal the greater of: (a) $[***] per Calendar Quarter in the [***] Contract Year, $[***] per
Calendar Quarter in the [***] Contract Year, and $[***] per Calendar Quarter in the [***] Contract
Year; or (b) the estimated FTE Cost as set forth in the Annual Research Plan for such Calendar
Quarter.



     1.106 “Radio Therapeutic” means any product for human therapeutic use that contains
one or more Aptamers that targets specifically any diseased tissue, cells or disease-specific
molecules or any tissue or cells which are affected by a disease or located in the close
neighborhood of a disease process and is linked to or incorporates (a) radionucleotides or (b) any
structure or elements which develop therapeutic effects similar to the effect of linking or
incorporating radionucleotides after submission of any kind of radiation.



     1.107 “Regulatory Approval” means, with respect to any country or region in the
Territory, any approval, product and establishment license, registration or authorization of any
Regulatory Authority required for the manufacture, use, storage, importation, exportation,
distribution, transport or sale of a Product for use in the Field in such country or region.



     1.108 “Regulatory Authority” means the FDA, or any counterpart of the FDA outside the
United States, or any other national, supra-national, regional, state or local regulatory agency,
department, bureau, commission, council or other governmental entity with authority over the
distribution, importation, exportation, manufacture, production, use, storage, transport, clinical
testing or sale of a Product.



     1.109 “Regulatory Filings” means, collectively: (a) all INDs, establishment license
applications, drug master files, applications for designation as an “Orphan Product(s)” under the
Orphan Drug Act, for “Fast Track” status under Section 506 of the FDCA (21 U.S.C. § 356) or for a
Special Protocol Assessment under Section 505(b)(4)(B) and (C) of the FDCA (21 U.S.C. §
355(b)(4)(B)), NDAs and BLAs and all other similar filings (including, without limitation,
counterparts of any of the foregoing in any country or region in the Territory); (b) all
supplements and amendments to any of the foregoing; and (c) all data and other information
contained in, and correspondence relating to, any of the foregoing.



     1.110 “Representative” means an individual (including a medical service liaison, sales
representative or other representative) employed and trained by either Party or employed by a Third
Party or self-employed and trained by or on behalf of a Party, in any case, to Detail a Co-Promoted
Product.



     1.111 “Research Program” means the research program to be conducted by the Parties
during the Research Program Term pursuant to the Annual Research Plan up to and including the
selection of Optimized Lead Compounds from Lead Compounds. For purposes of clarity, the



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




15









 







Research Program does not include any Development activities performed in the course of the
Development Program.



     1.112 “Research Program Term” means the period beginning on the Effective Date and
ending on the last day of the third Contract Year; provided, that, if this Agreement is terminated
prior to the end of the Research Program Term, the effective date of such early termination shall
become the last day of the Research Program Term.



     1.113 “Royalty Term” means, on a Product-by-Product and country-by-country basis, the
period beginning on the date of First Commercial Sale of a Product in a country and ending on the
later to occur of (a) expiration of the last to expire Valid Claim of the Licensed Patent Rights,
Program Aptamer-Specific Patent Rights or Joint Patent Rights in such country that covers such
Product or its identification, manufacture, use, import, offer for sale or sale or (b) (i) with
regard to the first Product for each Program Target sold in such country, fifteen (15) years from
the date of the First Commercial Sale of such first Product in such country or (ii) with regard to
each additional Product for such Program Target sold in such country, ten (10) years from the date
of the First Commercial Sale of each such additional Product in such country.



     1.114 “SELEX® Portfolio” means those Patent Rights licensed by Gilead to
ARCHEMIX pursuant to the ARCHEMIX-Gilead License Agreement.



     1.115 “SELEX® Process” means any process for the identification or
generation of a nucleic acid that binds to a Target by means other than Watson-Crick base-pairing,
including without limitation any such process that (a) is covered by, or is described in, the
SELEX® Portfolio, including without limitation U.S. Patent Nos. [***] or [***] (b) is
covered by, or is described in, any other Patent Rights Controlled by ARCHEMIX, and (c) any
continuations, divisionals and continuations-in part substitutions, renewals, reissues,
re-examinations and extensions of and improvements to the inventions covered by, or described in,
the foregoing Patent Rights.



     1.116 “SELEX® Technology” means (a) generic aptamer compositions and (b)
any process for modifying, optimizing and/or stabilizing an aptamer wherein such modification,
optimization or stabilization includes, without limitation minimization, truncation, conjugation,
pegylation, complexation, substitution, deletion and/or incorporation of modified nucleotides.



     1.117 “sNDA” means a Supplemental New Drug Application, as defined in the FDCA and
applicable regulations promulgated thereunder.



     1.118 “Sublicense Agreement” means any agreement entered into by MERCK with a
Sublicensee.



     1.119 “Sublicensee” means any Third Party to which MERCK grants a sublicense under the
licenses granted to it under Section 7.1 or 7.2.



     1.120 “Supplemental Product” means a product having independent, supplementary or
enabling therapeutic effect (e.g., as a catalyst or adjuvant) or diagnostic utility.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




16









 





     1.121 “Target” means a protein, cytokine, enzyme, receptor, transducer, transcription
factor, antigen or any other non-nucleic acid molecule.



     1.122 “Target Replacement List” means the list of Targets on Schedule 2B
attached hereto, as amended pursuant to Section 3.5.1.



     1.123 “Target Selection Field” means the treatment or prevention in humans of cancer.



     1.124 “Technology” means, collectively, inventions, discoveries, improvements, trade
secrets and proprietary methods, whether or not patentable, including without limitation: (a)
methods of production or use of, and structural and functional information pertaining to, chemical
compounds; and (b) compositions of matter, data, formulations, processes, techniques, know-how and
results (including, without limitation, any negative results).



     1.125 “Terminated Compounds” means (a) all Collaboration Aptamers upon any termination
of this Agreement by ARCHEMIX pursuant to Section 10.2.3 or Section 10.2.2 or by MERCK pursuant to
Section 10.2.1; and (b) the relevant Collaboration Aptamers binding specifically to the Program
Target for which MERCK’s license is terminated by ARCHEMIX pursuant to Section 10.2.2 due to
failure of MERCK to meet its diligence obligations, as provided in Section 10.4.



     1.126 “Territory” means all countries and territories of the world.



     1.127 “Third Party” means a Person other than MERCK and ARCHEMIX and their respective
Affiliates.



     1.128 “URC License Agreement” means the Restated Assignment and License Agreement,
dated July 17, 1991, by and between University Research Corporation and Gilead as successor in
interest to NeXstar.



     1.129 “UTC” means University Technology Corporation, the successor to the University
Research Corporation.



     1.130 “Valid Claim” means any claim of a pending patent application or an issued
unexpired patent that (a) has not been finally cancelled, withdrawn, abandoned or rejected by any
administrative agency or other body of competent jurisdiction, (b) has not been permanently
revoked, held invalid, or declared unpatentable or unenforceable in a decision of a court or other
body of competent jurisdiction that is unappealable or unappealed within the time allowed for
appeal, (c) has not been rendered unenforceable through disclaimer or otherwise, and (d) is not
lost through an interference proceeding.



     1.131 “Waived Compound” means any Collaboration Aptamer directed against a Waived
Target.



     1.132 “Waived Target” means (a) any Program Target for which MERCK, in its sole
discretion, discontinues Development of a Development Candidate; provided, that, no other



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




17









 







Development Candidates for such Program Target are in Development at such time and (b) any
Program Target which MERCK designates as a Waived Target in writing to ARCHEMIX.



     Additional Definitions. In addition, each of the following definitions shall have the
respective meanings set forth in the section of this Agreement indicated below:



	 	 	 	 	 
	Definition	 	Section	 
	Annual Reconciliation Statement
	 	 	5.3.1	 
	ARCHEMIX Change of Control Notice
	 	 	13.2.1(a)	 
	ARCHEMIX Indemnitees
	 	 	12.2	 
	Claims
	 	 	12.1	 
	Collaboration Manager
	 	 	2.2.6	 
	Co-Promote
	 	 	4.9.2(a)	 
	Co Promoted Product
	 	 	4.9.2(a)	 
	Co-Promotion
	 	 	4.9.2(a)	 
	Co-Promotion Agreement
	 	 	4.9.2(a)	 
	Designated Senior Officers
	 	 	2.1.6	 
	Dispute
	 	 	13.1.1	 
	Disputed Matter
	 	 	2.1.6	 
	Expert
	 	 	13.1.2(a)	 
	Filing Party
	 	 	9.1.4	 
	Gilead Indemnitee
	 	 	12.3	 
	Indemnified Party
	 	 	12.4	 
	Indemnifying Party
	 	 	12.4	 
	Infringement
	 	 	9.2.1(a)	 
	Infringement Notice
	 	 	9.2.1(a)	 
	JPT Term
	 	 	2.2.1	 
	JSC Term
	 	 	2.1.1	 
	Losses
	 	 	12.1	 
	MERCK Change of Control Notice
	 	 	13.2.2(a)	 
	MERCK Contribution
	 	 	5.3.1	 
	MERCK Indemnitees
	 	 	12.1	 
	Non-Filing Party
	 	 	9.1.4	 
	Patent Coordinator
	 	 	8.4	 
	Requested Chemistry
	 	 	5.5.1(b)	 
	Recipient Party
	 	 	3.8	 
	Term
	 	 	10.1	 
	Third Party Chemistry Payments
	 	 	5.5.1(b)	 
	Third Party Costs
	 	 	5.3.3	 
	Third Party Payments
	 	 	5.5.1(b)	 
	Transferring Party
	 	 	3.8	 






Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




18









 






2. ADMINISTRATION OF THE COLLABORATION




     2.1 Joint Steering Committee.



          2.1.1 Establishment. Within [***] days from the Effective Date, ARCHEMIX and MERCK
shall establish the Joint Steering Committee. Unless otherwise agreed by the Parties, the term for
the JSC shall commence as of the Effective Date and continue until the last day of the Research
Program Term (“JSC Term”); provided, that, the JSC Term shall be extended in the event that, and
for so long as, the JPT Term is extended or any Co-Promoted Products are being Commercialized. The
JSC shall have and perform the responsibilities set forth in Section 2.1.4.




          2.1.2 Membership. Upon establishment of the JSC, each Party shall designate in
writing, in its sole discretion, [***] members to the JSC, which shall be members of its
management. Unless otherwise agreed by the Parties, one of MERCK’s designees shall be designated
by MERCK as the Chair. Each Party shall have the right at any time to substitute individuals, on a
permanent or temporary basis, for any of its previously designated representatives to the JSC, by
giving written notice to the other Party. Initial designees of the Parties to the JSC shall be
designated by each Party by written notice to the other Party as soon as is reasonably practicable
following the Effective Date.




          2.1.3 Meetings.




               (a) Schedule of Meetings; Agenda. The JSC shall establish a schedule of times for
regular meetings, taking into account the planning needs of the Collaboration and its
responsibilities. In urgent cases, special meetings of the JSC may be convened by any member upon
[***] days (or, if such meeting is proposed to be conducted by teleconference, upon [***] days)
written notice to the other members; provided, that, (i) notice of any such special meeting may be
waived at any time, either before or after such meeting, and such waiver shall be the equivalent to
the giving of a valid notice hereunder, and (ii) attendance of any member at a special meeting
shall constitute a valid waiver of notice from such member. In no event shall the JSC meet less
frequently than once in each Calendar Year. Regular and special meetings of the JSC may be held in
person or by teleconference or videoconference; provided, that, meetings held in person shall
alternate between the respective offices of the Parties. The Chair shall prepare and circulate to
each JSC member an agenda for each JSC meeting not later than one (1) week prior to such meeting.



               (b) Quorum; Voting; Decisions. At each JSC meeting (i) the presence in person of at
least [***] [***] designated by each Party shall constitute a quorum and (ii) all members
designated by each Party who are present shall have [***] on all matters before the JSC at such
meeting. All decisions of the JSC shall be made by unanimous vote. Alternatively, the JSC may act
by written consent signed by at least [***] [***] designated by each Party subject to Section
2.1.6. Whenever any action by the JSC is called for hereunder during a time period in which the
JSC is not scheduled to meet, the Chair shall cause the JSC to take the action in the requested
time period by calling a special meeting or by circulating a written consent. Representatives of
each Party or of its Affiliates who are not members of the JSC may attend



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




19









 







JSC meetings as non-voting observers with the consent of the other Party, which shall not be
unreasonably withheld, conditioned or delayed.



               (c) Minutes. The JSC shall keep minutes of its meetings that record all decisions and
all actions recommended or taken in reasonable detail. Drafts of the minutes shall be prepared and
circulated to the members of the JSC within a reasonable time after the meeting, not to exceed
[***] business days. The Chair shall have responsibility for the preparation and circulation of
draft minutes. Each member of the JSC shall have the opportunity to provide comments on the draft
minutes. The minutes shall be approved, disapproved and revised as necessary at the next JSC
meeting or within [***] days of the meeting whichever occurs first. Upon approval, final minutes
of each meeting shall be circulated to the members of the JSC by the Chair.



          2.1.4 Responsibilities. The JSC shall be responsible for overseeing the conduct and
progress of the Research Program and the Development of Optimized Lead Compounds and Development
Candidates for which ARCHEMIX is performing Development activities. Without limiting the
generality of the foregoing, the JSC shall have the following responsibilities:




               (a) overseeing the JPT’s performance of its responsibilities;



               (b) reviewing and approving each Annual Research Plan and each Annual Development Plan under
which ARCHEMIX is responsible for performing Development activities;



               (c) reviewing and approving any amendment to an Annual Research Plan approved by the JPT and
submitted to it for its approval;



               (d) reviewing and approving any amendment to an Annual Development Plan under which ARCHEMIX
is responsible for performing Development activities approved by the JPT and submitted to it for
its approval;



               (e) reviewing data, reports or other information submitted to it by the JPT from time to time;



               (f) resolving all JPT matters that are in dispute;



               (g) reviewing and either approving or rejecting any decision of the JPT to nominate any Lead
Compound as an Optimized Lead Compound or any decision of the JPT to nominate any Optimized Lead
Compound as a Development Candidate;



               (h) resolving any dispute as to whether a milestone event under this Agreement has occurred;
and



               (i) implementing a mutually acceptable mechanism for reporting Adverse Events between the
Parties for each Development Candidate and Product; and



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




20









 





               (j) making such other decisions as may be delegated to the JSC pursuant to this Agreement or
by mutual written agreement of the Parties after the Effective Date.



          2.1.5 Interests of the Parties. Notwithstanding any other provisions of this
Agreement, all decisions made and all actions taken by the JSC shall be made or taken in the best
interest of the Collaboration.




          2.1.6 Dispute Resolution. The JSC members shall use reasonable efforts to reach
agreement on any and all matters. Such reasonable efforts shall, if requested by any member of the
JSC, include the engagement of a mutually acceptable Person who is not affiliated with either Party
and has particular experience or expertise with respect to a particular matter to advise the JSC,
the expense of any such Person to be borne equally by the Parties. In the event that, despite such
reasonable efforts, agreement on a particular matter cannot be reached by the JSC within thirty
(30) days after the JSC first meets to consider such matter (each such matter, a “Disputed
Matter”), then, if the Disputed Matter does not involve an Excepted Decision or an ARCHEMIX
Decision, and except as set forth in the last sentence of this section, MERCK shall have the right
to make the final decision on such Disputed Matter, but shall only exercise such right in good
faith after full consideration of the positions of both Parties. Notwithstanding the foregoing,
(i) if the Disputed Matter involves an ARCHEMIX Decision, then ARCHEMIX shall have the right to
make the final decision on such Disputed Matter but shall only exercise such right in good faith
after full consideration of the positions of both Parties and (ii) if the Disputed Matter involves
an Excepted Decision, (A) the Chair of the JSC shall refer such Disputed Matter to the President of
ARCHEMIX and the head of pre-clinical R&D of MERCK (the “Designated Senior Officers”), who shall
promptly initiate discussions in good faith to resolve such Disputed Matter and (B) if such
Disputed Matter is not resolved by the Designated Senior Officers within ten (10) days after the
date the Designated Senior Officers first met to consider such Disputed Matter or forty-five (45)
days after the date the JSC first met to consider such Disputed Matter, the Disputed Matter shall
be resolved in accordance with Section 13.1. For purposes of clarity, under no circumstances shall
the determination of whether MERCK or ARCHEMIX has used or is using Commercially Reasonable Efforts
be submitted for resolution under this Section 2.1.6.




     2.2 Joint Project Team.



          2.2.1 Establishment. Within [***] days from the Effective Date, ARCHEMIX and MERCK
shall establish the Joint Project Team. Unless otherwise agreed by the Parties, the term for the
JPT shall commence as of the Effective Date and continue until the last day of the Research Program
Term (“JPT Term”); provided, that, the JPT Term shall be extended in the event that, and for so
long as, ARCHEMIX has obligations to perform ARCHEMIX Development Activities. The JPT shall have
and perform the responsibilities set forth in Section 2.2.4.




          2.2.2 Membership. Upon establishment of the JPT, each Party shall designate in
writing, in its sole discretion, [***] members to the JPT (which members shall be employees
of such Party). Unless otherwise agreed by the Parties, one of ARCHEMIX’s designees shall be
designated by ARCHEMIX as the Chair of the JPT; provided, that, to the extent the JPT Term is  


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




21









 







extended as provided in Section 2.2.1 beyond the Research Program Term, MERCK shall have the right
to designate one of MERCK’s designees as the Chair of the JPT. Each Party shall have the right at
any time to substitute individuals, on a permanent or temporary basis, for any of its previously
designated representatives to the JPT, by giving written notice to the other Party. Initial
designees of the Parties to the JPT shall be designated by each Party by written notice to the
other Party as soon as is reasonably practicable following the Effective Date.




          2.2.3 Meetings.




               (a) Schedule of Meetings; Agenda. The JPT shall establish a schedule of times for
regular meetings, in no event less frequently than once per [***] during the JPT Term taking into
account, without limitation, the planning needs of the Research Program and its responsibilities.
In urgent cases special meetings may be convened by any member upon [***] days (or, if such meeting
is proposed to be conducted by teleconference, upon [***] days) written notice to the other
members; provided, that, (i) notice of any such special meeting may be waived at any time, either
before or after such meeting, and such waiver shall be the equivalent to the giving of a valid
notice hereunder, and (ii) attendance of any member at a special meeting shall constitute a valid
waiver of notice from such member. Regular and special meetings of the JPT may be held in person
or by teleconference or videoconference; provided, that, meetings held in person shall alternate
between the respective offices of the Parties. The chair of the JPT shall prepare and circulate to
each JPT member an agenda for each JPT meeting no later than one (1) week prior to such meeting.



               (b) Quorum; Voting; Decisions. At each JPT meeting, (i) the presence in person of at
least [***] members designated by each Party shall constitute a quorum and (ii) all members
designated by each Party who are present shall have [***] on all matters before the JPT at such
meeting. All decisions of the JPT shall be made by unanimous vote. Alternatively, the JPT may act
by written consent signed by at least [***] members designated by each Party. Whenever any action
by the JPT is called for hereunder during a time period in which the JPT is not scheduled to meet,
the chair of the JPT shall cause the JPT to take the action in the requested time period by calling
a special meeting or by circulating a written consent. Representatives of each Party or of its
Affiliates who are not members of the JPT (including, without limitation, the Patent Coordinators)
may attend JPT meetings as non-voting observers without the consent of the other Party. In the
event that the JPT is unable to resolve any matter before it, such matter shall be referred to the
JSC for decision, and, in case the JSC is unable to resolve the matter, it shall be resolved in
accordance with Section 2.1.6.



               (c) Minutes. The JPT shall keep minutes of its meetings that record all decisions and
all actions recommended or taken in reasonable detail. Drafts of the minutes shall be prepared and
circulated to the members of the JPT within a reasonable time after the meeting, not to exceed
[***] business days. The chair of the JPT shall have responsibility for the preparation and
circulation of draft minutes. Each member of the JPT shall have the opportunity to provide
comments on the draft minutes. The minutes shall be approved, disapproved and
revised as necessary at the next JPT meeting. Upon approval, final minutes of each meeting
shall be circulated to the members of the JPT by the chair of the JPT.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




22









 





          2.2.4 Responsibilities. The JPT shall be responsible for (a) overseeing the conduct
and progress of the Research Program, the recommendation of Optimized Lead Compounds and the
recommendation of Development Candidates for which ARCHEMIX is responsible for performing
Development activities; and (b) overseeing the Development of Optimized Lead Compounds and
Development Candidates for which, and the conduct and progress of each Development Program under
which, ARCHEMIX is responsible for performing Development activities. Without limiting the
generality of the foregoing, the JPT shall have the following responsibilities:




               (a) preparing or directing the preparation of, approving, and recommending to the JSC for its
approval all Annual Research Plans;



               (b) preparing or directing the preparation of and approving amendments to JSC-approved Annual
Research Plans as it deems appropriate in furtherance of the objectives of the Research Program as
set forth in the Research Plan and, if any member of the JPT asserts that any such JPT-approved
amendment would change the objectives of such Annual Research Plan, submitting such amendment to
the JSC for its consideration;



               (c) monitoring the progress of each Annual Research Plan and of each Party’s activities
thereunder;



               (d) providing a forum for consensual decision making with respect to the Research Program;



               (e) reviewing data, reports or other information submitted by either Party with respect to
work conducted in the Research Program;



               (f) preparing for the JSC on at least a semi-annual basis a progress report for the Research
Program in reasonable detail and providing to the JSC such additional information as it may
request;



               (g) recommending amendments to the OLSC and/or DCSC as it deems appropriate in furtherance of
the objectives of the Research Program or Development Program, as applicable, as set forth in the
Research Plan or Development Plan, as applicable;



               (h) nominating Lead Compounds as Optimized Lead Compounds for acceptance by the JSC;



               (i) nominating Optimized Lead Compounds for which ARCHEMIX is responsible for performing
Development activities as Development Candidates for acceptance by the JSC;



               (j) preparing or directing the preparation of, approving, and recommending to the JSC for its
approval all Annual Development Plans under which ARCHEMIX is responsible for performing
Development activities;



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




23









 





               (k) preparing or directing the preparation of and approving amendments to JSC-approved Annual
Development Plans under which ARCHEMIX is responsible for performing Development activities, as it
deems appropriate in furtherance of the Development of Development Candidates and, if any member of
the JPT asserts that any such JPT-approved amendment would change the objectives of that Annual
Development Plan, submitting such amendment to the JSC for its consideration;



               (l) monitoring the progress of the Development of each Development Candidate for which
ARCHEMIX is performing Development activities, in accordance with, and of each Party’s activities
under, the applicable Annual Development Plan;



               (m) providing a forum for consensual decision making with respect to the Development Program
under which ARCHEMIX is responsible for performing Development activities;



               (n) reviewing data, reports or other information submitted by either Party with respect to
work conducted in the Development Program under which ARCHEMIX is responsible for performing
Development activities;



               (o) preparing for the JSC on at least a semi-annual basis a progress report for the
Development Program under which ARCHEMIX is responsible for performing Development activities, in
reasonable detail and providing to the JSC such additional information as it may request;



               (p) making any other decisions as may be delegated to the JPT pursuant to this Agreement or by
mutual written agreement of the Parties after the Effective Date and performing such activities as
may be delegated to the JPT pursuant to this Agreement, or by mutual written agreement of the
Parties after the Effective Date.



          2.2.5 Interests of the Parties. Notwithstanding any other provisions of this
Agreement, all decisions made and all actions taken by the JPT shall be made or taken in the best
interest of the Collaboration.




          2.2.6 Alliance Management. Within [***] days of the Effective Date, each Party shall
appoint a person who shall oversee contact between the Parties for all matters related to the
Collaboration between meetings of the JSC and JPT and shall have such other responsibilities as the
Parties may mutually agree in writing after the Effective Date (each, a “Collaboration Manager”).
Each Party may replace its Collaboration Manager at any time by notice in writing to the other
Party.




3. RESEARCH PROGRAM




     3.1 Implementation of the Research Program. The objectives of the Research Program
shall be the identification of Lead Compounds for nomination by the JPT to the JSC for approval as
Optimized Lead Compounds pursuant to this Agreement. Except for the MERCK Research Activities, if
any, which shall be conducted by MERCK at its sole expense, ARCHEMIX shall have the primary right
and responsibility to conduct the Research Program.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




24









 





     3.2 Annual Research Plans.



          3.2.1 Research Plan. The initial Annual Research Plan and budget, which describes the
research activities to be carried out by each Party during the first Contract Year of the Research
Program Term, shall be prepared by the JPT and submitted to, and approved by, the JSC within [***]
days of the Effective Date. For each Contract Year during the Research Program Term commencing
with the second Contract Year, an Annual Research Plan and budget shall be prepared by or at the
direction of the JPT and submitted to the JSC for its approval. The JPT shall manage the
preparation of each Annual Research Plan in a manner designed to obtain JSC approval no later than
[***] days prior to the end of the then-current Contract Year. Each Annual Research Plan shall:
(a) set forth (i) the research objectives and activities to be performed for the Contract Year
covered by the Annual Research Plan with reasonable specificity, (ii) the research plans and
protocols to be employed to complete each stage of the Research Program, (iii) changes to the OLSC
and any other criteria that the JPT will utilize to evaluate the results of the Research Program to
nominate Optimized Lead Compounds, (iv) the Party that shall be responsible for performing such
activities, (v) a timeline and budget for such activities (including Third Party expenses to be
incurred for outsourced studies managed by ARCHEMIX), and (vi) with respect to ARCHEMIX Research
Activities, the number of FTEs estimated to be required to perform such activities; and (b) shall
be consistent with the other terms of this Agreement. Without limiting the generality of the
foregoing, the objectives of each Annual Research Plan shall include, as appropriate from time to
time during the Research Program Term, conducting the necessary research activities to identify
Lead Compounds or to determine whether Lead Compounds should be nominated to the JSC as Optimized
Lead Compounds. Any Annual Research Plan may be amended from time to time by the JPT pursuant to
Section 2.2.4 or by the JSC pursuant to 2.1.4. Each amendment, modification and update to the
Annual Research Plan shall include the resulting changes to the budget, including the number of
FTEs to be utilized by ARCHEMIX, shall be set forth in a written document prepared by, or at the
direction of, the JPT and approved by the JSC, shall specifically state that it is an amendment,
modification or update to the Annual Research Plan and shall be attached to the minutes of the
meeting of the JSC at which such amendment, modification or update was approved by the JSC.
Without limiting the nature or frequency of any other amendments, modifications or updates to the
Research Plan that may be approved by the JSC, the Annual Research Plan shall be updated at least
once prior to the end of each Contract Year to describe the research activities to be carried out
by each Party during the applicable Contract Year during the Research Program Term in conducting
the Research Program pursuant to this Agreement.




          3.2.2 Minimum FTEs. MERCK shall request and fund a minimum of [***] FTEs per Contract
Year during the three (3) year Research Program Term. MERCK shall have
the right to increase the number of FTEs to be provided by ARCHEMIX for any Contract Year;
provided, that, (a) any increase above [***] FTEs for any Contract Year shall be subject to MERCK’s
notice obligation under Section 3.3.2(c) and (b) any increase, at MERCK’s request, above [***] FTEs
for any Contract Year shall be an ARCHEMIX Decision.




     3.3 Conduct of Research Program.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




25









 





          3.3.1 ARCHEMIX Responsibilities. During the Research Program Term, ARCHEMIX shall use
Commercially Reasonable Efforts to conduct the ARCHEMIX Research Activities using the number of
FTEs set forth in the Annual Research Plan.




          3.3.2 MERCK Responsibilities. During the Research Program Term, MERCK shall: (a) pay
ARCHEMIX the Minimum Quarterly FTE Payment in accordance with Section 5.3; (b) pay ARCHEMIX the
applicable FTE Rate per FTE per Contract Year for FTEs greater than [***] in accordance with
Section 5.3.1; (c) give ARCHEMIX not less than [***] days’ written notice in the event that MERCK
requires a number of FTEs above [***] FTEs in any Contract Year; (d) commit such resources as are
reasonably necessary to conduct the MERCK Research Activities set forth in the Annual Research
Plan; and (e) use Commercially Reasonable Efforts to conduct the MERCK Research Activities, if any,
set forth in the Annual Research Plan.




          3.3.3 Compliance and Funding. Each Party shall perform its obligations under each
Annual Research Plan in compliance in all material respects with all Applicable Laws. For purposes
of clarity, with respect to each activity performed under an Annual Research Plan that will or
would reasonably be expected to generate data to be submitted to a Regulatory Authority in support
of a Regulatory Filing or Drug Approval Application, the Party performing such activity shall
comply in all material respects with the regulations and guidance of the FDA that constitute Good
Laboratory Practice or Good Manufacturing Practice (or, if and as appropriate under the
circumstances, International Conference on Harmonization (ICH) guidance or other comparable
regulation and guidance of any Regulatory Authority in any country or region in the Territory).
Each Party shall be solely responsible for paying the salaries and benefits of its employees.




          3.3.4 Cooperation. Scientists at ARCHEMIX and MERCK shall cooperate in the
performance of the Research Program and, subject to the terms of this Agreement and any
confidentiality obligations to Third Parties, shall exchange such data, information and materials
as are reasonably necessary for the other Party to perform its obligations under any Annual
Research Plan.




     3.4 Records.



          3.4.1 Record Keeping.




               (a) Research Program Records. Each Party shall maintain complete and accurate records
of its activities in the Research Program in sufficient detail, in good scientific manner and
otherwise in a manner that reflects all work done and results achieved.
Subject to Article 6, each Party shall provide the other Party with access during normal
business hours and upon reasonable advance notice to review such records to the extent reasonably
required for such other Party’s performance of its obligations under this Agreement; provided,
that, the non-reviewing Party may redact information not relevant to the Research Program prior to
such review. Notwithstanding the foregoing, MERCK shall not have the right to review any records
that relate to any Failed Compounds, Waived Compounds or Terminated Compounds.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




26









 





               (b) Record Keeping Policies. Without limiting the generality of Section 3.4.1(a),
each Party agrees to maintain a policy that requires its employees and consultants to record and
maintain all data and information developed during the Research Program.



          3.4.2 Reports. ARCHEMIX shall keep the JPT regularly informed of the progress of the
Research Program. Without limiting the generality of the foregoing, ARCHEMIX shall, at least once
each [***] during the Research Program Term, (a) provide reports to the JPT in reasonable detail
regarding the status of its activities under the Research Program, (b) advise the JPT of its
identification of Lead Compounds and provide the JPT with any supporting data applicable to such
Lead Compounds, (c) provide the JPT with the results of activities conducted in the Research
Program with respect to each Lead Compound so as to enable the JPT to determine whether such Lead
Compound meets the OLSC and should be proposed to the JSC as an Optimized Lead Compound, (d)
provide the JPT with the results of activities conducted in the Development Program, if any, with
respect to each Optimized Lead Compound so as to enable the JPT to determine whether such Optimized
Lead Compound meets the DCSC and should be proposed to the JSC as a Development Candidate, (e)
provide the JPT with such additional information that it has in its possession as may be reasonably
requested from time to time by the JPT, and (f) provide MERCK, on or before [***] days from the
termination or expiration of the Research Program Term, with a final report regarding all ARCHEMIX
Research Activities conducted by ARCHEMIX during the Research Program Term to the extent not
previously included in the reports described above. MERCK shall (i) provide the JPT, at least once
per [***], with reports in reasonable detail regarding the status of all MERCK Research Activities
and such additional information that it has in its possession as may be reasonably requested from
time to time by the JPT, (ii) provide the JPT with the results of activities conducted in the
Development Program under which ARCHEMIX is responsible for performing Development activities with
respect to each Optimized Lead Compound so as to enable the JPT to determine whether such Optimized
Lead Compound meets the DCSC and should be proposed to the JSC as a Development Candidate, and
(iii) provide ARCHEMIX, on or before [***] days from the termination or expiration of the Research
Program Term, with a final report regarding all MERCK Research Activities conducted by MERCK during
the Research Program Term to the extent not previously included in the reports described above.




     3.5 Selection of Program Targets.



          3.5.1 Selection of Program Targets.




               (a) Initial Program Targets. The Parties hereby acknowledge and agree that one (1)
Program Target, as set forth on Schedule 2A, has been so designated by the
Parties as of the Effective Date. MERCK shall provide written notice of a second Program
Target to ARCHEMIX within [***] weeks of the Effective Date. ARCHEMIX shall accept or reject the
proposed Target as specified under 3.5.1.d) for the inclusion of a Target into the Research
Program.



               (b) Target Replacement List. The Parties hereby acknowledge and agree that two (2)
Targets, as set forth on the Target Replacement List on Schedule 2B, have



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




27









 




been designated
by the Parties as replacement Targets as of the Effective Date. MERCK shall have the right to
request that a Target on the Target Replacement List be replaced (a) [***] and (b) [***]. During
the first [***] Contract Years of the Research Program Term, ARCHEMIX will inform MERCK in writing,
if it intends to commence negotiations with a Third Party with respect to a license, collaboration
or similar agreement relating to Aptamers against a Target on the Target Replacement List.




               (c) Replacement of Program Targets. If at any time during the first [***] Contract
Years of the Research Program Term, the JSC agrees that a Program Target is unlikely to produce an
[***] or [***], then (i) all activities under the Research Program with respect to such Program
Target shall cease; (ii) such Program Target shall thereafter be deemed to be a Failed Target; and
(iii) MERCK shall have the right to replace such Failed Target with a Target from the Target
Replacement List in accordance with Section 3.5.1(d). In addition, MERCK shall have the right at
any time during the first [***] Contract Years of the Research Program Term to replace a Program
Target with a Target from the Target Replacement List in accordance with Section 3.5.1(d) if: (i)
MERCK reasonably believes based on published literature or proprietary data first available after
the designation of a Target as a Program Target that such Program Target is [***] for use in the
Target Selection Field; or (ii) MERCK reasonably determines that it is legally necessary to obtain
a license or other right, title or interest in and to an issued patent that had not issued and/or
had not been published as a pending application at the time a Target was designated as a Program
Target in order to successfully research, Develop and Commercialize a Product that binds such
Program Target. Notwithstanding anything to the contrary herein, any Program Target replaced in
accordance with the preceding sentence of this Section 3.5.1(c) shall be deemed a Failed Target. A
Target proposed by MERCK for inclusion in the Research Program which is not on the Target
Replacement List may be rejected by ARCHEMIX for any reason, in its sole discretion.



               (d) Replacement of Targets. To the extent MERCK has the right to propose that a
Target be added to the Target Replacement List as described in Section 3.5.1(b) or that a Failed
Target be replaced by a Target from the Target Replacement List as described in Section 3.5.1(c),
MERCK shall provide written notice to ARCHEMIX. ARCHEMIX shall accept or reject the proposed
Target within [***] days after receipt of such notice from MERCK. A Target proposed by MERCK for
inclusion on the Target Replacement List or in the Research Program shall only be rejected by
ARCHEMIX if prior to MERCK’s notice: (A) it is an [***], (B) ARCHEMIX is prohibited by an executed
contract from licensing Aptamers against such proposed Target or its natural ligand(s), to MERCK,
(C) ARCHEMIX is in active negotiations, as [***] by [***] with a Third Party with respect to a
license, collaboration or similar agreement relating to Aptamers against such Target or its natural
ligand(s), or (D) ARCHEMIX is developing, for its own benefit, Aptamers against such Target or its
natural ligand(s) under a
bona fide internal development program against such Target, has adopted a research plan for
such Target or its natural ligand, or has formally designated such Target or its natural ligand(s)
for research. In addition to the reasons specified in the foregoing clauses (A)-(D), ARCHEMIX also
may reject a Target proposed by MERCK for inclusion on the Target Replacement List if such Target
does not fall within the Target Selection Field. ARCHEMIX shall give MERCK prompt written notice
during the Research Program Term if any of the restrictions on any Target that is rejected by
ARCHEMIX pursuant to the foregoing clause (A), (B), (C) or (D) lapse, or are



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




28









 







otherwise terminated,
such that the previously rejected Target becomes eligible for inclusion as a Program Target or for
inclusion on the Target Replacement List.



               (e) Obligations of JPT. As promptly as practicable after designation of a new Program
Target in accordance with Section 3.5.1(d), the JPT shall (i) develop and submit to the JSC for its
approval the OLSC and DCSC for such new Program Target and (ii) prepare an update to the Annual
Research Plan to include the ARCHEMIX Research Activities to be conducted to identify Lead
Compounds against such new Program Target for potential nomination as an Optimized Lead Compound.



          3.5.2 Termination of Replacement Right. Notwithstanding anything to the contrary in
this Agreement, MERCK’s right to add Targets to the Target Replacement List pursuant to Section
3.5.1(b) and/or replace Program Targets pursuant to Section 3.5.1(c) shall terminate on the [***]
of the [***] Contract Year.




3.6 Identification of Lead Compounds and Optimized Lead Compounds.




          3.6.1 Lead Compounds. ARCHEMIX shall use Commercially Reasonable Efforts in good
faith to perform the SELEX® Process to identify Lead Compounds in accordance with each
Annual Research Plan, as amended.




          3.6.2 Optimized Lead Compounds. Within [***] days after its receipt of each report
from ARCHEMIX pursuant to Section 3.4.2 identifying a Lead Compound as meeting the applicable OLSC
(or which either Party reasonably believes should be an Optimized Lead Compound), the JPT shall
review the data and information and determine whether to nominate the Lead Compound to the JSC for
designation as an Optimized Lead Compound. If the JPT elects to nominate any such Lead Compound as
an Optimized Lead Compound, the JPT shall promptly furnish all available information to the JSC.
The JSC shall consider such nomination within [***] days, and if the JSC approves the nomination of
the Lead Compound, such Lead Compound shall be deemed to be an Optimized Lead Compound for purposes
of this Agreement.




     3.7 Development Candidates. Within [***] days after either Party reasonably concludes
based upon available project reports that an Optimized Lead Compound meets the applicable DCSC, the
JPT shall review the data and information and determine whether to nominate the Optimized Lead
Compound for designation as a Development Candidate. If the JPT elects to nominate any such
Optimized Lead Compound as a Development Candidate, the JPT shall promptly furnish all available
information to the JSC. The JSC shall consider such nomination within [***] days so as to enable
MERCK to determine whether or not continue Development of such compound, and if the Optimized Lead
Compound meets the DCSC and
MERCK accepts such Optimized Lead Compound for further Development, such Optimized Lead
Compound shall be deemed to be a Development Candidate for purposes of this Agreement.



     3.8 MERCK Decision Not to Go Forward. MERCK has the right to determine in [***] not
to continue the Development and Commercialization of a Development Candidate against a specific
Program Target.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




29









 





     3.9 Supply of Proprietary Materials. From time to time during the Research Program
Term, either Party (the “Transferring Party”) may supply the other Party (the “Recipient Party”)
with Proprietary Materials of the Transferring Party for use in the Research Program. In
connection therewith, each Recipient Party hereby agrees that (a) it shall not use such Proprietary
Materials for any purpose other than exercising its rights or performing its obligations under this
Agreement; (b) it shall use such Proprietary Materials only in compliance with all Applicable Laws;
(c) it shall not transfer any such Proprietary Materials to any Third Party without the prior
written consent of the Transferring Party, except as expressly permitted by this Agreement; (d) the
Recipient Party shall not acquire any right, title or interest in or to such Proprietary Materials
as a result of such supply by the Transferring Party; and (e) upon the expiration or termination of
the Research Program Term, the Recipient Party shall, if and as instructed by the Transferring
Party, either destroy or return any such Proprietary Materials that are not the subject of the
grant of a continuing license hereunder.



     3.10 Research Program Term. The Research Program shall commence on the Effective Date
and shall continue until the last day of the Research Program Term.



4. DEVELOPMENT PROGRAM; COMMERCIALIZATION OF PRODUCTS




     4.1 Objectives of the Development Program. The objectives of the Development Program
shall be the selection and Development of Development Candidates to enable the Commercialization of
Products in the Field in the Territory.



     4.2 Responsibility for Development of Development Candidates and Commercialization of
Products. Except for the ARCHEMIX Development Activities, if any, MERCK shall have [***], for
all aspects of the Development of Optimized Lead Compounds and Development Candidates in accordance
with the applicable Annual Development Plan, and all aspects of the Commercialization of Products
in accordance with the applicable Product Commercialization Plan, in the Field in the Territory,
including, without limitation, the conduct of: (a) all IND-enabling non-clinical studies that are
outside of the Research Program; (b) all activities related to human clinical trials (including,
without limitation, Phase I Clinical Trials, Phase II Clinical Trials and Phase III Clinical
Trials); (c) all activities relating to the manufacture and supply of Development Candidates and
Products (including all required process development and scale up work with respect thereto); and
(d) all pre-marketing, marketing, promotion, sales, distribution, import and export activities
(including securing reimbursement, conducting sales and marketing activities and any post-marketing
trials or post-marketing safety surveillance and maintaining databases), subject in each case to
Section 4.9.2. Without limiting
the generality of the foregoing, MERCK shall have [***], (i) to make all Regulatory Filings
for Development Candidates and Products and file all Drug Approval Applications and otherwise seek
all Regulatory Approvals for Products, as well as to conduct all correspondence and communications
with Regulatory Authorities regarding such matters, subject in each case to Section 4.9.2, and (ii)
to report all Adverse Events to Regulatory Authorities if and to the extent required by Applicable
Laws. All Regulatory Approvals for Products shall be owned by MERCK, subject to Section 10.3.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




30









 





     4.3 Annual Development Plans. The initial Annual Development Plan shall be prepared
by MERCK and submitted to the JSC for its review within [***] days of the date on which the JSC
approves the selection of an Optimized Lead Compound and in any event, on or prior to the
initiation of Development activities with respect thereto, which shall describe the Development
activities to be conducted for the balance of the Contract Year. Thereafter, for each Contract
Year during the Term, an Annual Development Plan for each Optimized Lead Compound and Development
Candidate shall be prepared by MERCK and provided to the JSC for its review and MERCK shall consult
with the JSC with respect to all significant Development decisions to be made with respect to such
Annual Development Plan. Each Annual Development Plan shall: (a) set forth (i) the Development
objectives, activities, and timelines for the Contract Year covered by the Annual Development Plan
with reasonable specificity, (ii) which activities, if any, are ARCHEMIX Development Activities;
provided, that, ARCHEMIX has agreed to perform such activities, (iii) with respect to such ARCHEMIX
Development Activities, the number of FTEs estimated to be required to perform such activities and
the corresponding FTE Cost and (iv) the expected Regulatory Filings and Drug Approval Applications
to be prepared and filed and the expected timetable of completing such Development activities; and
(b) be consistent with the other terms of this Agreement. Any Annual Development Plan may be
amended from time to time by MERCK. Without limiting the nature or frequency of any other
amendments, modifications or updates to the Annual Development Plan, the Annual Development Plan
shall be updated at least once prior to the end of each Contract Year to describe the Development
activities to be carried out by each Party during the applicable Contract Year in conducting the
Development Program pursuant to this Agreement. Notwithstanding the above, the preparation and
management of the Annual Development Plan by the JPT and JSC approval is only required for any
Annual Development Plan or amendment thereto under which ARCHEMIX is responsible for performing any
Development activities.



     4.4 Product Commercialization Plans. Within [***] days after the Initiation of a
Phase III Clinical Trial with respect to each Development Candidate, MERCK shall prepare and
provide to the JSC for its review a Product Commercialization Plan for each Product Derived from
such Development Candidate, and shall inform the JSC with respect to all significant
Commercialization decisions to be made with respect to such Product.



     4.5 Development and Commercialization Diligence.




               (a) Diligence Obligations. MERCK shall exercise Commercially Reasonable Efforts
during the Term to conduct the MERCK Development Activities, to Develop
[***] Development Candidate targeted at [***] Program Target and to Commercialize [***]
Product targeted at [***] Program Target in the Field in the Territory.



               (b) Effect of Breach of Diligence Obligations. If ARCHEMIX at any time believes that
MERCK, on a country-by-country and Product-by-Product basis, is not meeting its diligence
obligations pursuant to subsection (a) above, ARCHEMIX may give written notice to MERCK requesting
written justification, in the form of detailed reasons that would support the proposition that
MERCK is meeting such diligence obligation. In such event, MERCK shall provide such written
justification to ARCHEMIX within [***] days after such



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




31









 







notice is given. In the event that ARCHEMIX
does not receive such justification within such [***] day period or does not agree with such
justification, then ARCHEMIX shall have the right, in its sole discretion, on a country-by-country
and Product-by-Product basis, to terminate MERCK’s rights with respect to such Target, Development
Candidate or Product, and the Collaboration Aptamers against such Target pursuant to Section 10.4
(but leaving unaffected MERCK’s rights under this Agreement to any other Target and Collaboration
Aptamer directed against such Target).



     4.6 Compliance. Each Party shall perform its obligations under each Annual
Development Plan in good scientific manner and in compliance in all material respects with all
Applicable Laws. For purposes of clarity, with respect to each activity performed under an Annual
Development Plan that will or would reasonably be expected to generate data to be submitted to a
Regulatory Authority in support of a Regulatory Filing or Drug Approval Application, the Party
performing such activity shall comply in all material respects with, if and as applicable, the
regulations and guidance of the FDA that constitute Good Laboratory Practice, Good Manufacturing
Practice or Good Clinical Practices (or, if and as appropriate under the circumstances,
International Conference on Harmonization (ICH) guidance or other comparable regulation and
guidance of any Regulatory Authority in any country or region in the Territory). Each Party shall
be solely responsible for paying the salaries and benefits of its employees conducting its
activities under Annual Development Plans.



     4.7 Cooperation. Scientists at ARCHEMIX and MERCK shall cooperate in the performance
of each Development Program and, subject to the terms of this Agreement and any confidentiality
obligations to Third Parties, shall exchange such data, information and materials as are reasonably
necessary for the other Party to perform its obligations under any Annual Development Plan.



     4.8 Exchange of Reports; Information; Updates.




          4.8.1 Development Program Reports. MERCK shall keep the JSC regularly informed of the
progress of its efforts to Develop Development Candidates in the Field in the Territory. Without
limiting the generality of the foregoing, MERCK shall, at least once each [***], provide the JSC
with reports in reasonable detail regarding the status of all preclinical IND-enabling studies and
activities (including toxicology and pharmacokinetic studies), clinical trials and other activities
conducted under the Development Program; provided, that, for so long as ARCHEMIX is obligated to
perform ARCHEMIX Development Activities, (a) MERCK shall provide the JSC with the reports described
above at least once each [***] and (b) ARCHEMIX
and MERCK shall, not less than once each [***], provide the JSC with reports in reasonable
detail regarding the status of all Development Activities and such additional information that they
have in their possession as may be reasonably requested from time to time by the JSC.




          4.8.2 Commercialization Reports. MERCK shall keep the JSC and ARCHEMIX regularly
informed of the progress of MERCK’s efforts to Commercialize Products in the Field in the Territory
through periodic updates. Without limiting the generality of the foregoing, MERCK shall provide
the JSC and ARCHEMIX with [***] written updates to each Product Commercialization Plan, which shall
(a) summarize MERCK’s efforts to Commercialize



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




32









 







Products, (b) identify the Regulatory Filings and
Drug Approval Applications with respect to such Product that MERCK or any of its Affiliates or
Sublicensees have filed, sought or obtained in the prior [***] month period or reasonably expect to
make, seek or attempt to obtain in the following [***] month period and (c) summarize all clinical
and other data generated by MERCK with respect to Products. In addition, MERCK shall provide such
additional information that it has in its possession as may be reasonably requested by ARCHEMIX
regarding the Commercialization of any Product, which request shall not be made more than once each
Calendar Year.




          4.8.3 Adverse Event Reports; Review of Regulatory Filings and Correspondence.




               (a) Adverse Events. In addition to the updates described in Section 4.8.1 and 4.8.2,
MERCK shall provide ARCHEMIX with all Adverse Event information and product complaint information
relating to Development Candidates or Products as such information is compiled or prepared by MERCK
in the normal course of business in connection with the Development of any Development Candidates
or Commercialization of any Product and, in any event, within time frames consistent with reporting
obligations under Applicable Laws. MERCK shall provide such Adverse Event and product complaint
information hereunder to ARCHEMIX in accordance with Section 13.3. ARCHEMIX may provide all such
Adverse Event information to other licensees of ARCHEMIX who have the right to sell Aptamers for
therapeutic purposes under a license from ARCHEMIX; provided, that, such other licensees agree to
maintain the confidentiality thereof. ARCHEMIX will provide to MERCK Adverse Event information
obtained from other licensees of ARCHEMIX who have the right to develop and sell Aptamers for
therapeutic purposes under a license from ARCHEMIX; provided, that, such other licensees agree to
share such information and MERCK agrees to maintain the confidentiality thereof.



               (b) Preparation of Drug Approval Applications. MERCK shall (i) consult with ARCHEMIX
in good faith in the preparation of all Drug Approval Applications for Products in the United
States, Japan and in the European Union and (ii) consider all comments of ARCHEMIX in good faith,
taking into account the best interests of the Collaboration and of the Development of the
applicable Development Candidate and Commercialization of the applicable Product on a global basis.



               (c) Meeting Attendance and Information. MERCK shall use reasonable efforts to provide
ARCHEMIX with at least [***] days advance notice of any
meeting with the FDA or other Regulatory Authority regarding a Drug Approval Application
relating to, or Regulatory Approval for, any Development Candidate or Product, (i) prior to the
acceptance of an IND with respect to each Development Candidate or Product and (ii) after
acceptance of an IND with respect to each Development Candidate or Product if the subject matter of
the meeting shall include any milestone event applicable to such Development Candidate or Product.
Upon written request ARCHEMIX may send one person [***] to participate as an observer in such
meeting [***]; provided, that, (A) MERCK approves such ARCHEMIX request for any such meetings
occurring after acceptance of the IND and (B) to the extent MERCK’s approval is required, MERCK
shall [***] any such request of ARCHEMIX.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




33









 







With regard to any meeting with the FDA or other
Regulatory Authority regarding a Drug Approval Application relating to, or Regulatory Approval for,
any Development Candidate or Product, to which ARCHEMIX did not send a representative as provided
in this Section 4.8.3(c), MERCK will provide ARCHEMIX with a written summary of information
communicated and received thereat.



               (d) Right to Review. Notwithstanding anything to the contrary in this Section 4.8.3,
ARCHEMIX shall have the right, upon written notice, to review all such Regulatory Filings and
correspondence at MERCK’s office at ARCHEMIX’s sole expense.



     4.9 Development and Commercialization Rights and Restrictions.



          4.9.1 Development and Commercialization Rights in the Field. Except as provided in
this Section 4.9, MERCK shall have the [***] during the Term to Develop Development Candidates and
Commercialize Products in the Territory for use in the Field.




          4.9.2 Co-Promotion.




               (a) Negotiation of a Potential Co-Promotion Agreement. Within thirty (30) days from
filing the NDA for a Product, ARCHEMIX shall provide MERCK with (i) a written notice indicating
ARCHEMIX’ interest in the promotion and Detailing of such Product in the United States of America
and its territories and possessions jointly with MERCK using a coordinated sales force consisting
of Representatives of both Parties (“Co-Promote” or “Co-Promotion”) and (ii) a business plan so as
to document how such proposed Co-Promotion for such Product is in the best interest of both
Parties. Upon receipt of such written notice, MERCK shall enter into good faith negotiations with
ARCHEMIX with the aim of determining whether or not to enter into a separate Co-Promotion agreement
(“Co-Promotion Agreement”) between the Parties. In the event MERCK, in its sole discretion, agrees
to enter into such Co-Promotion Agreement with ARCHEMIX, then the terms applicable to such
Co-Promotion of the Product identified therein (each, a “Co-Promoted Product”) shall conform in all
material respects with the terms, conditions and provisions set forth in Schedule 9
attached hereto and such additional provisions as are usual and customary for inclusion in a
co-promotion agreement between companies in the pharmaceutical industry of comparable sizes to the
respective Parties. For purposes of clarity, such additional terms shall supplement and shall not
materially expand, limit or change the terms set forth on Schedule 9. The Parties shall
negotiate the Co-Promotion Agreement in good faith and with sufficient diligence as is required to
execute and deliver the Co-Promotion Agreement
within [***] days after ARCHEMIX provides its written indication of interest pursuant to the
first sentence of this paragraph.



               (b) Failure to Agree. To the extent that MERCK enters into and conducts negotiations
with respect to the Co-Promotion Agreement for a Product in good faith and the Parties fail to
execute and deliver the Co-Promotion Agreement within [***] day period described in Section
4.9.2(a) above, then (i) MERCK shall continue to have the exclusive right and responsibility during
the Term to Commercialize such Product in the Territory (including the United States of America and
its territories and possessions) for use in the Field and (ii) the fact



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




34









 







that the Parties were
unable to agree on a Co-Promotion Agreement shall not entitle ARCHEMIX to claim damages or any
other sort of compensation whatsoever.



     4.10 Product Recalls. In the event that any Regulatory Authority issues or requests a
recall or takes similar action in connection with a Product, or in the event a Party reasonably
believes that an event, incident or circumstance has occurred that may result in the need for a
recall, market withdrawal or other corrective action regarding a Product, such Party shall promptly
advise the other Party thereof by telephone or facsimile. Following such notification, MERCK shall
decide and have control of whether to conduct a recall or market withdrawal (except in the event of
a recall or market withdrawal mandated by a Regulatory Authority, in which case it shall be
required) or to take other corrective action in any country and the manner in which any such
recall, market withdrawal or corrective action shall be conducted; provided, that, MERCK shall keep
ARCHEMIX regularly informed regarding any such recall, market withdrawal or corrective action.
MERCK shall bear all expenses of any such recall, market withdrawal or corrective action
(including, without limitation, expenses for notification, destruction and return of the affected
Product and any refund to customers of amounts paid for such Product).



5. PAYMENTS




     5.1 Technology Access and License Fee. MERCK shall pay ARCHEMIX a non-refundable
technology access and license fee in the amount of Three Million Dollars (US $3,000,000) by wire
transfer within thirty (30) days of the Effective Date, according to instructions that ARCHEMIX
shall provide.



     5.2 License Maintenance Fee. MERCK shall pay ARCHEMIX a non-refundable license
maintenance fee in the amount of [***] Dollars (US $[***]) by wire transfer within [***] days of
(i) the Effective Date and (ii) on each of the [***] of the Effective Date during the Research
Program Term, according to instructions that ARCHEMIX shall provide.



     5.3 R&D Funding.




          5.3.1 Payment of R&D Funding. In consideration of the performance by ARCHEMIX of its
activities under the Annual Research Plan(s) as described in Section 3.2, during the Research
Program Term MERCK will pay ARCHEMIX the applicable Quarterly FTE Payment on or prior to the first
day of each Calendar Quarter; provided, that, an invoice corresponding with such Calendar Quarter
has been received by MERCK. Notwithstanding the
above, in view of the activities to be performed by ARCHEMIX during the initial Calendar
Quarter, MERCK will pay ARCHEMIX [***] Dollars (US $[***]) on the Effective Date; provided, that,
an invoice corresponding with the initial Calendar Quarter has been received by MERCK. ARCHEMIX
shall provide a report to the JPT within [***] days of the end of each Calendar Quarter during the
Research Program Term that specifies the actual number of FTEs expended during the period covered
therein. Within [***] days of the end of each Calendar Year during the Research Program Term,
ARCHEMIX shall provide MERCK with an annual reconciliation statement (“Annual Reconciliation
Statement”) that specifies the actual number of FTEs expended during the previous [***] Calendar
Quarters in the aggregate. MERCK shall



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




35









 







reimburse ARCHEMIX in full for any FTEs expended by
ARCHEMIX in excess of the cumulative FTE Costs owed by MERCK for such Calendar Year (the “MERCK
Contribution”) as indicated by any Annual Reconciliation Statement if such excess was approved by
the JSC. To the extent that any Annual Reconciliation Statement indicates that ARCHEMIX expended
FTEs in excess of the MERCK Contribution and such excess was not approved by the JSC then, (a)
MERCK shall reimburse ARCHEMIX for all amounts in excess of the MERCK Contribution, not to exceed
[***] percent ([***]%) of the MERCK Contribution and (b) all FTE Costs in excess of [***] percent
([***]%) of the MERCK Contribution shall be borne by ARCHEMIX.




          5.3.2 R&D Funding Audit Rights. ARCHEMIX shall keep complete and accurate books and
financial records pertaining to the number of FTEs utilized in conducting the Research Program and
the ARCHEMIX Development Activities, if any, which books and financial records shall be kept in
accordance with GAAP and shall be retained by ARCHEMIX until [***] years after the end of the
Contract Year to which they pertain. Upon [***] days written notice, MERCK shall have the right to
appoint at its expense an independent certified public accountant reasonably acceptable to ARCHEMIX
to audit the books and financial records of ARCHEMIX relating to the number of FTEs utilized in
conducting the Research Program and the ARCHEMIX Development Activities during any Contract Year;
provided, that, MERCK shall not have the right to audit any Contract Year more than once or more
than [***] years after the end of such Contract Year or to conduct more than one such audit in any
[***] period. All books and financial records made available for audit shall be deemed to be
Confidential Information of ARCHEMIX. The results of each audit, if any, shall be reported in
writing to both Parties promptly (but in no event later than [***] days) after the audit and shall
be binding on both Parties. In the event that there was an error relating to the reported FTEs
utilized in conducting the Research Program and/or the ARCHEMIX Development Activities during such
Contract Year, (a) if the effect of the error resulted in an overpayment by MERCK, ARCHEMIX shall
promptly (but in any event no later than [***] days) after ARCHEMIX’ receipt of the report so
concluding, make payment to MERCK of the overpayment and (b) if the effect of the error resulted in
an underpayment by MERCK, then MERCK shall promptly (but in no event later than [***] days after
MERCK’s receipt of the report so concluding) make payment to ARCHEMIX of the underpayment amount.
MERCK shall bear the full cost of such audit unless such audit discloses an over reporting by
ARCHEMIX of more than [***] percent ([***]%) of the aggregate amount of FTE Costs reportable in any
Calendar Year, in which case ARCHEMIX shall reimburse MERCK for all reasonable costs incurred by
MERCK in connection with such audit.




          5.3.3 R&D External Costs. In addition to the funding obligations in Section 5.3.1
above, and without limiting the generality of the provisions of Section 4.2 hereof, MERCK shall
[***] for the payment of [***] Third Party research and Development activity costs (“Third Party
Costs”), including, without limitation, contract research organizations, contract personnel and
consultant costs, incurred by ARCHEMIX to the extent set forth in an Annual Research Plan or Annual
Development Plan or otherwise agreed to in writing by MERCK.




     5.4 Milestone Payments.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




36









 





          5.4.1 Milestones. Within [***] days after the occurrence of the following milestone
events, MERCK shall make the corresponding non-refundable, non-creditable (except as provided in
Section 5.4.2) payments to ARCHEMIX for each Program Target, regardless of the number of Products
that are Developed and Commercialized under this Agreement against such Program Target:




	 	 	 
	Milestone Event	 	Milestone Payment
	1. [***]
	 	$[***]
	2. [***]
	 	$[***]
	3. [***]
	 	$[***]
	4. [***]
	 	$[***]
	5. [***]
	 	$[***]
	6. [***]
	 	$[***]
	7. [***]
	 	$[***]
	8. [***]
	 	$[***]
	9. [***]
	 	$[***]
	10. [***]
	 	$[***]
	11. [***]
	 	$[***]
	12. [***]
	 	$[***]
	13. [***]
	 	$[***]
	14. [***]
	 	$[***]






     For purposes of clarity (a) milestone 1 shall be paid for the first [***] Project Targets to yield
an Optimized Lead Compounds; (b) [***] shall be paid for a given Product for up to [***] different
Indications; and (c) if payment is made for any of [***] with respect to any Product and any of the
preceding milestone payments have not been made with respect to such Product, then such earlier
milestone payments shall be made concurrently therewith (for example, if milestone 5 [***] is paid,
but milestone 4[***] has not been paid, then milestone payments 5 and 4 shall [***] on the basis of
[***]). Notwithstanding anything contained herein to the contrary, in no event will MERCK be liable
for milestone payments accrued for achievement of any of milestones 1-14 in excess of milestone
payments made by MERCK of [***] Dollars ($[***]) in the aggregate for each Program Target.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




37









 





          5.4.2 Determination that Milestone Events have Occurred; Invoice for Milestone
Payments. MERCK shall provide ARCHEMIX with written notice within [***] days of each
occurrence of a milestone event set forth in Section 5.4.1. ARCHEMIX shall provide MERCK with an
invoice for the amount of the milestone payment that is due and payable as promptly as possible
after receipt of such notice. In the event that, notwithstanding the fact that MERCK has not given
such a notice, ARCHEMIX believes any such milestone event has occurred, it shall so notify MERCK in
writing and shall provide to MERCK data, documentation or other information that supports its
belief. Any dispute under this Section 5.4.2 that relates to whether or not a milestone event has
occurred shall be referred to the JSC to be resolved in accordance with Section 2.1.6.




     5.5 Payment of Royalties; Royalty Rates; Accounting and Records.



          5.5.1 Payment of Royalties.




               (a) Royalty Rates. MERCK shall pay ARCHEMIX a royalty based on Annual Net Sales of
each Product in each Calendar Year (or partial Calendar Year) commencing with the First Commercial
Sale of such Product in any country in the Territory and ending upon the last day of the last
Royalty Term for such Product, at the following rates:



	 	 	 
	Annual Net Sales	 	Royalty Rate (%)
	[***]

	 	[***]%
	[***]

	 	[***]%
	[***]

	 	[***]%
	[***]

	 	[***]%






     The following hypothetical example illustrates the calculation of royalties under Section
5.5.1(a): If, in any Calendar Year during the Term, Annual Net Sales of a Product are $[***], the
applicable royalty would be $[***], [***]% of Net Sales for Net Sales up to $[***], [***]% of Net
Sales for Net Sales over $[***] and up to $[***] and [***]% of Net Sales for Net Sales over $[***].



               (b) Royalty Offsets. In the event that MERCK, in order to practice the license
granted to it under Section 7.2 of this Agreement in any country in the Territory, is
required to and actually makes royalty, milestone or license fee payments to any Third Party
(“Third Party Payments”) in order (A) to obtain a license to an issued patent or patents in the
absence of which the Lead Compound portion of the Product could not legally be manufactured,
imported, sold, exported, or otherwise exploited in such country and/or (B) to obtain a license to
an issued patent or patents, in the absence of which the Licensed Patent Rights cannot legally be
practiced in such country for making, using, importing, offering for sale, selling, exporting or
otherwise exploiting such Product, then the royalties payable to ARCHEMIX for such Product under
Section 5.5.1(a) with respect to such country may be reduced by [***] percent ([***]%) of the
amount of such Third Party Payments. Notwithstanding the foregoing, (i) such reductions



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




38









 







shall in
no event reduce the royalty that would otherwise be payable for such Product under Section 5.5.1
with respect to such country by more than [***] percent ([***]%) of the amount otherwise payable
with respect to Net Sales of such Product in such country, (ii) MERCK shall be responsible for the
payment of any royalty, milestone or license fee payments to any Third Party relating to methods or
processes for making or manufacturing the Product and the royalties payable to ARCHEMIX pursuant to
Section 5.5.1(a) [***], and (iii) in the event that MERCK requires that ARCHEMIX use in the
Research Program molecules, methods and/or processes not identified in Schedule 11 or MERCK
requires that ARCHEMIX use in the Research Program specific molecules, methods and/or processes
where such molecules, methods and/or processes are generically identified in Schedule 11
(“Requested Chemistry”), thereby giving rise to the obligation to pay royalty, milestone or license
fee payments to a Third Party (“Third Party Chemistry Payments”), MERCK [***] of such Third Party
Chemistry Payments and the royalties payable to ARCHEMIX pursuant to Section 5.5.1(a) [***] Third
Party Chemistry Payments.



               (c) Competing Aptamer Products. In the event that a Third Party sells a Competing
Aptamer Product (as defined below) in a country in which a Product is then being sold and such
Competing Aptamer Product is not covered by a Valid Claim under the Licensed Patent Rights, Program
Aptamer-Specific Patent Rights, or Joint Patent Rights in such country, then, during the period in
which sales of the Competing Aptamer Product by such Third Party are equal to at least [***]
percent ([***]%) of MERCK’s volume-based market share of the Product in such country (as measured
by prescriptions or other similar information available in such country) all applicable royalties
in effect with respect to such Product in such country as specified in Section 5.5.1(a) shall be
[***] by [***] percent ([***]%). Notwithstanding the foregoing, (i) MERCK’s obligation to pay
royalties at the full royalty rates shall be reinstated on the first day of the Calendar Quarter
immediately following the Calendar Quarter in which sales of such Competing Aptamer Product account
for less than [***] percent ([***]%) of MERCK’s volume-based market share in such country and (ii)
the provisions of this Section 5.5.1(c) shall not apply for any country in which MERCK has not
[***] for [***] for the applicable Collaboration Aptamer(s) or has not otherwise used commercially
reasonable efforts to [***] for such Collaboration Aptamer(s). For purposes of this Section
5.5.1(c), a “Competing Aptamer Product” means a pharmaceutical product that (i) contains an [***]
and (ii) is marketed in such country for the same [***] as the [***].



               (d) Generic Products. In the event that a Third Party sells a Generic Product (as
defined below) in a country in which a Product is then being sold and such Generic
Product is not covered by a Valid Claim under the Licensed Patent Rights, Program
Aptamer-Specific Patent Rights, or Joint Patent Rights in such country, then during the period in
which sales of the Generic Product by such Third Party are equal to: (i) at least [***] percent
([***]%) of MERCK’s volume-based market share of the Product in such country (as measured by
prescriptions or other similar information available in such country), MERCK shall pay [***]
percent ([***]%) of the full applicable royalties in effect with respect to such Product in such
country as specified in Section 5.5.1(a). Notwithstanding the foregoing, (i) MERCK’s obligation to
pay royalties at the full royalty rates shall be reinstated on the first day of the Calendar
Quarter immediately following the Calendar Quarter in which sales of such Generic Product account
for less than [***] percent ([***]%), (ii) the provisions of this Section 5.5.1(d) shall not apply
for any country in which MERCK has not [***] for [***] for the applicable Collaboration



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




39









 







Aptamer(s)
or has not otherwise used commercially reasonable efforts to [***] for such Collaboration
Aptamer(s). For purposes of this Section 5.5.1(d), a “Generic Product” means a pharmaceutical
product that contains the [***] and [***] to such [***].



               (e) Maximum Adjustment of Royalty Rate. Notwithstanding anything to the contrary in
this Agreement, under no circumstances shall the royalty rates in Section 5.5.1(a) be cumulatively
reduced below [***] percent ([***]%) of the rates set forth therein.



               (f) Know-How Payments. The Parties hereby acknowledge and agree that any royalties
that are payable for a Product for which no Patent Rights exist shall be in consideration of (i)
ARCHEMIX’s expertise and know-how concerning the identification of Aptamers in the Field, including
its development of the SELEX® Process and its other Aptamer-related development
activities conducted prior to the Effective Date; (ii) the performance by ARCHEMIX of the Research
Program, (iii) the disclosure by ARCHEMIX to MERCK of results obtained in the Research Program;
(iv) the licenses granted to MERCK hereunder with respect to Licensed Technology and Joint
Technology that are not within the claims of any Patent Rights Controlled by ARCHEMIX; (v) the
restrictions on ARCHEMIX in Section 7.6.1; and (vi) the “head start” afforded to MERCK by each of
the foregoing.



               (g) Payment Dates and Reports. Royalty payments shall be made by MERCK within [***]
days after the end of each [***] commencing with the [***] in which the First Commercial Sale of a
Product occurs. MERCK shall also provide, at the same time each such payment is made, a report
showing: (a) the Net Sales of each Product by type of Product and country in the Territory; (b) the
basis for any deductions from gross amounts billed or invoiced to determine Net Sales; (c) the
applicable royalty rates for such Product; (d) the exchange rates used in calculating any of the
foregoing; and (e) a calculation of the amount of royalty due to ARCHEMIX.



               (h) Combination Products. The earned royalty due on a Combination Product shall be
determined pro rata on a Combination Product-by-Combination Product and country-by-country basis,
by multiplying Net Sales of the Combination Product by the fraction A/(A+B), where A is the invoice
price of the Product when sold separately and B is the invoice price of the Supplemental Product
when sold separately by a Party, its Affiliate or its Sublicensee or, if not sold by them, then the
average invoice price when sold separately by Third Parties. If the Supplemental Product in the
Combination Product is not sold separately by any Person, Net
Sales shall be calculated by multiplying actual net revenues derived from sales of the
Combination Product by the fraction A/C, where A is as previously defined and C is the invoice
price of the Combination Product sold by a Party, its Affiliate or its Sublicensee. For purposes
of clarity, the average invoice price and the actual net revenues for any Supplemental Product
shall be for a quantity comparable to that contained in the Combination Product and shall be of the
same class, purity and potency as that contained in the Combination Product. If neither the
Product nor the Supplemental Product included in the Combination Product are sold separately, Net
Sales shall be calculated based on the mutual written agreement of the Parties as to a reasonable
allocation between the Product and the Supplemental Product, taking into account total
manufacturing costs, proprietary protection and relative contribution thereof. If the Parties



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




40









 







are
unable to reach agreement on an appropriate method of determining royalties for a Combination
Product, the matter shall be submitted to the JSC for resolution under Section 2.1.6.



          5.5.2 Records; Audit Rights. MERCK and its Affiliates and Sublicensees shall keep and
maintain for [***] years from the date of each payment of royalties hereunder complete and accurate
records of gross sales and Net Sales by MERCK and its Affiliates and Sublicensees of each Product,
in sufficient detail to allow royalties to be determined accurately. ARCHEMIX shall have the right
for a period of [***] years after receiving any such royalty payment to appoint at its expense an
independent certified public accountant reasonably acceptable to MERCK to audit the relevant
records of MERCK and its Affiliates and Sublicensees to verify that the amount of such payment was
correctly determined. MERCK and its Affiliates and Sublicensees shall each make its records
available for audit by such independent certified public accountant during regular business hours
at such place or places where such records are customarily kept, upon [***] days written notice
from ARCHEMIX, solely to verify that royalty payments hereunder were correctly determined. Such
audit right shall not be exercised by ARCHEMIX more than [***] in any [***] or more than [***] with
respect to sales of a particular Product in a [***]. All records made available for audit shall be
deemed to be Confidential Information of MERCK. The results of each audit, if any, shall be
binding on both Parties. In the event there was an underpayment by MERCK hereunder, MERCK shall
promptly (but in any event no later than [***] days after MERCK’s receipt of the report so
concluding) make payment to ARCHEMIX of any shortfall. ARCHEMIX shall bear the full cost of such
audit unless such audit discloses an underreporting by MERCK of more than [***] percent ([***]%) of
the aggregate amount of royalties payable in any Calendar Year, in which case MERCK shall reimburse
ARCHEMIX for all costs incurred by ARCHEMIX in connection with such audit.




          5.5.3 Overdue Royalties and Milestones. All royalty payments not made within the time
period set forth in Section 5.5.1(g), including underpayments discovered during an audit, and all
milestone payments not made within the time period specified in Section 5.4.1, shall bear interest
at a rate of [***] percent ([***]%) per month from the due date until paid in full or, if less, the
maximum interest rate permitted by Applicable Laws. Any such overdue royalty or milestone payment
shall, when made, be accompanied by, and credited first to, all interest so accrued.




          5.5.4 Payments. All payments made by MERCK hereunder shall be made by wire transfer
in US Dollars in accordance with instructions given in writing from time to time by
ARCHEMIX and shall be free and clear of any taxes, duties, levies, fees or charges including
any withholding taxes. If by law, regulations or fiscal policy of a particular country in the
Territory, remittance of royalties in United States Dollars is restricted or forbidden, written
notice thereof shall promptly be given to ARCHEMIX, and such payment shall be made by the deposit
thereof in local currency to the credit of ARCHEMIX in a recognized banking institution designated
by ARCHEMIX by written notice to MERCK. When in any country in the Territory the law or
regulations prohibit both the transmittal and the deposit of royalties, on sales in such country,
such payments shall be suspended for as long a such prohibition is in effect and as soon as such
prohibition ceases to be in effect, all royalties that MERCK would have been under an



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




41









 







obligation to
transmit or deposit but for the prohibition shall forthwith be deposited or transmitted, to the
extent allowable.




          5.5.5 Taxes. Any income taxes or other taxes which MERCK is required by law to pay or
withhold on behalf of ARCHEMIX with respect to milestones, royalties and any other monies or other
transfer for value payable or provided to ARCHEMIX under this Agreement shall be deducted from such
milestones, royalties and any other monies due to ARCHEMIX under this Agreement. MERCK shall
provide ARCHEMIX with documentation of such withholding in a manner that is satisfactory for
purposes of reporting to the U.S. Internal Revenue Service. Payments made by either Party for
goods and services provided by the other Party under this Agreement are exclusive of Value Added
Tax, sales tax or any other similar or substitute tax which will be additionally payable by the
Party receiving the goods or services in the event that Value Added Tax, sales tax or any other
similar or substitute tax applies to any of these payments; provided, that, the Party providing the
goods or services will issue to the other Party an appropriate invoice to support any such charge.
MERCK shall submit to ARCHEMIX reasonable proof of payment of the withholding taxes contemplated by
this Section, together with an accounting of the calculations of such taxes, within [***] days
after which such withholding taxes are remitted to the proper authority. The Parties will
cooperate reasonably in completing and filing documents required under the provisions of any
applicable tax laws or under any other Applicable Law, in connection with the making of any
required tax payment or withholding payment, or in connection with any claim to a refund of or
credit for any such payment. The Parties will cooperate to minimize such taxes in accordance with
Applicable Law.




          5.5.6 Foreign Currency Exchange. All royalties shall be payable in full in the United
States in United States Dollars, regardless of the countries in which sales are made. With respect
to amounts invoiced by MERCK (or its Affiliates or Sublicensees) for Products, all such amounts
shall be expressed in EURO and, if applicable, the currency in which the amount was invoiced. Any
conversion from a currency to EURO shall be calculated using MERCK’s standard exchange rate
methodology applied in its external reporting in effect as of the Effective Date and set forth on
Schedule 10 attached hereto. Such Net Sales shall be converted into United States Dollars
as follows:




               (A/B), where



               A = “Net Sales” (as defined above) in such Calendar Quarter expressed in
EURO; and



               B = foreign exchange conversion rate, expressed in EURO per United States
Dollar (using, the applicable EURO exchange rate, set forth on Schedule
10 attached hereto or any other mutually agreed upon source, for such
Calendar Quarter).



6. TREATMENT OF CONFIDENTIAL INFORMATION;

PUBLICITY; NON-SOLICITATION.




     6.1 Confidentiality.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




42









 





          6.1.1 Confidentiality Obligations. ARCHEMIX and MERCK each recognizes that the other
Party’s Confidential Information and Proprietary Materials constitute highly valuable assets of
such other Party. ARCHEMIX and MERCK each agrees that, subject to Section 6.1.2, it will not
disclose, and will cause its Affiliates and sublicensees (or Sublicensees, as the case may be) not
to disclose, any Confidential Information or Proprietary Materials of the other Party and it will
not use, and will cause its Affiliates and sublicensees (or Sublicensees, as the case may be) not
to use, any Confidential Information or Proprietary Materials of the other Party except as
expressly permitted hereunder; provided, that, such obligations shall apply during the Term and for
an additional [***] years thereafter.




          6.1.2 Limited Disclosure. ARCHEMIX and MERCK each agrees that disclosure of its
Confidential Information or any transfer of its Proprietary Materials may be made by the other
Party to any employee, consultant or Affiliate of such other Party to enable such other Party to
exercise its rights or to carry out its responsibilities under this Agreement; provided, that, any
such disclosure or transfer shall only be made to Persons who are bound by written obligations as
described in Section 6.1.3. In addition, ARCHEMIX and MERCK each agrees that the other Party may
disclose its Confidential Information (a) on a need-to-know basis to such other Party’s legal and
financial advisors, (b) as reasonably necessary in connection with an actual or potential (i)
permitted sublicense of such other Party’s rights hereunder, (ii) Third Party collaborators,
subject to written obligations of confidentiality substantially similar to those of ARCHEMIX
hereunder, and provided that any Confidential Information so provided will in no event include
information identifying any Program Targets, (iii) debt or equity financing of such other Party or
(iv) Change of Control involving such other Party, (c) if such other Party is ARCHEMIX, to any
Third Party that is or may be engaged by ARCHEMIX to perform services in connection with the
Research Program, and (d) for any other purpose with the other Party’s written consent, not to be
unreasonably withheld, conditioned or delayed. In addition, each Party agrees that the other Party
may disclose such Party’s Confidential Information or Proprietary Materials (A) as reasonably
necessary to file, prosecute or maintain Patent Rights, or to file, prosecute or defend litigation
related to Patent Rights, in accordance with this Agreement; or (B) as required by Applicable Laws;
provided, that, in the case of any disclosure under this clause (B), the disclosing Party shall (1)
if practicable, provide the other Party with reasonable advance notice of and an opportunity to
comment on any such required disclosure and (2) if requested by the other Party, cooperate in all
reasonable respects with the other Party’s efforts to obtain confidential treatment or a protective
order with respect to any such disclosure, at the other Party’s expense.








          6.1.3 Employees and Consultants. ARCHEMIX and MERCK each hereby represents that all
of its employees and consultants, and all of the employees and consultants of its Affiliates, who
participate in the activities of the Collaboration or have access to Confidential Information or
Proprietary Materials of the other Party are or will, prior to their participation or access, be
bound by written obligations to maintain such Confidential Information or Proprietary Materials in
confidence and not to use such information except as expressly permitted hereunder. Each Party
agrees to use, and to cause its Affiliates to use, reasonable efforts to enforce such obligations.





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




43









 








     6.2 Publicity. The Parties acknowledge that the terms of this Agreement constitute
Confidential Information of each Party and may not be disclosed except as permitted by Section
6.1.2 and this Section 6.2. Such terms may be disclosed by a Party to investment bankers,
investors, and potential investors, lenders and potential lenders and other sources and other
potential sources of financing, acquirer or merger partners and potential acquirer or merger
partners and Gilead and University License Equity Holdings, Inc. In addition, a copy of this
Agreement may be filed by either Party with the Securities and Exchange Commission if such filing
is required by law or regulation. In connection with any such filing, such Party shall endeavor to
obtain confidential treatment of economic and trade secret information, and shall provide the other
Party with the proposed confidential treatment request with reasonable time for such other Party to
provide comments, which comments shall be reasonably considered by the filing Party.
Notwithstanding anything to the contrary in Section 6.1, the Parties, upon the execution of this
Agreement, shall agree to a press release with respect to this Agreement, in the form attached here
to as Schedule 7, and either Party may make subsequent public disclosure of the contents of
such press release without further approval of the other Party. After issuance of such press
release, except as required by Applicable Laws, neither Party shall issue a press or news release
or make any similar public announcement (it being understood that publication in scientific
journals, presentation at scientific conferences and meetings and the like are intended to be
covered by Section 6.3 and not subject to this Section 6.2) related to the Research Program or to
any Development Program without the prior written consent of the other Party; provided, that, (a)
notwithstanding the foregoing, ARCHEMIX shall be expressly permitted to publicly announce the
occurrence of any milestone event under Section 5.4 and any other event that ARCHEMIX reasonably
believes is material to ARCHEMIX; (b) MERCK (i) expressly acknowledges that ARCHEMIX is an emerging
company the success of which is substantially dependent on its ability to attract and raise capital
and that ARCHEMIX’s ability to attract and raise capital is substantially dependent on its ability
to announce publicly developments in its research and development programs or product development
pipeline and (ii) agrees that it shall not unreasonably withhold, condition or delay its consent to
any request by ARCHEMIX to announce publicly developments in the Research Program or any
Development Program; and (c) ARCHEMIX (i) expressly acknowledges that MERCK’s Development and
Commercialization is substantially dependent on its ability to protect confidential information and
(ii) agrees that it shall not unreasonably request to announce developments in the Research Program
or any Development Program that may reduce a competitive advantage versus competing entities.



     6.3 Publications and Presentations. The Parties acknowledge that scientific
publications and presentations must be strictly monitored to prevent any adverse effect from
premature publication or dissemination of results of the activities hereunder. Each Party agrees
that, except as required by Applicable Laws, it shall not publish or present, or permit to be
published or presented, the results of the Research Program or any Development Program without the
prior review by and approval of the other Party. Each Party shall provide to the other Party the
opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or
presentations (including, without limitation, information to be presented verbally) that relate to
the Research Program or any Development Program at least [***] days prior to its intended
presentation or submission for publication, and such submitting Party agrees, upon written request
from the other Party given within such [***] period, not to submit such abstract or manuscript for
publication or to make such presentation until the other Party is given up to [***]



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




44









 







days from the
date of such written request to seek appropriate patent protection for any material in such
publication or presentation that it reasonably believes may be patentable. Once such abstracts,
manuscripts or presentations have been reviewed and approved by each Party, the same abstracts,
manuscripts or presentations do not have to be provided again to the other Party for review for a
later submission for publication. Each Party also shall have the right to require that any of its
Confidential Information that is disclosed in any such proposed publication or presentation be
deleted prior to such publication or presentation. In any permitted publication or presentation by
a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be
determined in accordance with customary standards. Each Party (i) expressly acknowledges that the
other Party’s business may be substantially dependent on its ability to publish results in
scientific journals, presentation at scientific conferences and meetings and (ii) agrees that it
shall not unreasonably withhold, condition or delay its consent to any request by the other Party
to publish results of the Research Program or any Development Program in accordance with its
internal publication guidelines.



     6.4 Prohibition on Solicitation. Without the written consent of the other Party,
neither Party nor its Affiliates shall, during the [***] or for [***] year thereafter, solicit
(directly or indirectly) any employee of the other Party or its Affiliates who participated in the
Research Program at any time during the Research Program Term. This provision shall not restrict
either Party or its Affiliates from advertising employment opportunities in any manner that does
not directly target the other Party or its Affiliates.



7. LICENSE GRANTS; EXCLUSIVITY




     7.1 Research and Development Licenses.



          7.1.1 ARCHEMIX License Grants.




               (a) Research Program. Subject to the terms and conditions of this Agreement, ARCHEMIX
hereby grants to MERCK and its Affiliates a non-exclusive, royalty-free, worldwide license during
the Research Program Term, including the right to grant sublicenses as provided in Sections 7.3 and
7.4, under Licensed Technology and Licensed Patent Rights, for the sole purpose of conducting MERCK
Research Activities in the Research Program.



               (b) Development Programs. Subject to the terms and conditions of this Agreement,
ARCHEMIX hereby grants to MERCK and its Affiliates, an exclusive, royalty-
free, worldwide license during the Term, including the right to grant sublicenses as provided
in Sections 7.3 and 7.4, under Licensed Technology and Licensed Patent Rights, for the sole purpose
of Developing Optimized Lead Compounds and Development Candidates in the Field and in the
Territory.



          7.1.2 MERCK Grants.




               (a) Research Program. Subject to the terms and conditions of this Agreement, MERCK
hereby grants to ARCHEMIX and its Affiliates a non-exclusive, royalty-




Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




45









 




free, worldwide license during the Research Program Term, including the right to grant
sublicenses as provided in Sections 7.3 and 7.4, under MERCK Technology and MERCK Patent Rights and
MERCK’s interest in Joint Technology and Joint Patent Rights, for the sole purpose of conducting
the Research Program.




               (b) Development Program. Subject to the terms and conditions of this Agreement, MERCK
hereby grants to ARCHEMIX and its Affiliates a non-exclusive, royalty-free, worldwide license
during the Term, without the right to grant sublicenses, under MERCK Technology and MERCK Patent
Rights and MERCK’s interest in Joint Technology and Joint Patent Rights and under Licensed
Technology and Licensed Patent Rights exclusively licensed to MERCK under Section 7.1.1(b), for the
sole purpose of conducting ARCHEMIX Development Activities in any Development Program, to the
extent such ARCHEMIX Development Activities are mutually agreed by the Parties.



               (c) Waived Targets.



                    (i) Designation Notice. Upon its designation of any Program Target as a Waived
Target, MERCK shall provide written notice (“Designation Notice”) to ARCHEMIX identifying each such
Program Target.



                    (ii) Assignment. MERCK hereby assigns to ARCHEMIX all right, title and interest in
and to all MERCK Program Technology, Patent Rights claiming MERCK Program Technology and MERCK’s
interest in Joint Technology and Joint Patent Rights relating to Waived Compounds or Waived
Targets. ARCHEMIX may, at its option, continue to Develop a Waived Compound, subject to the
payment by ARCHEMIX to MERCK, for any Waived Compound, and any Products Derived therefrom, that are
Developed and Commercialized by ARCHEMIX, its Affiliates or sublicensees, of (A) a [***] on the
Milestone Payment Due Date (as defined below) [***] the Applicable Milestone Payment (as defined
below) and (B) royalty payments at rates [***] the Applicable Percentage (as defined below) of the
rates set forth in Sections 5.5.1, for the remainder of the applicable Royalty Term.



                    (iii) Calculation of Royalties. In calculating the payments due to MERCK for the
licenses granted in this Section 7.1.2(c), the terms of Sections 5.5 and all related obligations
(including the right to offset payments in accordance with Section 5.5.1(b) through (e)) shall
apply mutatis mutandis to each such Waived Compound and Product Derived therefrom.



                    (iv) Transition Plan. ARCHEMIX shall have a period of up to [***] months commencing
on the date of receipt of the Designation Notice or a Program Target otherwise becomes a Waived
Target to notify MERCK that it intends to continue to Develop or Commercialize a Waived Compound.
Upon receipt of such notice, the Parties will agree on a transition plan pursuant to which MERCK
will, depending on the stage of development of such Waived Compound(s), obligate MERCK to timely
perform the activities in Sections 7.1.2(c)(iv)(1) through (10). In order for MERCK to agree to
each such transition plan, ARCHEMIX shall agree to use Commercially Reasonable Efforts to Develop
and Commercialize the Waived Compound(s) identified by ARCHEMIX and which are the subject


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




46









 




of a transition plan for continued Development and Commercialization. The transition plan
shall include, as applicable, an obligation by MERCK to:




                         (1) grant to ARCHEMIX an exclusive, worldwide, royalty-free, paid-up license under all Product
Trademarks applicable to such Waived Compound(s), if any;



                         (2) transfer to ARCHEMIX all of its right, title and interest in all Regulatory Filings, Drug
Approval Applications and Regulatory Approvals then in its name applicable to such Waived
Compound(s), if any;



                         (3) notify the applicable Regulatory Authorities and take any other action reasonably
necessary to effect such transfer;



                         (4) provide ARCHEMIX with copies of all correspondence between MERCK and such Regulatory
Authorities relating to such Regulatory Filings, Drug Approval Applications and Regulatory
Approvals;



                         (5) unless expressly prohibited by any Regulatory Authority, transfer control to ARCHEMIX of
all clinical trials of such Waived Compound(s) being conducted as of the time of designation by
MERCK of the Waived Compound and continue to conduct such trials at its expense for up to [***]
months commencing on the date of receipt of the Designation Notice or a Program Target otherwise
becomes a Waived Target to enable such transfer to be completed without interruption of any such
trial, unless ARCHEMIX demonstrates to MERCK to MERCK’s satisfaction that ARCHEMIX shall not be
able to assume such clinical trials within four months, in which case MERCK shall continue to
conduct such trials for up to [***] additional months;



                         (6) assign (or cause its Affiliates to assign) to ARCHEMIX all agreements with any Third Party
with respect to the conduct of clinical trials for such Waived Compound(s) including, without
limitation, agreements with contract research organizations, clinical sites and investigators,
unless expressly prohibited by any such agreement (in which case MERCK shall cooperate with
ARCHEMIX in all reasonable respects to secure the consent of such Third Party to such assignment);



                         (7) provide ARCHEMIX with all supplies of such Waived Compound(s) in the possession of MERCK
or any Affiliate or contractor of MERCK;



                         (8) provide ARCHEMIX with copies of all reports and data generated or obtained by MERCK or its
Affiliates pursuant to this Agreement that relate to such Waived Compound(s) that have not
previously been provided to ARCHEMIX;



                         (9) reimburse ARCHEMIX for all internal and out-of-pocket costs incurred by ARCHEMIX in
continuing the research and Development according to the pre-agreed Annual Development Plan of such
Waived Compound(s) for a period of [***] days; and


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




47









 







                    (10) if MERCK has manufactured, is manufacturing or having manufactured such Waived
Compound(s) or any intermediate thereof as of the date the applicable Program Target becomes a
Waived Target: (i) MERCK shall, if requested by ARCHEMIX, supply ARCHEMIX with its requirements for
such Waived Compound(s) and intermediates for up to [***] months following such date at a transfer
price equal to [***] for the supply of such Waived Compound(s) or intermediate, plus [***] percent
([***]%), (ii) within [***] days after ARCHEMIX’s request, MERCK shall provide to ARCHEMIX or its
designee all information in its possession with respect to the manufacture of each such Waived
Compound(s) or intermediate.




                    (v) Definitions. For purposes of this Section 7.1.2(c), the following terms shall
have the following definitions:




“Applicable Milestone Payment” shall mean, with respect to each Waived Compound, an
aggregate amount equal to [***] previously made by MERCK with respect to such Waived
Compound for (a) milestone events 2, 3 and 4 to the extent ARCHEMIX makes [***] of [***]
applicable to such Waived Compound; or (b) milestone events 2 and 3 to the extent ARCHEMIX
makes [***] of [***] and/or [***] applicable to such Waived Compound.




“Applicable Percentage” shall mean, with respect to each Waived Compound, (a) [***]
percent ([***]%), to the extent ARCHEMIX makes [***] of [***] in the development and
commercialization of such Waived Compound; (b) [***] percent ([***]%), to the extent
ARCHEMIX makes [***] of [***] and/or [***] in the development and commercialization of such
Waived Compound, (c) [***] percent ([***]%), if neither of the foregoing (a) nor (b) apply,
but ARCHEMIX is developing and commercializing a Waived Compound that was a [***], and (d)
[***] percent ([***]%) if ARCHEMIX is developing and commercializing an [***], other than a
[***] or an [***], against the Waived Target, provided that in such case ARCHEMIX shall not
make [***] of [***].




“Clinical Data” means all data, results and information produced in the conduct of a
Phase I Clinical Trial (“Phase I Clinical Data”), a Phase II Clinical Trial
(“Phase II Clinical Data”) or a Phase III Clinical Trial (“Phase III Clinical
Data”) conducted by MERCK with respect to a Waived Compound.




“Material Use” means, with respect to Clinical Data, the inclusion of such Clinical
Data in a core report of an NDA filed by ARCHEMIX as evidenced by (i) the use of a bridging
study to utilize such Clinical Data, (ii) the elimination for the need to duplicate such
Clinical Data, or (iii) the ability to reduce the number of patients enrolled in a clinical
trial due to the use of such Clinical Data.




“Milestone Payment Due Date” means, with respect to a Waived Compound, (a) to the
extent a Program Target becomes a Waived Target prior to the Initiation of [***], the date
of the Initiation of [***] with respect to such Waived Compound; (b) to the extent a Program
Target becomes a Waived Target after [***] but prior to the Initiation of [***], the date of
the Initiation of [***] with respect to such Waived Compound; and (c) to the


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




48









 






extent a Program Target becomes a Waived Target after [***] but prior to filing for [***],
the date on which such filing for [***] occurs.



                    (vi) Further Assurances. Upon ARCHEMIX’s written request, MERCK shall execute and
deliver any documents of ownership, assignment or conveyance that are necessary or desirable to
convey the ownership rights granted pursuant to this Section 7.1.2(c).



               (d) Failed Target. Subject to the terms and conditions of this Agreement, MERCK
hereby grants to ARCHEMIX and its Affiliates an exclusive, worldwide, royalty-free license, with
the right to grant sublicenses under MERCK Program Technology, Patent Rights claiming MERCK Program
Technology and MERCK’s interest in Joint Technology and Joint Patent Rights to research, develop,
have developed, make, have made, use, distribute for sale, sell, offer for sale, import and have
imported Aptamers and products Derived therefrom directed against any Failed Target for all uses in
or outside the Field. For purposes of clarity, Failed Targets for the purpose of this Agreement
shall not be construed as encompassing Waived Targets, and, ARCHEMIX shall have no payment
obligations to MERCK with regard to any Failed Target.



               (e) Terminated Compounds. Subject to the terms and conditions of this Agreement,
MERCK hereby grants to ARCHEMIX and its Affiliates an exclusive, worldwide, royalty-free license,
with the right to grant sublicenses, under MERCK Program Technology, Patent Rights claiming MERCK
Program Technology and MERCK’s interest in Joint Technology and Joint Patent Rights to research,
develop, have developed, make, have made, use, distribute for sale, sell, offer for sale, import
and have imported Terminated Compounds and products Derived therefrom in or outside of the Field.
For purposes of clarity, an Aptamer directed against a Waived Target as set forth in sub-paragraph
(c) above shall in no event be considered a Terminated Compound.



               (f) Non-Exclusive License For Aptamers Outside the Collaboration. MERCK hereby grants
to ARCHEMIX and its Affiliates a non-exclusive, royalty-free, worldwide license, with the right to
grant sublicenses, under MERCK Program Technology and Patent Rights claiming MERCK Program
Technology to the extent necessary to research, develop, have developed, make, have made, use,
distribute for sale, sell, offer for sale, import and have imported Aptamers and products Derived
from Aptamers other than those targeted to a Program Target for any and all uses, except as
otherwise provided herein.



               (g) Exclusive License For Aptamers Outside the Collaboration. To the extent requested
in writing by ARCHEMIX, MERCK may grant to ARCHEMIX and its Affiliates an exclusive,
royalty-bearing, worldwide license, with the right to grant sublicenses, under MERCK Program
Technology and Patent Rights claiming MERCK Program Technology and MERCK’s interest in Joint
Technology and Joint Patent Rights to the extent necessary to research, develop, have developed,
make, have made, use, distribute for sale, sell, offer for sale, import and have imported Aptamers
and products Derived from Aptamers other than those targeted to a Program Target for any and all
uses, except as otherwise provided herein. The Parties agree to negotiate in good faith with
respect to the foregoing license.


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




49









 





          7.2 Commercialization License. Subject to the terms and conditions of this Agreement,
ARCHEMIX hereby grants to MERCK and its Affiliates an exclusive, royalty-bearing license during the
Term, including the right to grant sublicenses as provided in Section 7.3, under Licensed
Technology and Licensed Patent Rights for the sole purpose of Commercializing Products in the Field
in the Territory.




          7.3 Right to Sublicense. MERCK shall have the right to grant sublicenses to
Sublicensees under the licenses granted to it under Section 7.1.1(b) with respect to any Optimized
Lead Compounds and Development Candidates and Section 7.2 with respect to any Product; provided,
that, (a) it shall be a condition of any such sublicense that such Sublicensee agrees to be bound
by all terms of this Agreement applicable to the Development or Commercialization, as the case may
be, of Products in the Field in the Territory (including, without limitation, Article 6); (b) MERCK
shall provide written notice to ARCHEMIX of any such proposed sublicense at least [***] days prior
to such execution and provide copies to ARCHEMIX of each such sublicense in the form to be executed
at least [***] business days prior to such execution; (c) if MERCK grants a sublicense to a
Sublicensee, MERCK shall be deemed to have guaranteed that such Sublicensee will fulfill all of
MERCK’s obligations under this Agreement applicable to the subject matter of such sublicense; and
(d) MERCK shall not be relieved of its obligations pursuant to this Agreement as a result of such
sublicense.




          7.4 Right to Subcontract. Each Party shall have the right to subcontract portions,
but not all, of its responsibilities to be performed by it under the Annual Research Plan or Annual
Development Plan in the normal course of its business, and to grant sublicenses for such
activities, to any Third Party without the prior consent of the other Party; provided, that, (a)
such subcontracting shall not involve the transfer of Confidential Information of the other Party
to any Third Party unless the subcontracted party shall enter into a confidentiality agreement with
the subcontracting Party in accordance with Article 6; (b) the subcontracting Party shall provide
written notice to the other Party of any such proposed subcontract at least [***] days prior to
such execution; (c) if a Party enters into a subcontract as provided in this Section 7.4, such
Party shall be deemed to have guaranteed that such subcontractor will fulfill all of such Party’s
obligations under this Agreement applicable to the subject matter of such subcontract; (d) such
subcontracting Party shall not be relieved of its obligations pursuant to this Agreement as a
result of such subcontract, and (e) in the event ARCHEMIX is the subcontracting Party, MERCK shall
not be obligated to reimburse ARCHEMIX for any cost or expense related to such subcontracting
unless MERCK has approved such subcontracting, and the related cost and expense, in the Annual
Research Plan, the Annual Development Plan or otherwise in writing.




          7.5 No Other Rights. MERCK shall have no rights to use or otherwise exploit ARCHEMIX
Technology, ARCHEMIX Patent Rights, or ARCHEMIX Proprietary Materials, and ARCHEMIX shall have no
rights to use or otherwise exploit MERCK Technology, MERCK Patent Rights or MERCK Proprietary
Materials, in each case, except as expressly set forth herein. Without limiting the generality of
the foregoing or Section 11.3, MERCK shall have no right to practice the SELEX® Process
or to use the SELEX® Technology for any reason or to research, develop, make, have made,
use, offer for sale, distribute for sale, sell, import and have imported Diagnostic Products.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




50









 





          7.6 Exclusivity.




               7.6.1 ARCHEMIX. During the Term, ARCHEMIX shall not, and shall cause each of its
Affiliates to not, conduct any activity, either on its own, or with, for the benefit of, or
sponsored by any Third Party, that is designed to research, develop or commercialize, or grant any
license or other rights to any Third Party to utilize, any Proprietary Materials, Technology or
Patent Rights Controlled in whole or in part by ARCHEMIX or any of its Affiliates for the purpose
of researching, developing or commercializing (a) any Aptamer binding to a Program Target, or (b)
any Collaboration Aptamer or Aptamer Derived therefrom, except for the conduct of Permitted
Screening Activities and as otherwise provided under this Agreement.



               7.6.2 MERCK. During the Term, MERCK shall not, and shall cause each of its Affiliates
to not conduct any activity, either on its own, or with, for the benefit of, or sponsored by any
Third Party, that is [***] to [***] or [***], or [***]or other [***] to any [***] to [***]MERCK
[***] for the purpose of [***] to a [***] or any [***] that [***] to the [***], except as provided
under this Agreement.



8. INTELLECTUAL PROPERTY RIGHTS




          8.1 ARCHEMIX Intellectual Property Rights. ARCHEMIX shall have sole and exclusive
ownership of all right, title and interest on a worldwide basis in and to any and all ARCHEMIX
Technology and ARCHEMIX Patent Rights.




          8.2 MERCK Intellectual Property Rights. MERCK shall have sole and exclusive ownership
of all right, title and interest on a worldwide basis in and to any and all MERCK Technology and
MERCK Patent Rights.




          8.3 Joint Technology Rights. MERCK and ARCHEMIX shall jointly own all Joint
Technology and Joint Patent Rights. Notwithstanding anything to the contrary contained in this
Agreement or under Applicable Law, except to the extent exclusively licensed to one Party under
this Agreement, the Parties hereby agree that either Party may use or license or sublicense to
Affiliates or Third Parties all or any portion of its interest in Joint Technology, Joint Patent
Rights or jointly owned Confidential Information or Proprietary Materials for any purposes without
the prior written consent of the other Party, without restriction and without the obligation to
provide compensation to the other Party, except as otherwise provided under this Agreement.




          8.4 Patent Coordinators. ARCHEMIX and MERCK shall each appoint a patent coordinator
reasonably acceptable to the other Party (each, a “Patent Coordinator”) to serve as such Party’s
primary liaison with the other Party on matters relating to patent filing, prosecution, maintenance
and enforcement. Each Party may replace its Patent Coordinator at any time by notice in writing to
the other Party. The initial Patent Coordinators shall be:




	 	 	 	 	 
	 

	 	          For ARCHEMIX:
	 	[***]
	 
	 	 	 	 
	 

	 	          For MERCK:
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




51









 





          8.5 Inventorship. In case of a dispute between ARCHEMIX and MERCK over inventorship
and, as a result, whether any particular Technology is ARCHEMIX Technology, MERCK Technology or
Joint Technology, such dispute shall be resolved by patent counsel who (and whose firm) is not at
the time of the dispute, and was not at any time during the [***] years prior to such dispute,
performing services for either of the Parties, such patent counsel to be selected by the Patent
Coordinators. Expenses of such patent counsel shall be shared equally by the Parties.




          8.6 Cooperation. Each Party shall cooperate with the other Party to effect the intent
of this Article 8, including without limitation by executing documents and making its employees and
independent contractors available to execute documents as necessary to achieve the foregoing
allocation of ownership rights.




     9. FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS



          9.1 Patent Filing, Prosecution and Maintenance




               9.1.1 MERCK’s Prosecution Rights.



                    (a) Program Technology. Subject to Sections 9.1.4 and 9.1.5, MERCK, acting through
patent counsel or agents of its choice, shall be responsible for the preparation, filing,
prosecution and maintenance in the countries listed on Schedule 8, at its sole cost and
expense, of Patent Rights covering MERCK Program Technology; provided, that, ARCHEMIX, acting
through patent counsel or agents of its choice, shall have the right but not the obligation, for
each Program Target, to prepare on MERCK’s behalf and with MERCK’s approval the first patent
application disclosing the corresponding Collaboration Aptamers. MERCK shall have no right or
responsibility with respect to the preparation, filing, prosecution and/or maintenance of any
claims within the Licensed Patent Rights that relate to any Failed Compound, Waived Compound or
Terminated Compound or their manufacture, formulation, delivery, or use. MERCK shall nationalize
such filings in the European Patent Office and the other countries or regional offices listed on
Schedule 8 and shall validate such filings in the EPO contracting states as detailed in
Schedule 8 hereto and the contracting states of any other regional offices identified on
Schedule 8 and, at MERCK’s sole discretion, in any other country. At MERCK’s request,
ARCHEMIX shall cooperate with MERCK in all reasonable respects in connection with such preparation,
filing, prosecution and maintenance of such Patent Rights, including but not limited to obtaining
assignments to reflect chain of title consistent with the terms of this Agreement, gaining United
States patent term extensions, supplementary protection certificates and any other extensions that
are now or become available in the future wherever applicable to Licensed Patent Rights. For
purposes of clarity, notwithstanding anything to the contrary herein, MERCK shall have no rights to
prepare, file, prosecute and/or maintain any (1) Licensed Patent Rights related to the SELEX®
Process or SELEX® Technology, or (2) Patent Rights included in the SELEX®
Portfolio.



                    (b) MERCK Background Technology. MERCK, at its sole expense and acting through patent
counsel or agents of its choice, shall be responsible for the preparation, filing, prosecution and
maintenance of all Patent Rights covering MERCK Background Technology.


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




52









 





               9.1.2 ARCHEMIX Prosecution Rights.



                    (a) Program Technology. ARCHEMIX, at its sole expense and acting through patent
counsel or agents of its choice, shall be responsible for the preparation, filing, prosecution and
maintenance of Patent Rights covering ARCHEMIX Program Technology. At ARCHEMIX’ request, MERCK
shall cooperate with and assist ARCHEMIX in all reasonable respects, at ARCHEMIX’ expense, in
connection with such preparation, filing, prosecution and maintenance of such Patent Rights,
including but not limited to obtaining assignments to reflect chain of title consistent with the
terms of this Agreement, gaining United States patent term extensions, supplementary protection
certificates and any other extensions that are now or become available in the future wherever
applicable.



                    (b) ARCHEMIX Background Technology. ARCHEMIX, at its sole expense and acting through
patent counsel or agents of its choice, shall be responsible for the preparation, filing,
prosecution and maintenance of all Patent Rights covering ARCHEMIX Background Technology.



               9.1.3 Joint Prosecution.



                    (a) Certain Program Technology. Notwithstanding anything to the contrary in Section
9.1.1(a) or 9.1.2(a), with respect to Patent Rights that contain one or more claims that cover both
Program Aptamer-Specific Technology and ARCHEMIX Program Technology, unless the Parties in good
faith otherwise agree, (a) the Parties, acting through patent counsel or agents of its choice,
shall separate such Patent Rights into separate patent applications seeking protection for Program
Aptamer-Specific Technology and ARCHEMIX Program Technology, respectively, and (b) the Parties
shall contemporaneously file the separate patent applications for such Patent Rights. Solely to the
extent the Parties mutually determine it is not feasible to prepare and file separate patent
applications covering such Technology: (i) the Parties shall be jointly responsible for the
preparation, filing and maintenance of such Patent Rights; (ii) MERCK shall be responsible for the
prosecution of any claims of such Patent Rights covering Program Aptamer-Specific Technology; (iii)
ARCHEMIX shall be responsible for the prosecution of any claims of such Patent Rights covering
ARCHEMIX Program Technology; and (iv) each Filing Party shall provide the Non-Filing Party and its
patent counsel with an opportunity to consult with the Filing Party and its patent counsel
regarding the filing and contents of any application, amendment, submission or response filed
pursuant to this Section 9.1.3(a); and (v) each Party shall be responsible for all expenses
incurred by it for the preparation, filing prosecution and maintenance of any Patent Rights for
which it has primary responsibility pursuant to this Section 9.1.3.



                    (b) Joint Patent Rights. In the case of Joint Patent Rights, the Parties shall meet
through the JSC and/or the Patent Coordinators to discuss in good faith and agree upon the content
and form of any application for a Joint Patent Right and hereby agree that only the application in
the form as agreed between the Parties may be filed in respect of the Joint


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




53









 





Patent Rights. The Parties shall share the costs equally in respect of the preparation of the application, filing,
prosecution, grant and maintenance of any Joint Patent Right jointly filed; and jointly instruct an
appropriately qualified patent attorney to draft, file and prosecute the application and each Party
will have equal control over the prosecution of the filing such that the
patent attorney will only be able to act on unanimous instructions. In the event that one
Party (i) is not interested, or (ii) not willing to equally share the related cost and expense,
with respect to any Joint Patent Rights in a given country, then the other Party shall have the
right, at its own cost and expense, to file for and prosecute such Joint Patent Rights in such
country in both Parties’ names.




               9.1.4 Information and Cooperation. Each Party that has responsibility for filing and
prosecuting any Patent Rights under this Section 9.1 (a “Filing Party”) shall (a) regularly provide
the other Party (the “Non-Filing Party”) with copies of all patent applications filed hereunder for
Program Technology and Development Program Technology and other material submissions and
correspondence with the patent offices, in sufficient time to allow for review and comment by the
Non-Filing Party; and (b) provide the Non-Filing Party and its patent counsel with an opportunity
to consult with the Filing Party and its patent counsel regarding the filing and contents of any
such application, amendment, submission or response. The advice and suggestions of the Non-Filing
Party and its patent counsel shall be taken into consideration in good faith by such Filing Party
and its patent counsel in connection with such filing. Each Filing Party shall pursue in good
faith all reasonable claims and take such other reasonable actions, as may be requested by the
Non-Filing Party in the prosecution of any Patent Rights covering any Program Technology or
Development Program Technology under this Section 9.1; provided, however, if the Filing Party
incurs any additional expense as a result of any such request, the Non-Filing Party shall be
responsible for the cost and expenses of pursuing any such additional claim or taking such other
activities. In addition, MERCK (a) agrees that if ARCHEMIX claims any action taken under Section
9.1.1(a) would be detrimental to Patent Rights covering ARCHEMIX Background Technology (including
without limitation the SELEX® Portfolio), ARCHEMIX shall provide written notice to MERCK
and the Patent Coordinators shall, as promptly as possible thereafter, meet to discuss and resolve
such matter and, if they are unable to resolve such matter, the Parties shall refer such matter to
a mutually agreeable outside patent counsel for resolution.



               9.1.5 Abandonment. If a Filing Party decides to abandon or to allow to lapse any of
the Patent Rights covering any Program Technology or Development Program Technology for which it
has responsibility, it shall inform the Non-Filing Party of such decision promptly and, in any
event, so as to provide the Non-Filing Party a reasonable amount of time to meet any applicable
deadline to establish or preserve such Patent Rights in such country or region. The Non-Filing
Party shall have the right to assume responsibility for continuing the prosecution of such Patent
Rights in such country or region and paying any required fees to maintain such Patent Rights in
such country or region or defending such Patent Rights, through patent counsel or agents of its
choice, which shall be at the Non-Filing Party’s sole expense. The Non-Filing Party shall not
become an assignee of any such Patent Rights as a result of its assumption of any such
responsibility. Upon transfer of such responsibility under this Section 9.1.5, the Filing Party
shall promptly deliver to the Non-Filing Party copies of all necessary files related to the Patent
Rights with respect to which responsibility has been transferred and shall


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




54









 







take all actions and execute all documents reasonably necessary for the Non-Filing Party to assume such responsibility.




          9.2 Legal Actions.




               9.2.1 Third Party Infringement.



                    (a) Notice. In the event either Party becomes aware of (i) any possible infringement
of any Licensed Patent Rights, MERCK Patent Rights or Joint Patent Rights through the Development
or Commercialization of an Aptamer covered by the Program Aptamer-Specific Patent Rights, or (ii)
the submission by any Third Party of an abbreviated new drug application under the Hatch-Waxman Act
for a product that includes an Aptamer covered by the Program Aptamer-Specific Patent Rights (each,
an “Infringement”), that Party shall promptly notify the other Party and provide it with all
details of such Infringement of which it is aware (each, an “Infringement Notice”).



                    (b) MERCK Right to Enforce.



                         (i) Enforcement of Section 9.1.1(b) Patent Rights. In the event that any Infringement
relates to any Patent Rights covering MERCK Background Technology, MERCK shall have the sole right
but not the obligation to enforce such claim.



                         (ii) Enforcement of Sections 9.1.1(a) Patent Rights and Certain 9.1.3 (a) Patent
Rights. In the event that any Infringement relates to any Patent Right that MERCK is
responsible for prosecuting pursuant to Sections 9.1.1(a) and/or 9.1.3, MERCK shall have the first
right (but not the obligation) to enforce such claim, which may include the institution of legal
proceedings or other action; provided, that, notwithstanding the foregoing, MERCK shall not admit
the invalidity or unenforceability of any Licensed Patent Rights without ARCHEMIX’ prior written
consent. MERCK shall keep ARCHEMIX reasonably informed on a quarterly basis, in person or by
telephone, prior to and during any such enforcement. ARCHEMIX shall assist MERCK, upon request, in
taking any action to enforce any such Patent Rights and shall join in any such action if deemed to
be a necessary party. MERCK shall incur no liability to ARCHEMIX as a consequence of such
litigation or any unfavorable decision resulting therefrom, including any decision holding any such
claim invalid, not infringed or unenforceable. All costs, including without limitation attorneys’
fees, relating to such legal proceedings or other action shall be borne by MERCK. If MERCK does
not take commercially reasonable steps to abate the Infringement of such Patent Rights within [***]
days from any Infringement Notice (or [***] days in the case of an Infringement resulting from the
submission by any Third Party of an abbreviated new drug application under the Hatch-Waxman Act),
then ARCHEMIX shall have the right and option to do so at its expense.



                    (c) ARCHEMIX Right to Enforce.



                         (i) Enforcement of Section 9.1.2(b) Patent Rights. In the event that any Infringement
relates to any Patent Rights covering ARCHEMIX Background Technology, ARCHEMIX shall have the sole
right but not the obligation to enforce such claim.


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




55









 





                         (ii) Enforcement of Section 9.1.2(a) Patent Rights and Certain 9.1.3(a) Patent Rights.
In the event that any Infringement relates to any Patent Right that ARCHEMIX is responsible for
prosecuting pursuant to Sections 9.1.2(a) and/or 9.1.3, ARCHEMIX shall have the first right (but
not the obligation) to enforce such claim, which may
include the institution of legal proceedings or other action. ARCHEMIX shall keep MERCK
reasonably informed on a quarterly basis, in person or by telephone, prior to and during any such
enforcement. MERCK shall assist ARCHEMIX, upon request, in taking any action to enforce any such
Patent Rights and shall join in any such action if deemed to be a necessary party. ARCHEMIX shall
incur no liability to MERCK as a consequence of such litigation or any unfavorable decision
resulting therefrom, including any decision holding any such claim invalid, not infringed or
unenforceable. All costs, including without limitation attorneys’ fees, relating to such legal
proceedings or other action shall be borne by ARCHEMIX. If ARCHEMIX does not take commercially
reasonable steps to abate the Infringement of such Patent Rights within [***] days from any
Infringement Notice (or [***] days in the case of an Infringement resulting from the submission by
any Third Party of an abbreviated new drug application under the Hatch-Waxman Act), then MERCK
shall have the right and option to do so at its expense. For purposes of clarity, notwithstanding
anything to the contrary herein, MERCK shall have no rights to enforce any (1) ARCHEMIX Patents
Rights covering the SELEX® Process or SELEX® Technology, or (2) the
SELEX® Portfolio.



                    (d) Joint Patent Rights. In the event of an Infringement of a Joint Patent Right, the
Parties shall enter into good faith discussions as to whether and how to eliminate the
Infringement. Subject to the foregoing, (i) ARCHEMIX shall have the first right and option to
eliminate such Infringement by reasonable steps, which may include the institution of legal
proceedings or other action and (ii) all costs, including without limitation attorneys’ fees,
relating to such legal proceedings or other action shall be borne by ARCHEMIX. If ARCHEMIX does not
take or initiate commercially reasonable steps to eliminate the Infringement within [***] days from
any Infringement Notice (or [***] days in the case of an Infringement resulting from the submission
by any Third Party of an abbreviated new drug application under the Hatch-Waxman Act), then MERCK
shall have the right and option to do so at its expense.



                    (e) Representation of Either Party. Each Party shall have the right to be represented
by counsel that it selects in any legal proceedings or other action instituted under this Section
9.2.1 by the other Party.



                    (f) Cooperation by the Parties. In any action, suit or proceeding instituted under
this Section 9.2.1, the Parties shall cooperate with and assist each other in all reasonable
respects. Upon the reasonable request of the Party instituting such action, suit or proceeding,
the other Party shall join such action, suit or proceeding and shall be represented using counsel
of its own choice, at the requesting Party’s expense. If a Party with the right to initiate legal
proceedings under this Section 9.2.1 lacks standing to do so and the other Party has standing to
initiate such legal proceedings, then the Party with standing shall initiate such legal proceedings
at the request and expense of the other Party.



                    (g) Allocation of Recoveries. Any amounts recovered by MERCK pursuant to actions
under Section 9.2.1(b)(ii), whether by settlement or judgment, shall be


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




56









 







allocated in the following order: (i) first, to reimburse MERCK and ARCHEMIX for their reasonable out-of-pocket expenses in
making such recovery (which amounts shall be allocated pro rata if insufficient to cover the
totality of such expenses); and (ii) second (A) with respect to actual damages, then, to MERCK and
ARCHEMIX [***] MERCK’s historic Net Sales of the Product or Products affected by the Infringement
bears to ARCHEMIX’ historic royalties hereunder in respect of such Net Sales, in each case as determined in good faith, and (B) with
respect to punitive, special or consequential damages, [***] percent ([***]%) to MERCK. Any
amounts recovered by ARCHEMIX pursuant to actions under Section 9.2.1(c)(ii) shall be allocated in
the following order: (X) first, to reimburse ARCHEMIX and MERCK for their reasonable out of pocket
expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to
cover the totality of such expenses); and (Y) then, [***]% to ARCHEMIX.




               9.2.2 Defense of Claims.



                    (a) Notice. In the event that a Third Party alleges that the conduct of the Research
Program or the Development or Commercialization of an Optimized Lead Compound, Development
Candidate or Product infringes the Patent Rights of a Third Party, the Party becoming aware of such
allegation shall promptly notify the other Party hereof, in writing, reasonably detailing the
claim.



                    (b) Third Party Suit Relating Primarily to Program Targets or Requested Chemistry.



                         (i) In the event that any action, suit or proceeding is brought against either Party or any
Affiliate or sublicensee of either Party alleging the infringement of the Patent Rights of a Third
Party relating specifically to the Program Targets by reason of activities conducted pursuant to
this Agreement, (A) MERCK shall have the right and obligation to defend or otherwise resolve such
action, suit or proceeding (e.g., by way of entering into a settlement agreement or consent) at its
sole expense; (B) ARCHEMIX or any of its Affiliates or sublicensees shall have the right to
separate counsel at its own expense in any such action, suit or proceeding and, if such action,
suit or proceeding has been brought against ARCHEMIX or any of its Affiliates or sublicensees,
ARCHEMIX may elect to defend itself at its sole expense; and (C) the Parties shall cooperate with
each other in all reasonable respects in any such action, suit or proceeding. Settlement costs,
royalties paid in settlement of any such suit, and the payment of any damages to the Third Party
shall be borne solely by MERCK.



                         (ii) In the event that any action, suit or proceeding is brought against either Party or any
Affiliate or sublicensee of either Party alleging the infringement, by reason of activities
conducted pursuant to this Agreement, of the Technology or Patent Rights of a Third Party relating
specifically to the use of Requested Chemistry in (A) the Research Program or any Product
independent of any challenge to the right to practice the SELEX® Process or SELEX®
Technology or the SELEX® Portfolio, (B) the Development of any Development
Candidate, or (C) the Commercialization, including without limitation the manufacture, use or sale,
of any Product, MERCK shall have the right and obligation to defend


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




57









 







or otherwise resolve such action, suit or proceeding (e.g., by way of entering into a settlement agreement or consent) at its
sole expense.




                    (c) Third Party Suit Relating Primarily to the use of the SELEX®
Process or the SELEXTM Technology. In the event that any action, suit or proceeding
is brought against either Party or any Affiliate or sublicensee of either Party alleging the
infringement of the Patent Rights of a Third Party by reason of the use of the SELEXTM Process or
the use of the SELEX® Technology (excluding in either case any action, suit or proceeding based
solely on the use of Requested Chemistry) in the conduct of the Research Program (i) ARCHEMIX shall
have the right and obligation to defend or otherwise resolve such action, suit or proceeding (e.g.,
by way of entering into a settlement agreement or consent) at its sole expense; and (ii) MERCK or
any of its Affiliates or Sublicensees shall have the right to separate counsel at its own expense
in any such action, suit or proceeding and, if such action, suit or proceeding has been brought
against MERCK or any of its Affiliates or Sublicensees, MERCK or its Affiliate or Sublicensee may
elect to defend itself at its sole expense. Settlement costs, royalties paid in settlement of any
such suit, and the payment of any damages to the Third Party shall be borne solely by ARCHEMIX.



                    (d) Cooperation in Defense. The Parties shall cooperate with each other in all
reasonable respects in any action, suit or proceeding under this Section 9.2.2. Each Party shall
provide the other Party with prompt written notice of the commencement of any such suit, action or
proceeding, or of any evidence or allegation of infringement of which such Party becomes aware, and
shall promptly furnish the other Party with a copy of each communication relating to the alleged
infringement that is received by such Party. The Party that is a party to the action, suit or
proceeding shall not admit the invalidity of any patent within the Licensed Patent Rights, Joint
Patent Rights or MERCK Patent Rights, nor settle such action, suit or proceeding in a manner that
adversely affects the other Party’s rights under this Agreement, without the written consent of the
other Party, which consent shall not be unreasonably withheld, delayed or conditioned.



          9.3 Trademark and Copyright Ownership Prosecution, Defense and Enforcement. MERCK
shall own and be responsible for the filing, prosecution, maintenance, defense and enforcement of
all Product Trademarks and copyrights created during the Research Program, Development and/or
Commercialization at MERCK’s expense.




10. TERM AND TERMINATION




          10.1 Term. The term (“Term”) of this Agreement shall commence on the Effective Date
and shall continue in full force and effect until the end of the Research Program Term and, if
MERCK is Developing a Development Candidate or Commercializing a Product as of the end of the
Research Program Term, thereafter until (a) such time as MERCK is no longer Developing at least one
(1) Development Candidate or (b) if, as of the time MERCK is no longer Developing at least one (1)
Development Candidate, MERCK is Commercializing a Product, such time as all Royalty Terms for all
Products have ended, unless earlier terminated in accordance with the provisions of this Article
10. Thereafter MERCK’s rights and licenses contained herein shall



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




58









 




revert to a non-exclusive, worldwide, fully paid up and perpetual license to Commercialize a Product.




          10.2 Termination. This Agreement may be terminated at any time by either Party as
follows:




               10.2.1 Unilateral Right to Terminate. MERCK may terminate this Agreement, effective
upon not less than [***] days written notice to ARCHEMIX, (a) at any time on or after expiration of
the Research Program Term, or (b) on and after the [***] anniversary of the
Effective Date in the event that both [***] listed on Schedule 2A on the Effective
Date have been designated as [***] and the Parties cannot [***] on any Targets to [***] such [***].



               10.2.2 Termination for Breach. Either Party may terminate this Agreement, effective
immediately upon written notice to the other Party, for a material breach by the other Party of any
term of this Agreement that remains uncured for [***] days ([***] days in the event that the breach
is a failure of MERCK to make any payment required hereunder) after the non-breaching Party first
gives written notice to the other Party of such breach and its intent to terminate this Agreement
if such breach is not cured.



               10.2.3 Termination for Insolvency. In the event that either Party files for
protection under bankruptcy laws, makes a general assignment for the benefit of creditors, appoints
or suffers appointment of a receiver or trustee over its business, files a petition under any
bankruptcy or insolvency act or has any such petition filed against it which is not dismissed or
stayed within [***] days of the filing thereof, the other Party may terminate this Agreement
effective immediately upon written notice to such Party. In connection therewith, all rights and
licenses granted under this Agreement are, and shall be deemed to be, for purposes of Section
365(n) of the United States Bankruptcy Code, licenses of rights to “intellectual property” as
defined under Section 101(35A) of the United States Bankruptcy Code.



          10.3 Consequences of Termination of Agreement. In the event of the termination of
this Agreement pursuant to Section 10.2, the following provisions shall apply, as applicable.




               10.3.1 Termination Pursuant to Section 10.2.1. If this Agreement is terminated by
MERCK pursuant to Section 10.2.1:



                    (a) MERCK shall make a [***] payment to ARCHEMIX no later than the effective date of
termination equal to the difference between (i) the greater of the Minimum FTE Funding Commitment
and the actual FTE Costs incurred by ARCHEMIX through the effective date of termination and (ii)
the aggregate amount of all payments made by MERCK to ARCHEMIX for FTE Costs incurred in accordance
with Section 5.3 through the effective date of termination and all accrued and agreed Third Party
Costs;



                    (b) all licenses granted to MERCK under Article 7 to any Collaboration Aptamers as of the
effective date of termination, if any, shall immediately terminate and all such Lead Compounds,
Optimized Lead Compounds, Development Candidates


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




59









 




and Products shall be Terminated Compounds, and ARCHEMIX shall have no further obligations under Section 7.6.1




                    (c) each Party shall promptly return all Confidential Information and Proprietary Materials of
the other Party that are not subject to a continuing license hereunder; provided, that, each Party
may retain one copy of the Confidential Information of the other Party in its archives solely for
the purpose of establishing the contents thereof and ensuring compliance with its obligations
hereunder;



                    (d) upon request of ARCHEMIX, MERCK and ARCHEMIX shall agree on a transition plan pursuant to
which MERCK will transfer to ARCHEMIX all of its right,
title and interest in Terminated Compounds to ARCHEMIX which transition plan shall, depending
on the stage of development of the Terminated Compounds, obligate MERCK to:



                         (i) grant to ARCHEMIX an exclusive, worldwide, royalty-free, paid-up license under all Product
Trademarks applicable to the Terminated Compounds, if any;



                         (ii) transfer to ARCHEMIX all of its right, title and interest in all Regulatory Filings, Drug
Approval Applications and Regulatory Approvals then in its name applicable to the Terminated
Compounds, if any;



                         (iii) notify the applicable Regulatory Authorities and take any other action reasonably
necessary to effect such transfer;



                         (iv) provide ARCHEMIX with copies of all correspondence between MERCK and such Regulatory
Authorities relating to such Regulatory Filings, Drug Approval Applications and Regulatory
Approvals;



                         (v) unless expressly prohibited by any Regulatory Authority, transfer control to ARCHEMIX of
all clinical trials of the Terminated Compounds being conducted as of the effective date of
termination and continue to conduct such trials at its expense for up to [***] months to enable
such transfer to be completed without interruption of any such trial, unless ARCHEMIX demonstrates
to MERCK to MERCK’s satisfaction that ARCHEMIX shall not be able to assume such clinical trials
within [***] months, in which case MERCK shall continue to conduct such trials for up to [***]
additional months;



                         (vi) assign (or cause its Affiliates to assign) to ARCHEMIX all agreements with any Third
Party with respect to the conduct of clinical trials for the Terminated Compounds including,
without limitation, agreements with contract research organizations, clinical sites and
investigators, unless expressly prohibited by any such agreement (in which case MERCK shall
cooperate with ARCHEMIX in all reasonable respects to secure the consent of such Third Party to
such assignment);



                         (vii) provide ARCHEMIX with all supplies of the Terminated Compounds in the possession of
MERCK or any Affiliate or contractor of MERCK;



                         (viii) provide ARCHEMIX with copies of all reports and data generated or obtained by MERCK or
its Affiliates pursuant to this Agreement that relate to any Terminated Compounds that have not
previously been provided to ARCHEMIX;


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




60









 





                         (ix) reimburse ARCHEMIX for all internal and out-of-pocket costs incurred by ARCHEMIX in
continuing the research and Development according to the pre-agreed Annual Development Plan of all
the Terminated Compounds for a period of [***] days; and



                         (x) if MERCK has manufactured, is manufacturing or having manufactured any Terminated
Compounds or any intermediate thereof: (i) MERCK shall, if requested by ARCHEMIX, supply ARCHEMIX
with its requirements for all Terminated
Compounds and intermediates for up to [***] months following such termination at a transfer
price equal to [***] for the supply of such Terminated Compounds or intermediates, plus [***]
percent ([***]%), (ii) within [***] days after ARCHEMIX’s request, MERCK shall provide to ARCHEMIX
or its designee all information in its possession with respect to the manufacture of each such
Terminated Compound or intermediate.



               10.3.2 Termination by MERCK Pursuant to Section 10.2.2. If this Agreement is
terminated by MERCK pursuant to Section 10.2.2, the license granted by ARCHEMIX to MERCK pursuant
to Section 7.1.1(b) shall survive solely as applied to Development Candidates being Developed by
MERCK as of the effective date of termination, if any, and the license granted by ARCHEMIX to MERCK
pursuant to Section 7.2 shall survive solely as applied to Products being Commercialized by MERCK
as of the effective date of termination or Derived from Development Candidates being Developed by
MERCK as of the effective date of termination, if any, in each case subject to MERCK’s continued
payment of all milestone, royalty and other payments under and in accordance with this Agreement
with respect thereto; provided, that, (a) to the extent the breach that gave rise to MERCK’s right
to terminate under Section 10.2.2 is with regard to ARCHEMIX’s obligations under Section 7.6.1
then, solely with respect to the Aptamer or Collaboration Aptamer and Products Developed therefrom,
that is the subject of such breach, the license granted by ARCHEMIX to MERCK under this Section
10.3.2(a) with respect to such Product shall survive as a fully paid-up, royalty-free license; and
(b) to the extent the breach that gave rise to MERCK’s right to terminate under Section 10.2.2 is
with respect to any other obligation of ARCHEMIX under this Agreement, all milestone, royalty and
other payments applicable to such Products under this Agreement shall be [***] by [***] percent
([***]%).



               10.3.3 Termination by MERCK Pursuant to Section 10.2.3. If this Agreement is
terminated by MERCK pursuant to Section 10.2.3, unless prohibited by Applicable Laws:



                    (a) the license set forth in Section 7.1.1(b) shall survive solely as applied to Development
Candidates being Developed by MERCK as of the effective date of termination, if any, and the license set forth in Section 7.2 shall survive solely as applied to Products being Commercialized
by MERCK as of the effective date of termination or Derived from Development Candidates being
Developed by MERCK as of the effective date of termination, if any, subject to MERCK’s continued
payment of [***] milestone, royalty and other payments under and in accordance with this Agreement
with respect thereto; and


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




61









 






                    (b) each Party shall promptly return all Confidential Information and Proprietary Materials of
the other Party that are not subject to a continuing license hereunder; provided, that, each Party
may retain one copy of the Confidential Information of the other Party in its archives solely for
the purpose of establishing the contents thereof and ensuring compliance with its obligations
hereunder.



               10.3.4 Termination by ARCHEMIX Pursuant to Section 10.2.2. If this Agreement is
terminated by ARCHEMIX pursuant to Section 10.2.2 (including, without limitation, for breach by
MERCK of its diligence obligations under Section 4.5):



                    (a) the provisions of Section 10.3.1 shall apply; and



                    (b) if such termination is effective prior to the end of the Research Program Term, (i) MERCK
shall, on the effective date of termination, pay ARCHEMIX the balance of the Minimum FTE Funding
Commitment that remains unpaid as of that date and (ii) the Research Program shall terminate
without any further obligation of ARCHEMIX.



               10.3.5 Termination by ARCHEMIX Pursuant to Section 10.2.3. If this Agreement is
terminated by ARCHEMIX pursuant to Section 10.2.3, unless prohibited by Applicable Laws, the
provisions of Section 10.3.1 shall apply, except that MERCK shall have no obligation to continue to
conduct any clinical trial.



          10.4 Rights and Duties of the Parties following Breach by MERCK of Diligence
Obligations. If MERCK breaches its diligence obligations pursuant to Section 4.5 with respect
to a given Program Target or Product, as the case may be, then in lieu of termination of this
Agreement pursuant to Section 10.2.2, ARCHEMIX shall have the right, in its sole discretion, upon
ten (10) days written notice to MERCK, to (i) convert the exclusive license granted to MERCK for
each such Program Target to a non-exclusive license, in which case the provisions of Section 7.6.1
will not apply to such Program Target, or (ii) exercise its rights pursuant to Section 10.2.2 only
on a Program Target-by-Program Target, Product-by-Product and country-by-country basis.




          10.5 Surviving Provisions. Termination or expiration of this Agreement for any reason
shall be without prejudice to:




                    (a) the rights and obligations of the Parties provided in Section 3.4.1 (Record Keeping),
Section 5.5.2 (Records; Audit Rights), Section 10.3 (Consequences of Termination of Agreement),
Section 10.5 (Surviving Provisions), Section 13.1 (Arbitration), Section 13.4 (Governing Law),
Section 13.9 (No Third Party Beneficiaries), Section 13.15 (Further Assurances), Article 6
(Confidentiality), Article 8 (Intellectual Property Rights), Sections 9.1.3(b) and 9.2.1(d) (Joint
Patent Rights), Article 12 (Indemnification) and all other Sections or Articles referenced in any
such Section or Article including Article 1, all of which shall survive such termination;


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




62









 





                    (b) unless otherwise provided for in this Agreement, ARCHEMIX’s rights to receive royalties
and milestone payments for the duration of all applicable Royalty Terms, if any; and



                    (c) any other rights or remedies provided at law or equity which either Party may otherwise
have.



11. REPRESENTATIONS AND WARRANTIES




          11.1 Mutual Representations and Warranties. ARCHEMIX and MERCK each represents and
warrants to the other, as of the Effective Date, as follows:




               11.1.1 Organization. It is a corporation duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization, and has all requisite power and
authority, corporate or otherwise, to execute, deliver and perform this Agreement.



               11.1.2 Authorization. The execution and delivery of this Agreement and the
performance by it of the transactions contemplated hereby have been duly authorized by all
necessary corporate action and will not violate (a) such Party’s certificate of incorporation or
bylaws, (b) any agreement, instrument or contractual obligation to which such Party is bound in any
material respect, (c) any requirement of any Applicable Law, or (d) any order, writ, judgment,
injunction, decree, determination or award of any court or governmental agency presently in effect
applicable to such Party.



               11.1.3 Binding Agreement. This Agreement is a legal, valid and binding obligation of
such Party enforceable against it in accordance with its terms and conditions.



               11.1.4 No Inconsistent Obligation. It is not under any obligation, contractual or
otherwise, to any Person that conflicts with or is inconsistent in any respect with the terms of
this Agreement or that would impede the diligent and complete fulfillment of its obligations
hereunder.



          11.2 ARCHEMIX’ Representations and Warranties. ARCHEMIX represents and warrants to
MERCK as follows:




               11.2.1 All Licensed Technology existing as of the Effective Date is Controlled by ARCHEMIX.



               11.2.2 All Licensed Patent Rights listed on Schedule 3 are Controlled by ARCHEMIX.



               11.2.3 To the Knowledge of ARCHEMIX, as of the Effective Date, except as previously disclosed
to MERCK, no Third Party has initiated, or threatened in writing to initiate, any litigation
against ARCHEMIX or its Affiliates, including, without limitation, by initiating any declaratory
judgment lawsuit, or by sending a cease-and-desist letter, alleging that the Licensed Patent Rights


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




63









 




are invalid or unenforceable or that the use of the Licensed Patent Rights or Licensed Technology
as contemplated by this Agreement infringes the Patent Rights of such Third Party.




               11.2.4 To the Knowledge of ARCHEMIX, as of the Effective Date, except as previously disclosed
to MERCK, neither ARCHEMIX nor its Affiliates has received written notice from Gilead or URC or any
other Third Party alleging that (a) either the ARCHEMIX-Gilead License Agreement or the URC License
Agreement is not in full force and effect, (b) either the ARCHEMIX-Gilead License Agreement or the
URC License Agreement is subject to any dispute, either in court or otherwise, and (c) ARCHEMIX or
its Affiliates is in breach of the ARCHEMIX-Gilead License Agreement or the URC License Agreement,
respectively.



          11.3 Acknowledgment of MERCK. MERCK acknowledges that the licenses granted to MERCK
hereunder are subject to certain limitations and restrictions set forth in the ARCHEMIX-Gilead
License Agreement and the URC License Agreement and agrees that MERCK shall comply with the terms
of the ARCHEMIX-Gilead License Agreement and the URC License Agreement that ARCHEMIX is subject to
thereunder. MERCK hereby acknowledges and agrees and covenants that (a) it may and will not use
the SELEX® Process or the SELEX® Technology as described in the SELEX®
Portfolio for any reason, including without
limitation (i) to research, make, use, sell, offer for sale, import or export any Aptamers for
In Vitro Diagnostics, In Vivo Diagnostic Agents, or Radio Therapeutics or (ii) develop, modify,
manufacture, have manufactured, export, import, use, sell or offer to sell (A) any Aptamer other
than a Collaboration Aptamer, or (B) any Excluded Aptamer and/or any product containing an Excluded
Aptamer; (b) under the ARCHEMIX-Gilead License Agreement and under the URC License Agreement,
ARCHEMIX’ rights in the SELEX® Process or the SELEX® Technology as described
in the SELEX® Portfolio may revert to Gilead if ARCHEMIX, its Affiliates and all
assignees and sublicensees cease reasonable efforts to develop the commercial applications of
products and services utilizing the SELEX® Process or the SELEX® Technology;
(c) in the event of any termination of the URC License Agreement, the licenses granted to MERCK
hereunder shall remain in full force and effect in accordance with Section 3.4 of the URC License
Agreement; provided, that, MERCK is not then in breach of this Agreement and MERCK agrees to be
bound to UTC as the licensor under the terms and conditions of the URC License Agreement as
described in the SELEX® Portfolio; and (d) in the event of any termination of the
ARCHEMIX-Gilead License Agreement, the licenses granted to MERCK hereunder shall remain in full
force and effect in accordance with Section 2.3 of the ARCHEMIX-Gilead License Agreement; provided,
that, MERCK agrees to be bound to Gilead as the licensor under the terms and conditions of the
ARCHEMIX-Gilead License Agreement; and, provided, that, if the termination of the ARCHEMIX-Gilead
License Agreement arises out of the action or inaction of MERCK, Gilead, at its option, may
terminate such license.




12. INDEMNIFICATION




          12.1 Indemnification of MERCK by ARCHEMIX. ARCHEMIX shall indemnify, defend and hold
harmless MERCK, its Affiliates, their respective directors, officers, employees and agents, and
their respective successors, heirs and assigns (collectively, the “MERCK Indemnitees”), against all
liabilities, damages, losses and expenses (including, without limitation, reasonable attorneys’
fees and expenses of litigation) (collectively, “Losses”) incurred by or



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




64









 







imposed upon the MERCK Indemnitees, or any one of them, as a direct result of claims, suits, actions, demands or judgments
of Third Parties, including without limitation personal injury and product liability claims
(collectively, “Claims”), arising out of (i) ARCHEMIX’s research and development activities under
this Agreement, and (ii) the development, manufacture, use or sale of any Failed Compound, Waived
Compound or Terminated Compound by ARCHEMIX or any of its Affiliates, sublicensees, distributors or
agents, except with respect to any Claim or Losses that result from a breach of this Agreement by,
or the gross negligence or willful misconduct of, MERCK; provided, that, with respect to any Claim
for which ARCHEMIX has an obligation to any MERCK Indemnitee pursuant to this Section 12.1 and
MERCK has an obligation to any ARCHEMIX Indemnitee pursuant to Section 12.2, each Party shall
indemnify each of the other Party’s Indemnitees for its Losses to the extent of its responsibility,
relative to the other Party, for the facts underlying the Claim.




          12.2 Indemnification of ARCHEMIX by MERCK. MERCK shall indemnify, defend and hold
harmless ARCHEMIX, its Affiliates, their respective directors, officers, employees and agents, and
their respective successors, heirs and assigns (the “ARCHEMIX Indemnitees”), against any Losses
incurred by or imposed upon the ARCHEMIX Indemnitees, or any one of them, as a direct result of
Claims arising out of the Development of any Development Candidate or the Commercialization
(including, without limitation, the production, manufacture, promotion, import, sale or use by any
Person) of any Product by MERCK or any of its Affiliates, Sublicensees, distributors or agents,
except with respect to any Claim that results from a breach of this Agreement by, or the gross
negligence or willful misconduct of, ARCHEMIX; provided, that, with respect to any Claim for which
ARCHEMIX has an obligation to any MERCK Indemnitee pursuant to Section 12.1 and MERCK has an
obligation to any ARCHEMIX Indemnitee pursuant to this Section 12.2, each Party shall indemnify
each of the other Party’s Indemnitees for its Losses to the extent of its responsibility, relative
to the other Party, for the facts underlying the Claim.




          12.3 Indemnification of Gilead and UTC by MERCK. If, and solely to the extent,
legally required by the ARCHEMIX-Gilead License Agreement, MERCK shall indemnify, defend and hold
harmless Gilead, its Affiliates and UTC and any of their respective directors, officers, employees
and agents (each, a “Gilead Indemnitee”), from and against any Losses that are incurred by a Gilead
Indemnitee as a result of any Claims, to the extent such Claims arise out of the possession,
research, development, manufacture, use, offer for sale, sale or other commercialization,
distribution, administration, storage or transport, by MERCK or its Affiliates or Sublicensees of
(a) any Aptamers or Licensed Products, or (b) any other products, services and activities developed
by MERCK relating to the Covered Intellectual Property, including any Licensed Products, Aptamers
or Documentation (as such terms are defined in the ARCHEMIX-Gilead License Agreement), except with
respect to any Claim or Losses that result from the activities of ARCHEMIX under the
ARCHEMIX-Gilead License Agreement.




          12.4 Conditions to Indemnification. A Person seeking recovery under this Article 12
(the “Indemnified Party”) in respect of a Claim shall give prompt notice of such



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




65









 




Claim to the Party from which recovery is sought (the “Indemnifying Party”) and, provided that the Indemnifying Party
is not contesting its obligation under this Article 12, shall permit the Indemnifying Party to
control any litigation relating to such Claim and the disposition of such Claim; provided, that,
the Indemnifying Party shall (a) act reasonably and in good faith with respect to all matters
relating to the settlement or disposition of such Claim as the settlement or disposition relates to
such Indemnified Party and (b) not settle or otherwise resolve such claim without the prior written
consent of such Indemnified Party (which consent shall not be unreasonably withheld, conditioned or
delayed). Each Indemnified Party shall cooperate with the Indemnifying Party in its defense of any
such Claim in all reasonable respects and shall have the right to be present in person or through
counsel at all legal proceedings with respect to such Claim.




          12.5 Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT,
NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER
SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR
IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, VALIDITY AND NONINFRINGEMENT.




          12.6 No Warranty of Success. Nothing contained in this Agreement shall be construed
as a warranty on the part of either Party that (a) the Research Program will yield any Lead
Compound, Optimized Lead Compound or Development Candidate or otherwise be successful, (b) any
Development Program will yield a Product or otherwise be successful or (c) the outcome of the
Research Program or any Development Program will be commercially exploitable in any respect.




          12.7 Limited Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT,
NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR (I) ANY SPECIAL,
PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING WITHOUT LIMITATION LOST PROFITS
OR LOST REVENUES, OR (II) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES, WHETHER
UNDER ANY CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY.




13. MISCELLANEOUS




          13.1 Arbitration.




               13.1.1 Full Arbitration. Any dispute, controversy or claim arising between the Parties
with respect to this Agreement, including any dispute, controversy or claim relating to any
Excepted Decision (each, a “Dispute”), shall be resolved by binding arbitration before a panel of
three (3) arbitrators in accordance with the rules of the ICC in effect at the time the proceeding
is initiated; provided, that, any Dispute as to an Excepted Decision shall be resolved pursuant to
Section 13.1.2. In any such arbitration, the following procedures shall apply:



                    (a) The panel will be comprised of one arbitrator chosen by MERCK, one by ARCHEMIX and the
third by the two so chosen. If either, or both, of MERCK or


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




66









 




ARCHEMIX fails to choose an arbitrator or arbitrators within thirty (30) days after receiving notice of commencement of arbitration or if
the two arbitrators fail to choose a third arbitrator within thirty (30) days after their
appointment, then either or both Parties shall immediately request that the ICC select the
remaining number of arbitrators to be selected, which arbitrator(s) shall have the requisite
scientific background, experience and expertise. The place of arbitration shall be New York, New
York.




                    (b) Either Party may apply to the arbitrators for interim injunctive relief until the
arbitration decision is rendered or the Dispute is otherwise resolved. Either Party also may,
without waiving any right or remedy under this Agreement, seek from any court having jurisdiction
any injunctive or provisional relief necessary to protect the rights or property of that Party
pending resolution of the Dispute pursuant to this Section 13.1.1. The arbitrators shall have no
authority to award punitive or any other type of damages not measured by a Party’s compensatory
damages. Each Party shall bear its own costs and expenses and attorneys’ fees in connection with
any such arbitration; provided, that, the non-prevailing Party shall pay the costs and expenses
incurred by the prevailing Party in connection with any such arbitration, including reasonable
attorneys’ fees and costs. The Parties acknowledge that while Section 13.4 shall apply
to any such Dispute, it is the intention of the Parties not to use the discovery rules of the
State of New York in connection with any such Dispute.



                    (c) Except to the extent necessary to confirm an award or decision or as may be required by
Applicable Laws, neither Party nor any arbitrator may disclose the existence or results of any
arbitration without the prior written consent of both Parties. In no event shall any arbitration be
initiated after the date when commencement of a legal or equitable proceeding based on the Dispute
would be barred by the applicable New York statute of limitations.



                    (d) In the event of a Dispute involving the alleged breach of this Agreement (including,
without limitation, whether a Party has satisfied its diligence obligations hereunder), (i) neither
Party may terminate this Agreement under Section 10.2.2 until resolution of the Dispute pursuant to
this Section 13.1.1 and (ii) if the arbitrators render a decision that a breach of this Agreement
has occurred, the arbitrators shall have no authority to modify the right of the non-breaching
Party to terminate this Agreement in accordance with Section 10.2.2.



                    (e) Any disputed performance or suspended performance pending the resolution of a Dispute that
the arbitrators determine to be required to be performed by a Party shall be completed within a
reasonable time period following the final decision of the arbitrators.



                    (f) The decision of the arbitrators shall be the sole, exclusive and binding remedy between
the Parties regarding the determination of all Disputes presented. Any monetary payment to be made
by a Party pursuant to a decision of the arbitrators shall be made in United States dollars, free
of any tax or other deduction.



               13.1.2 Accelerated Arbitration. To the extent a Dispute submitted to arbitration by a
Party under Section 13.1.1 is claimed, by either Party, to involve an Excepted Decision, the
following procedures shall apply:


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




67









 








                    (a) The Parties shall mutually select a single independent, conflict-free arbitrator (the
“Expert”), who shall have sufficient scientific background and experience to resolve the Dispute.
If the Parties are unable to reach agreement on the selection of an Expert within fifteen (15)
business days after submission to arbitration, then either or both Parties shall immediately
request that the ICC select an arbitrator with the requisite scientific background, experience and
expertise. The place of arbitration shall be New York, New York.



                    (b) Each Party shall prepare and submit a written summary of such Party’s position and any
relevant evidence in support thereof to the Expert within thirty (30) days of the selection of the
Expert. Upon receipt of such summaries from each Party, the Expert shall provide copies of the
same to the other Party. Within thirty (30) days of the delivery of such summaries by the Expert,
each Party shall submit a written rebuttal of the other Party’s summary and may also amend and
re-submit its original summary. Oral presentations shall not be permitted unless otherwise
requested by the Expert. The Expert shall make a final decision with respect to the Dispute within
thirty (30) days following receipt of the last of such rebuttal statements submitted by the
Parties. Each Party shall bear its own costs and expenses and
attorneys’ fees, and the Party that does not prevail in the arbitration proceeding shall pay
the Expert’s fees and any administrative fees of arbitration.



          13.2 Change of Control.




               13.2.1  ARCHEMIX Change of Control.



                    (a) Notice. If ARCHEMIX enters into an agreement that results or, if the transaction
contemplated thereby is completed, would result in a Change of Control, ARCHEMIX shall provide
MERCK with prompt written notice describing such Change of Control in reasonable detail (the
“ARCHEMIX Change of Control Notice”). The ARCHEMIX Change of Control Notice shall be provided by
ARCHEMIX prior to execution of such agreement, if permitted under Applicable Laws and not
prohibited by the terms of any agreement between ARCHEMIX and any Third Party, and otherwise as
soon as practicable thereafter and, in any event, not later than promptly following the
consummation of the transaction contemplated by such agreement.



                    (b) Change of Control Involving Competitive Entity. If the Change of Control that is
described in the ARCHEMIX Change of Control Notice results or, if completed, would result in a
Competitive Entity becoming an Affiliate of ARCHEMIX, then, within [***] days after such ARCHEMIX
Change of Control Notice is provided by ARCHEMIX, MERCK shall have the right to provide written
notice to ARCHEMIX, in its sole discretion, (i) if the ARCHEMIX Change of Control Notice is
provided prior to expiration of the Research Program Term, [***] the Research Program (subject to
MERCK’s obligation to [***] ARCHEMIX the [***] of the [***] that remains [***] as of on the
effective date of termination pursuant to Section 5.3); (ii) if the ARCHEMIX Change of Control
Notice is received at any time during the Term, (A) [***] ARCHEMIX’s [***] in any [***] pursuant to
Article 4 (including ARCHEMIX’s right to [***] in the [***], [***] and [***]); (B) to the extent
not mutually agreed as of the date of the ARCHEMIX Change of Control Notice is given, [***]
ARCHEMIX’s right to [***] a [***] pursuant to Section 4.9.2; and (C) to the extent MERCK is
prosecuting Program


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




68









 




Aptamer-Specific Patent Rights in accordance with Section 9.1.1(a), [***]
MERCK’s obligation to [***] pursuant to Section 9.1.4 with respect to such Program Aptamer-Specific
Patent Rights. In all other aspects, this Agreement remains unchanged. If MERCK should fail to
give such notice to ARCHEMIX within such [***] day period, MERCK shall have no further rights under
this Section 13.2.1 as a result of the Change of Control described in the ARCHEMIX Change of
Control Notice.




                    (c) Change of Control Involving Competitive Program. If the Change of Control that is
described in the ARCHEMIX Change of Control Notice involves a Third Party that has a Competitive
Program, then, notwithstanding any provision hereof, the existence and continuation of such
Competitive Program in any respect following the Change of Control shall not be deemed to be a
breach of this Agreement.



               13.2.2 MERCK Change of Control.



                    (a) Notice. If MERCK enters into an agreement that results or, if the transaction
contemplated thereby is completed, would result in a Change of Control, MERCK
shall provide ARCHEMIX with prompt written notice describing such Change of Control in
reasonable detail (the “MERCK Change of Control Notice”). The MERCK Change of Control Notice shall
be provided by MERCK prior to execution of such agreement, if permitted under Applicable Laws and
not prohibited by the terms of any agreement between MERCK and any Third Party, and otherwise as
soon as practicable thereafter and, in any event, not later than promptly following the
consummation of the transaction contemplated by such agreement.



                    (b) Change of Control Involving Competitive Program. If the Change of Control that is
described in the MERCK Change of Control Notice involves a Third Party that has a Competitive
Program, then, notwithstanding any provision hereof, the existence and continuation of such
Competitive Program in any respect following such Change of Control shall not be deemed to be a
breach of this Agreement; provided, that, each chemical compound or product that is part of the
Competitive Program shall be deemed to be an Optimized Lead Compound, Development Candidate or
Product in the event such chemical compound or product meets standards or criteria hereunder for
Optimized Lead Compounds, Development Candidates or Products, and shall be subject to royalty
payments as set forth in this Agreement (but not milestone payments) applicable to Optimized Lead
Compounds, Development Candidates and Products.



          13.3 Notices. All notices and communications shall be in writing and delivered
personally or by courier or mailed via certified mail, return receipt requested, addressed as
follows, or to such other address as may be designated from time to time:




	 	 	 	 	 
	 

	 	If to MERCK:
	 	If to ARCHEMIX:
	 
	 

	 	MERCK KGaA	 	 
	 

	 	Legal Department
	 	Archemix Corp.
	 

	 	Frankfurter Str. 250
	 	300 Third Street
	 

	 	64293 Darmstadt
	 	Cambridge, MA 02142





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




69









 





	 	 	 	 	 
	 

	 	Germany
	 	Tel: (617) 621-7700
	 

	 	Tel: +49 6151 72 0
	 	Fax: (617) 621-9300
	 

	 	Fax: +49 6151 72 [***]
	 	Attention: Chief Executive Officer
	 

	 	 	 	Attention: General Counsel
	 
	 	 	 	 
	 

	 	 	 	With a copy to:
	 
	 	 	 	 
	 

	 	 	 	Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C.
	 

	 	 	 	One Financial Center
	 

	 	 	 	Boston, Massachusetts 02111
	 

	 	 	 	Attention: John J. Cheney, Esq.
	 

	 	 	 	Tel: (617) 542-6000
	 

	 	 	 	Fax: (617) 542-2241






          In addition, all notices to the JPT or JSC shall be sent to each Party’s designees at such
Party’s address stated above or to such other address as such Party may designate by written notice
given in accordance with this Section 13.3.



          Except as otherwise expressly provided in this Agreement or mutually agreed in writing, any
notice, communication or document (excluding payment) required to be given or made shall be deemed
given or made and effective upon actual receipt or, if earlier, (a) three (3) business days after
deposit with an internationally-recognized overnight express courier with charges prepaid, or (b)
five (5) business days after mailed by certified, registered or regular mail, postage prepaid, in
each case addressed to a Parties at its address stated above or to such other address as such Party
may designate by written notice given in accordance with this Section 13.3.



          13.4 Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of New York, without regard to the application of principles of
conflicts of law.




          13.5 Binding Effect. This Agreement shall be binding upon and inure to the benefit of
the Parties and their respective legal representatives, successors and permitted assigns.




          13.6 Headings. Section and subsection headings are inserted for convenience of
reference only and do not form a part of this Agreement.




          13.7 Counterparts. This Agreement may be executed simultaneously in two or more
counterparts, each of which shall be deemed an original and both of which, together, shall
constitute a single agreement.




          13.8 Amendment; Waiver. This Agreement may be amended, modified, superseded or
canceled, and any of the terms of this Agreement may be waived, only by a written instrument
executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. The
delay or failure of either Party at any time or times to require performance of any provisions
shall in no manner affect the rights at a later time to enforce the same. No waiver by either
Party of any condition or of the breach of any term contained in this Agreement, whether by
conduct,



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




70









 




or otherwise, in any one or more instances, shall be deemed to be, or considered as, a
further or continuing waiver of any such condition or of the breach of such term or any other term
of this Agreement.




          13.9 No Third Party Beneficiaries. Except as set forth in Sections 12.1, 12.2 and
12.3, no Third Party (including, without limitation, employees of either Party) shall have or
acquire any rights by reason of this Agreement.




          13.10 Purposes and Scope. The Parties hereto understand and agree that this
Collaboration is limited to the activities, rights and obligations as set forth in this Agreement.
Nothing in this Agreement shall be construed (a) to create or imply a general partnership between
the Parties, (b) to make either Party the agent of the other for any purpose, (c) to alter, amend,
supersede or vitiate any other arrangements between the Parties with respect to any subject matters
not covered hereunder, (d) to give either Party the right to bind the other, (e) to create any
duties or obligations between the Parties except as expressly set forth herein, or (f) to grant any
direct or implied licenses or any other right other than as expressly set forth herein.




          13.11 Assignment and Successors. Neither this Agreement nor any obligation of a Party
hereunder may be assigned by either Party without the consent of the other which shall not be
unreasonably withheld, except that each Party may assign this Agreement and the rights, obligations
and interests of such Party, in whole or in part, to any of its Affiliates, to any purchaser of all
or substantially all of its assets or all or substantially all of its assets to which this
Agreement relates or to any successor corporation resulting from any merger, consolidation, share
exchange or other similar transaction.




          13.12 Force Majeure. Neither MERCK nor ARCHEMIX shall be liable for failure of or
delay in performing obligations set forth in this Agreement, and neither shall be deemed in breach
of its obligations, if such failure or delay is due to a Force Majeure. In event of such Force
Majeure, the Party affected shall use reasonable efforts to cure or overcome the same and resume
performance of its obligations hereunder.




          13.13 Interpretation. The Parties hereto acknowledge and agree that: (a) each Party
and its counsel reviewed and negotiated the terms and provisions of this Agreement and have
contributed to its revision; (b) the rule of construction to the effect that any ambiguities are
resolved against the drafting Party shall not be employed in the interpretation of this Agreement;
and (c) the terms and provisions of this Agreement shall be construed fairly as to each Party and
not in a favor of or against either Party, regardless of which Party was generally responsible for
the preparation of this Agreement.




          13.14 Integration; Severability. This Agreement is the entire agreement with respect
to the subject matter hereof and supersedes all other agreements and understandings between the
Parties with respect to such subject matter. If any provision of this Agreement is or becomes
invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it
is the intention of the Parties that the remainder of the Agreement shall not be affected.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




71









 





          13.15 Further Assurances. Each of ARCHEMIX and MERCK agrees to duly execute and
deliver, or cause to be duly executed and delivered, such further instruments and do and cause to
be done such further acts and things, including, without limitation, the filing of such additional
assignments, agreements, documents and instruments, as the other Party may at any time and from
time to time reasonably request in connection with this Agreement or to carry out more effectively
the provisions and purposes of, or to better assure and confer unto such other Party its rights and
remedies under, this Agreement.




[Remainder of page intentionally left blank.]



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




72









 





          IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives.




	 	 	 	 	 	 	 
	 	 	ARCHEMIX CORP.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	MERCK KGaA	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	ppa.            i.V.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	[***]
	 	 

	 	 





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




73









 





SCHEDULE 1




OPTIMIZED LEAD COMPOUND SELECTION CRITERIA



[Lead Compound is ready for efficacy testing in animal models including, at a minimum, binding
affinity, specificity, activity, size, and rodent PK criteria but shall not include animal
efficacy, animal toxicology, process development or cost of goods criteria.]





Optimized Lead Selection Criteria




	 	•	 	[***] for [***] is [***] or [***] to [***]
	 
	 	•	 	[***] in [***] with an [***] and an [***].
	 
	 	•	 	[***] for the [***] (e.g., no [***] to [[***]]).*
	 
	 	•	 	[***] to [***] (e.g., to [***] of [***] with an [***], [***]% of [***] in [***] and
[***]% of [***]).
	 
	 	•	 	[***] (e.g., [***] on [***]).
	 
	 	•	 	[***] as [***] by [***] of [***], a [***] of the [***], or [***] of [***].*
	 
	 	•	 	[***] can be [***] using [***] with [***].
	 
	 	•	 	[***] can be [***] for [***] at [***] and [***] of [***] and with [***] and [***].
	 
	 	•	 	[***] for [***] use as [***] using [***] that [***] (e.g., [***]).
	 
	 	•	 	[***] does not [***] an [***] in the [***] of [***] to [***] other [***]).






*Specific criteria would be [***] on a [***], reflecting [***] for each program and
[***] of [***], and approved by the JSC:




	 	•	 	[***]
	 
	 	•	 	[***] of the [***] for its [***] (e.g. [***])
	 
	 	•	 	[***] and [***] for [***]
	 
	 	•	 	[***]





Comments





	 	•	 	[***] include [***] but not [***]. [***] with [***] provides a [***] for [***]
from [***].
	 
	 	•	 	The [***] of [***] is [***] by [***] the [***] of [***]. No efforts at [***] are
envisioned [***] to [***].
	 
	 	•	 	[***] for [***], etc.) have yet to be established. We have [***] any [***] for
[***] in these [***] up to [***] of [***].




Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 1-1




 









 





SCHEDULE 2A




PROGRAM TARGETS





	•	 	[***]




Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 2A-1




 









 





SCHEDULE 2B




REPLACEMENT TARGETS





	•	 	[***]
	 
	•	 	[***]




Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 2B-1




 









 





SCHEDULE 3




LICENSED PATENT RIGHTS




	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-1




 









 





	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	 	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	 	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-2




 









 





	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-3




 









 





	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-4




 









 





	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-5




 









 





	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-6




 









 





	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-7




 









 





	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	 	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-8




 









 





	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-9




 









 





	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-10




 









 





	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	 	 	[***]
	 	[***]
	 





	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	  [***]	 	  [***]



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-11




 









 





	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-12




 









 





	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-13




 









 





	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-14




 









 





	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-15




 









 





	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-16




 









 





	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 3-17





 









 





SCHEDULE 4




EXCLUDED APTAMERS





	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]






Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.



Sched. 4-1



 









 





SCHEDULE 5




EXCLUDED TARGETS





	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]
	 
	•	 	[***]






Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.


Sched. 5-1




 









 





SCHEDULE 6




DEVELOPMENT CANDIDATE SELECTION CRITERIA




Development Candidate Selection Criteria





	•	 	[***] from [***] and [***] of [***] and [***] in [***] (e.g., [***] (or [***]) by a
[***]).
	 
	•	 	[***] of [***] with [***] or [***] of [***] with [***] to [***] of [***] in [***]
and [***] with the [***].
	 
	•	 	[***] in [***] appears [***] for the [***].
	 
	•	 	[***] and [***].
	 
	•	 	[***]
	 
	•	 	[***] with [***], as defined [***] the [***] (thus no [***])




(If [***] requires [***] of [***])





	 	o	 	[***] remain [***] than a [***] (as measured by [***]) [***]
the [***] (e.g., after [***]).






	•	 	(If [***] requires [***])






	 	o	 	[***] after [***] in [***], with [***] to [***].
	 
	 	o	 	With [***] in [***], no [***] of [***] in [***] of [***] the
[***] (e.g., after [***]) which would result in a [***] in the [***] to [***]
of [***].






	•	 	(If [***])






	 	o	 	[***] of [***]
	 
	 	o	 	[***] and [***] must permit a [***] that can [***] be [***]
though a [***] or [***].
	 
	 	o	 	[***] at [***] in [***] at [***] and [***].









Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.


Sched. 6-1




 









 





SCHEDULE 7




FORM OF PRESS RELEASE



Merck KGaA and Archemix to Collaborate on Aptamer-Based Cancer Therapeutics



Darmstadt, January xx, 2007 – Merck KGaA announced today that it has signed a multi-year,
multi-target agreement with Archemix Corp. of Cambridge, Massachusetts, that focuses on the
discovery, development, and commercialization of first-in-class aptamer-based therapeutics to treat
cancer.



Under terms of the agreement, Archemix will receive an upfront payment and committed research
funding of as much as $10 million. Archemix also could receive milestones and royalty payments for
products successfully commercialized under the collaboration. In addition, Archemix may participate
in the co-promotion of products that result from the collaboration. Other financial terms were not
disclosed.



“Archemix is the leader in the field of aptamers, a new class of drugs that has tremendous
potential in the battle against cancer,” said Dr. Bernhard Kirschbaum, Executive Senior Vice
President and Director of Research for Merck Serono. “We hope this collaboration will further our
efforts to provide physicians and oncology patients with innovative, targeted cancer treatments.”



Dr. Errol De Souza, President and Chief Executive Officer of Archemix, commented: “Merck is a
recognized global leader in oncology drug development and marketing and we are excited to be
working with them to apply our scientific expertise in developing novel aptamer therapeutics for
cancer. This alliance is the fourth major partnership we have formed over the past 6 months and is
consistent with our strategy to enable partners to leverage aptamers as drugs on a target by target
basis.”




Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.


Sched. 7-1





 









 





About Aptamers



Aptamers are single-stranded nucleic acids that form well-defined three-dimensional shapes,
allowing them to bind target molecules in a manner that is conceptually similar to antibodies.
Aptamers combine the optimal characteristics of small molecules and antibodies, including high
specificity and affinity, chemical stability, low immunogenicity and the ability to target
protein-protein interactions. In contrast to monoclonal antibodies, aptamers are chemically
synthesized rather than biologically expressed, offering a significant cost advantage.



About Archemix Corp.



Archemix Corp. is a privately-held biopharmaceutical company based in Cambridge, Massachusetts. The
company’s mission is to develop aptamers as a class of directed therapeutics for the prevention and
treatment of human disease. Because of their unique properties and proven efficacy, aptamers offer
an alternative to biologics and small molecules in numerous applications and offer the potential to
be a major class of drugs for the treatment of unmet medical needs.



Archemix’s aptamer expertise is complemented by a robust patent estate comprised of over 220 issued
and 230 pending patents covering the identification, composition, and use of therapeutic aptamers.
In addition to the company’s core aptamer generation technology, Archemix possesses strong
expertise in both pre-clinical and clinical drug development. Further information on Archemix can
be found at www.archemix.com.



All Merck Press Releases are distributed by e-mail at the same time they become available on
the Merck Website. Please go to http://www.subscribe.merck.de to register online, change
your selection or discontinue this service.



Merck is a global pharmaceutical and chemical company with sales of EUR 5.9 billion in 2005, a
history that began in 1668, and a future shaped about 35,000 employees in 56 countries. Its success
is characterized by innovations from entrepreneurial employees. Merck’s operating activities come
under the umbrella of Merck KGaA, in which the Merck family holds a 73% interest and free
shareholders own the remaining 27%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and
has been an independent company ever since.




Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.



Sched. 7-2




 









 





Archemix and Merck KGaA to Collaborate on Aptamer-Based Cancer Therapeutics



CAMBRIDGE, MA – January XX, 2007 – Archemix Corp. announced today that it has signed a
multi-year, multi-target agreement with Merck KGaA of Darmstadt, Germany, that focuses on the
discovery, development, and commercialization of first-in-class aptamer-based therapeutics to treat
cancer.



Under terms of the agreement, Archemix will receive an upfront payment and committed research
funding of as much as $10 million. Archemix also could receive milestones and royalty payments for
products successfully commercialized under the collaboration. In addition, Archemix may participate
in the co-promotion of products that result from the collaboration. Other financial terms were not
disclosed.



Dr. Errol De Souza, President and Chief Executive Officer of Archemix, commented: “Merck is a
recognized global leader in oncology drug development and marketing and we are excited to be
working with them to apply our scientific expertise in developing novel aptamer therapeutics for
cancer. This alliance is the fourth major partnership we have formed over the past six months and
is consistent with our strategy to enable partners to leverage aptamers as drugs on a target by
target basis.”



“Archemix is the leader in the field of aptamers, a new class of drugs that has tremendous
potential in the battle against cancer,” said Dr. Bernhard Kirschbaum, Executive Senior Vice
President and Director of Research for Merck Serono. “We hope this collaboration will further our
efforts to provide physicians and oncology patients with innovative, targeted cancer treatments.”




About Aptamers



Aptamers are single-stranded nucleic acids that form well-defined three dimensional shapes,
allowing them to bind target molecules in a manner that is conceptually similar to antibodies.
Aptamers combine the optimal characteristics of small molecules and antibodies, including high
specificity and affinity, chemical stability, low immunogenicity and the ability to target
protein-protein interactions. In contrast to monoclonal antibodies, aptamers are chemically
synthesized rather than biologically expressed, offering a significant cost advantage.




Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.



Sched. 7-3




 









 








About Archemix Corp.



Archemix Corp. is a privately-held biopharmaceutical company based in Cambridge, Massachusetts. The
company’s mission is to develop aptamers as a class of directed therapeutics for the prevention and
treatment of human disease. Because of their unique properties and proven efficacy, aptamers offer
an alternative to biologics and small molecules in numerous applications and offer the potential to
be a major class of drugs for the treatment of unmet medical needs.



Archemix’s aptamer expertise is complemented by a robust patent estate comprised of over 220 issued
and 230 pending patents covering the identification, composition, and use of therapeutic aptamers.
In addition to the company’s core aptamer generation technology, Archemix possesses strong
expertise in both pre-clinical and clinical drug development. Further information on Archemix can
be found at www.archemix.com.




     About Merck


Merck is a global pharmaceutical and chemical company with sales of EUR 5.9 billion in 2005, a
history that began in 1668, and a future shaped by about 35,000 employees in 56 countries. Its
success is characterized by innovations from entrepreneurial employees. Merck’s operating
activities come under the umbrella of Merck KGaA, in which the Merck family holds a 73% interest
and free shareholders own the remaining 27%. In 1917 the U.S. subsidiary Merck & Co. was
expropriated and has been an independent company ever since.





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.



Sched. 7-4



 









 





SCHEDULE 8




REGIONAL OFFICES OR COUNTRIES IN WHICH

PATENT APPLICATIONS ARE TO BE NATIONALIZED

OR OTHERWISE PROSECUTED, FILED AND MAINTAINED




	 	 	 
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]
	[***]
	 	 








 




			
	*	 	[***]




In addition, any country not listed above in which MERCK customarily pursues patent protection for
a commercial product, taking into account all relevant factors (including, as applicable and
without limitation, stage of development, mechanism of action, efficacy and safety relative to
competitive products in the marketplace, actual or anticipated Regulatory Authority approved
labeling, the nature and extent of market exclusivity (including patent coverage and regulatory
exclusivity), cost and likelihood of obtaining Commercialization Regulatory Approval, actual or
projected profitability and availability of capacity to manufacture and supply for commercial
sale).





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 8-1


 









 





SCHEDULE 9




MATERIAL TERMS TO BE INCLUDED IN

FORM OF CO-PROMOTION AGREEMENT




     The Co-Promotion Agreement is to be negotiated by the Parties in accordance with Section 4.9.2
and shall contain the following material terms. Capitalized terms used in this Schedule 9
and not otherwise defined have the meanings given to them in the Agreement.



     1. Joint Marketing Committee.



          (a) Establishment. [***] of the [***] but in [***], ARCHEMIX and MERCK shall [***]
ARCHEMIX and MERCK [***], which shall have and [***].




          (b) Membership. Each of ARCHEMIX and MERCK shall [***] to the [***] by the[***], one
of [***], on a [***] to the [***].




          (c) Meetings.




                         (i) Schedule of Meetings; Agenda. [***], without [***] for the [***] and its [***]by
any [***] (or, if such [***] to be [***] to the [***]; provided, that, [***], either before or
after such [***] of any [***], unless such [***] for the [***] to its [***]; provided, that, [***]
for each [***].



                         (ii) Quorum; Voting; Decisions. [***] of the [***]; provided, that, [***] from the
[***]. Whenever [***] by the [***] in which the [***]of the [***] or by [***] of the [***], which
shall not [***].



          (d) Responsibilities. [***] shall be [***] in the [***] shall have the [***]:




                         (i) the [***] for the [***] of each [***];



                         (ii) [***] of a [***] for each [***] in the [***];



                         (iii) [***] and [***] for [***];



                         (iv) [***] and the [***] of all [***] in the [***], but [***];



                         (v) [***] of [***] in the [***];



                         (vi) [***] and any [***] in the [***];



                         (vii) [***] to [***];



                         (viii) [***] to be [***] to [***] to [***];[***] to the [***] to[***]; and




Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 9-1


 









 





                         (ix) [***] as may be [***], or by [***] of the [***].



          (e) Dispute Resolution. The [***]. In the event that, [***] on a [***] after the
[***], then the [***].




     2. Co-Promotion Plan. The [***] for the [***], but not be [***] in the [***] and
[***] for such [***] for such [***] for such [***] shall be [***] ARCHEMIX’S [***] and shall be
[***] and [***] MERCK’s and ARCHEMIX’s [***]r.



     3. Labeling. [***] MERCK and ARCHEMIX. The [***] and [***] in the [***] and [***] or
in the [***].



     4. Co-Promotion Rights.



          (a) ARCHEMIX and MERCK [***] is to [***] of the [***] for [***] that the [***] to the [***]
but [***]; provided, that, the [***] of the [***] and the [***] in such [***] as the [***] for the
[***] of such [***] with the [***] from which each [***] and [***] of [***] that it may be
[***]shall be [***] to be [***].




          (b) The [***] to the [***] with a [***]. It is [***] to the [***]. With respect to each
[***] as the [***] to be [***].




          (c) MERCK s[***] ARCHEMIX a [***]MERCK [***] the MERCK [***] and MERCK [***].




          (d) ARCHEMIX and MERCK [***] if that [***] that is [***] that is [***] shall be [***] that its
[***] and/or the [***] of the [***] with an [***] for the [***] for its [***] in the [***].




     5. Commercialization Efforts. [***] with the [***], and to [***] with each [***] out
such [***].



     6. Co-Promotion Marketing and Sales Plan and Budget.



          (a) Preparation of Plan and Budget. MERCK, [***]ARCHEMIX, [***] for each [***] for
the [***], and each such [***] shall be [***] by the [***]; provided, that each such [***] with
ARCHEMIX’s [***] but not be[***] and [***] for the [***] in the [***] and [***] for the [***] for
each [***] for the [***]. Each [***] of the [***] shall be [***] to the [***] by a [***], but no
[***].




          (b) Changes to Plans/Budgets. [***] in a [***] of the [***] to the [***], MERCK
[***]to the [***] with such [***] by MERCK [***].




          (c) Detail Audit Rights. [***] MERCK and ARCHEMIX [***] for a [***] from the [***]
shall have the [***] of the [***] to the [***] at such [***] shall not be [***] in [***] in the
course of [***], shall be [***] of the [***]. The [***] of such [***] in the [***] in the [***] by
such [***].





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 9-2


 









 





     7. Control Over Advertising and Detailing.



          (a) [***] in any [***] or other [***] (to be [***] with a [***] in the [***] and [***] by the
[***].




          (b) [***] on the [***], but all [***] ARCHEMIX or MERCK and [***] shall be [***].




          (c) [***] shall be [***] with a [***] of the [***].




          (d) [***] with the [***] of the [***] of the [***] of the [***].




          (e) MERCK [***] and for [***] as may be [***]; and [***] but shall, in [***] with, and [***].




          (f) MERCK [***] for the [***].




          (g) [***] in any [***] or other [***] with a [***] unless the [***] by the [***] by the [***],
but all [***] ARCHEMIX or MERCK [***] which is not [***] shall be [***]. Without the [***] of the
[***] of the [***].




     8. Sales Efforts in the Co-Promotion Territory. As [***] for the [***] of the [***]
for the [***] and [***] in the [***], of the [***] to be [***] with the [***] that ARCHEMIX [***]
of the [***] to the [***] in an [***] with the [***] to each [***] in the [***] of such [***] of
the [***] that it may be [***] in the [***], and, [***] in the [***] as it [***] to be [***].



     9. Training Program. [***] for the [***] of all [***] to be [***] in the [***] that
is [***] that for the [***] and the [***] of such [***] as a [***] under this [***].



     10. Trademarks. MERCK [***], and MERCK [***]ARCHEMIX [***]MERCK [***] in the [***]
all such [***] in the [***] for all [***] be the [***] of the [***] in the [***].



     11. Product Recalls. In the [***], or in the [***] that an [***] in the [***] and
have [***] in the [***] by a [***] or to [***] in which [***], the [***] shall be [***] that
ARCHEMIX [***], ARCHEMIX [***] MERCK. MERCK [***] or [***] of the [***] for such [***].



     12. Co-Promotion Mechanism.



          (a) Sales. [***] in the [***] MERCK. If, during the [***], ARCHEMIX [***] for a
[***] MERCK.




          (b) Processing of Orders for Co-Promoted Products.




                         (i) [***] by MERCK [***] by MERCK in a [***] with the [***] by it in [***].




Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 9-3


 









 





                         (ii) MERCK [***] by it for a [***], that MERCK [***] on an [***], but only with [***] with the
[***] by it with [***].



                         (iii) MERCK [***] with [***].



     13. Termination of Co-Promotion Participation. I[***], at the [***], ARCHEMIX [***]
to MERCK, to [***] of any [***], provided that ARCHEMIX [***] from ARCHEMIX’ [***].



     14. Cost of Detailing. [***], in no event shall [***] to an [***] of the [***], such
as [***] MERCK [***] ARCHEMIX.




Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 9-4


 









 





SCHEDULE 10



MERCK’S STANDARD EXCHANGE RATE METHODOLOGY APPLIED

IN ITS EXTERNAL REPORTING



MERCK’s standard exchange rate methodology uses the applicable [***] foreign exchange
rate as published by the [***].



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.




Sched. 10-1


 









 





SCHEDULE 11




Program Chemistries



[***]: [***] containing [***], or [***] of [***].



[***]:




	 	 	 
	[***]
	 	 
	[***]
	 	 
	[***]
	 	 
	[***]
	 	 
	[***]
	 	 
	[***]

	 	 









Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
of the Securities Act.



Sched. 11-1




 









 





AMENDMENT TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENT

BETWEEN ARCHEMIX CORP. AND MERCK KGaA DATED JANUARY 17, 2007




     This AMENDMENT TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered
into as of June 6, 2007, by and between Archemix Corp., a Delaware corporation with offices at 300
Third Street, Cambridge, MA 02142 (“ARCHEMIX”), and Merck KGaA, a company organized under the laws
of Germany with offices at Frankfurter Str. 250, 64293 Darmstadt, Germany (“MERCK”). Each of MERCK
and ARCHEMIX is sometimes referred to individually herein as a “Party” and collectively as the
“Parties.”



     WHEREAS, MERCK and ARCHEMIX entered into a Collaborative Research and License Agreement (the
“First License Agreement”) on January 17, 2007; and



     WHEREAS, concurrent with the signature of this Agreement MERCK and ARCHEMIX shall enter into a
second Collaborative Research and License Agreement (the “Second License Agreement”); and



     WHEREAS, MERCK and ARCHEMIX now wish to amend certain provisions of the First License
Agreement to make them consistent with the provisions of the Second License Agreement.



     NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good
and valuable consideration, the Parties hereto, intending to be legally bound, hereby agree as
follows:




	1.	 	Effective as of the date first written above, Section 1.64 of the First License Agreement is
hereby amended to read as follows:
	 
	 	 	“In Vitro Diagnostics” means the use of the SELEX® Process or aptamers or
photoaptamers identified through the use of the SELEX® Process in the assay,
testing or determination, outside of a living organism, of a substance in a test material.
In Vitro Diagnostics shall include, among other things, the use of the SELEX®
Process or aptamers or photoaptamers identified through the use of the SELEX®
Process in the assay, testing or determination: (a) outside of a living organism, (i)
of a human substance in a test material, often to identify or follow the progression of a
disease or disorder, or to select a patient for treatment; (ii) of a plant substance, animal
substance or other substance in a test material, often to identify or follow the progression
of a disease, process, or disorder in a human or non-human organism; and (iii) of
environmental substances (as in water quality testing); and (b) of a substance on a test
material such as cells (as in FACS analysis or other measurements of pathogens within
biological samples).




Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application
requesting confidential treatment under Rule 406 of the
Securities Act.

1









 










	2.	 	Effective as of the date first written above, Section 1.65 of the First License Agreement is
hereby amended to read as follows:
	 
	 	 	“In Vivo Diagnostic Agent” means any product containing one or more aptamers that is
used for any human in vivo diagnostic purpose related to (inter alia) the identification,
quantification or monitoring of the propensity toward, or actual existence of, any disease
state.
	 
	3.	 	Effective as of the date first written above, Section 1.88 of the First License Agreement is
hereby amended to read as follows:
	 
	 	 	“Permitted Activities” means (a) with respect to any Program Target, any screening
activities conducted by ARCHEMIX with respect to such Program Target for itself and/or for
any Third Party for the purpose of identifying aptamers that bind to a Target other [***]
select or otherwise participate in the identification of the targets that are the subject of
any such grant of rights and (z) fund or participate in the discovery, development and/or
commercialization of any such aptamers outside of the Field.
	 
	4.	 	Effective as of the date first written above, Section 1.106 of the First License Agreement is
hereby amended to read as follows:
	 
	 	 	“Radio Therapeutic” means any product for human therapeutic use that contains one or
more aptamers that targets specifically any diseased tissue, cells or disease-specific
molecules or any tissue or cells which are affected by a disease or located in the close
neighborhood of a disease process and is linked to or incorporates (a) radionucleotides or
(b) any structure or elements which develop therapeutic effects similar to the effect of
linking or incorporating radionucleotides after submission of any kind of radiation.
	 
	5.	 	Effective as of the date first written above, Section 4.8.3(a) of the First License Agreement
is hereby amended to read as follows:
	 
	 	 	Adverse Events. In addition to the updates described in Section 4.8.1 and 4.8.2,
MERCK shall provide ARCHEMIX with all Adverse Event information and product complaint
information relating to Development Candidates or Products as such information is compiled
or prepared by MERCK in the normal course of business in connection with the Development of
any Development Candidates or Commercialization of any Product and, in any event, within
time frames consistent with reporting obligations under Applicable Laws. MERCK shall
provide such Adverse Event and product complaint information hereunder to ARCHEMIX in
accordance with Section 13.3. ARCHEMIX may provide all such Adverse Event information to
other licensees of ARCHEMIX who have the right to sell aptamers for therapeutic purposes
under a license from ARCHEMIX; provided, that, such other licensees agree to maintain the




Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application
requesting confidential treatment under Rule 406 of the
Securities Act.




2









 









	 	 	confidentiality thereof. ARCHEMIX will provide to MERCK Adverse Event information obtained
from other licensees of ARCHEMIX who have the right to develop and sell aptamers for
therapeutic purposes under a license from ARCHEMIX; provided, that, such other licensees
agree to share such information and MERCK agrees to maintain the confidentiality thereof.
	 
	6.	 	Effective as of the date first written above, Section 5.4.1 of the First License Agreement is
hereby amended to read as follows:





	 	 	 	 	 
	 	 	Milestone Event	 	Milestone Payment
	1.

	 	[***]
	 	$[***]
	2.

	 	[***]
	 	$[***]
	3.

	 	[***]
	 	$[***]
	4.

	 	[***]
	 	$[***]
	5.

	 	[***]
	 	$[***]
	6.

	 	[***]
	 	$[***]
	7.

	 	[***]
	 	$[***]
	8.

	 	[***]
	 	$[***]
	9.

	 	[***]
	 	$[***]
	10.

	 	[***]
	 	$[***]
	11.

	 	[***]
	 	$[***]
	12.

	 	[***]
	 	$[***]
	13.

	 	[***]
	 	$[***]
	14.

	 	[***]
	 	$[***]







	7.	 	Effective as of the date first written above, Section 5.5.1(f) of the First License Agreement
is hereby amended to read as follows:




Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application
requesting confidential treatment under Rule 406 of the
Securities Act.




3









 









	 	 	Know-How Payments. The Parties hereby acknowledge and agree that any royalties that
are payable for a Product for which no Patent Rights exist shall be in consideration of (i)
ARCHEMIX’s expertise and know-how concerning the identification of aptamers in the Field,
including its development of the SELEX® Process and its other aptamer-related
development activities conducted prior to the Effective Date; (ii) the performance by
ARCHEMIX of the Research Program, (iii) the disclosure by ARCHEMIX to MERCK of results
obtained in the Research Program; (iv) the licenses granted to MERCK hereunder with respect
to Licensed Technology and Joint Technology that are not within the claims of any Patent
Rights Controlled by ARCHEMIX; (v) the restrictions on ARCHEMIX in Section 7.6.1; and (vi)
the “head start” afforded to MERCK by each of the foregoing.
	 
	8.	 	Effective as of the date first written above, Section 7.1.2(f) of the First License Agreement
is hereby amended to read as follows:
	 
	 	 	Non-Exclusive License For Aptamers Outside the Collaboration. MERCK hereby grants
to ARCHEMIX and its Affiliates a non-exclusive, royalty-free, worldwide license, with the
right to grant sublicenses, under MERCK Program Technology and Patent Rights claiming MERCK
Program Technology to the extent necessary to research, develop, have developed, make, have
made, use, distribute for sale, sell, offer for sale, import and have imported aptamers and
products Derived from aptamers other than those targeted to a Program Target for any and all
uses, except as otherwise provided herein.
	 
	9.	 	Effective as of the date first written above, Section 7.1.2(g) of the First License Agreement
is hereby amended to read as follows:
	 
	 	 	Exclusive License For Aptamers Outside the Collaboration. To the extent requested
in writing by ARCHEMIX, MERCK may grant to ARCHEMIX and its Affiliates an exclusive,
royalty-bearing, worldwide license, with the right to grant sublicenses, under MERCK Program
Technology and Patent Rights claiming MERCK Program Technology and MERCK’s interest in Joint
Technology and Joint Patent Rights to the extent necessary to research, develop, have
developed, make, have made, use, distribute for sale, sell, offer for sale, import and have
imported aptamers and products Derived from aptamers other than those targeted to a Program
Target for any and all uses, except as otherwise provided herein. The Parties agree to
negotiate in good faith with respect to the foregoing license.
	 
	10.	 	Effective as of the date first written above, Section 7.6.1 of the First License Agreement is
hereby amended to read as follows:
	 
	 	 	ARCHEMIX. During the Term, ARCHEMIX shall not, and shall cause each of its
Affiliates to not, conduct any activity, either on its own, or with, for the benefit of, or




Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application
requesting confidential treatment under Rule 406 of the
Securities Act.




4









 









	 	 	sponsored by any Third Party, that is designed to research, develop or commercialize, or
grant any license or other rights to any Third Party to utilize, any Proprietary Materials,
Technology or Patent Rights Controlled in whole or in part by ARCHEMIX or any of its
Affiliates for the purpose of researching, developing or commercializing (a) any aptamer
binding to a Program Target, or (b) any Collaboration Aptamer or aptamer Derived therefrom,
except for the conduct of Permitted Activities and as otherwise provided under this
Agreement.
	 
	11.	 	Effective as of the date first written above, Section 9.2.1(a) of the First License Agreement
is hereby amended to read as follows:
	 
	 	 	Notice. In the event either Party becomes aware of (i) any possible infringement of
any Licensed Patent Rights, MERCK Patent Rights or Joint Patent Rights through the
Development or Commercialization of an aptamer covered by the Program Aptamer-Specific
Patent Rights, or (ii) the submission by any Third Party of an abbreviated new drug
application under the Hatch-Waxman Act for a product that includes an aptamer covered by the
Program Aptamer-Specific Patent Rights (each, an “Infringement”), that Party shall promptly
notify the other Party and provide it with all details of such Infringement of which it is
aware (each, an “Infringement Notice”).
	 
	12.	 	Effective as of the date first written above, Section 11.3 of the First License Agreement is
hereby amended to read as follows:
	 
	 	 	Acknowledgment of MERCK. MERCK acknowledges that the licenses granted to MERCK
hereunder are subject to certain limitations and restrictions set forth in the
ARCHEMIX-Gilead License Agreement and the URC License Agreement and agrees that MERCK shall
comply with the terms of the ARCHEMIX-Gilead License Agreement and the URC License Agreement
that ARCHEMIX is subject to thereunder. MERCK hereby acknowledges and agrees and covenants
that (a) it may and will not use the SELEX® Process or the SELEX®
Technology as described in the SELEX® Portfolio for any reason, including
without limitation (i) to research, make, use, sell, offer for sale, import or export any
aptamers for In Vitro Diagnostics, In Vivo Diagnostic Agents, or Radio Therapeutics or (ii)
develop, modify, manufacture, have manufactured, export, import, use, sell or offer to sell
(A) any aptamer other than a Collaboration Aptamer, or (B) any Excluded Aptamer and/or any
product containing an Excluded Aptamer; (b) under the ARCHEMIX-Gilead License Agreement and
under the URC License Agreement, ARCHEMIX’ rights in the SELEX® Process or the
SELEX® Technology as described in the SELEX® Portfolio may revert to
Gilead if ARCHEMIX, its Affiliates and all assignees and sublicensees cease reasonable
efforts to develop the commercial applications of products and services utilizing the
SELEX® Process or the SELEX®  Technology; (c) in the event
of any termination of the URC License Agreement, the




Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application
requesting confidential treatment under Rule 406 of the
Securities Act.




5









 









	 	 	licenses granted to MERCK hereunder shall remain in full force and effect in accordance with Section
3.4 of the URC License Agreement; provided, that, MERCK is not then in breach of this
Agreement and MERCK agrees to be bound to UTC as the licensor under the terms and conditions
of the URC License Agreement as described in the SELEX® Portfolio; and (d) in the
event of any termination of the ARCHEMIX-Gilead License Agreement, the licenses granted to
MERCK hereunder shall remain in full force and effect in accordance with Section 2.3 of the
ARCHEMIX-Gilead License Agreement; provided, that, MERCK agrees to be bound to Gilead as the
licensor under the terms and conditions of the ARCHEMIX-Gilead License Agreement; and,
provided, that, if the termination of the ARCHEMIX-Gilead License Agreement arises out of
the action or inaction of MERCK, Gilead, at its option, may terminate such license.
	 
	13.	 	Effective as of the date first written above, a new paragraph shall be inserted into the
First License Agreement as Section 11.4 which new Section 11.4 shall read as follows:
	 
	 	 	Covenant of ARCHEMIX. ARCHEMIX hereby covenants that to the extent it enters into an
agreement with a Third Party that grants a license to such Third Party to research, develop,
and/or commercialize aptamers that bind to a Program Target in accordance with Section 7.6.1
(as amended herein) it will include in any such license a covenant which prohibits such
Third Party and any sublicensee of such Third Party from asserting any patent rights
relating to the Program Targets arising under any such license (or any sublicense granted
thereunder) against ARCHEMIX or any licensee or sublicensee of ARCHEMIX (including, for
clarity, MERCK and its Affiliates) to which ARCHEMIX has granted a license or sublicense to
aptamers that bind to a Program Target for the treatment, prevention, cure or delay of
progression of an indication, disease or disorder for ARCHEMIX’s or its licensee’s or
sublicensee’s research, development or commercialization of aptamers that bind to a Program
Targets for the treatment, prevention, cure or delay of progression of an indication,
disease or disorder.
	 
	14.	 	Except to the extent amended herein, the First License Agreement shall remain unchanged and
in full force and effect.





[REMAINDER OF PAGE LEFT INTENTIONALLY BLANK]



Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application
requesting confidential treatment under Rule 406 of the
Securities Act.




6









 








	 	 	 	 	 	 	 
	 	 	IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives.
	 
	 	 	 	 	 	 
	 	 	ARCHEMIX CORP.
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	MERCK KGaA
	 	 	          ppa.	 	i.V.
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 	 	 	 	 
	 

	 	Name:
	 	Dr. B. Kirschbaum
	 	J. Eckhardt
	 
	 	 	 	 	 	 
	 

	 	 	 	Senior Executive
	 	Legal Counsel
	 

	 	 	 	Vice President	 	 





Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application
requesting confidential treatment under Rule 406 of the
Securities Act.





7